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Summary 
 
Clostridium difficile is the most common cause of hospital acquired infections. While the 
current treatments of choice, antibiotics, are generally effective in promoting recovery 
,the increased incidence of C. difficile infections and treatment failure associated with 
antibiotic resistance combined with the emergence of hypervirulent strains highlights the 
need to develop therapeutic approaches that specifically target the pathogen without 
causing collateral damage to the protective microbiota. Several non-antibiotic approaches 
are currently being investigated, such as bacteriophage therapy. For this reason, we 
attempted to isolate C. difficile specific lytic bacteriophages which could form the basis 
of a treatment for C. difficile. While we were unable to isolate lytic phages, we were able 
to isolate twelve temperate bacteriophages from twenty-three clinical isolates of C. 
difficile using mitomycin C. Unfortunately we failed to identify a susceptible host strain 
capable of supporting the replication of these phages. This failure may in part be due to 
repeated episodes of phage infection over time, which have resulted in the emergence of 
“phage resistant” species mediated by systems such as Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR). Employing a PCR-based approach using primers 
specific for the lysin genes of five previously isolated C. difficile phages, we found 
evidence to suggest that repeated bacteriophage infection is a common event for clinical 
isolates of C.  difficile. Our inability to isolate a lytic bacteriophage prompted us to adopt 
an alternative approach in which we used endolysin enzyme of five previously identified 
C. difficile phages as recombinant protein. These lysins showed broad spectrum activity 
against the vegetative forms of a large collection of C. difficile ribotypes with little or no 
activity against other species, supporting their potential as therapeutic agents. We also 
identified a genome associated lysin (CD630, YP_001088405), which lysed vegetative C. 
difficile in a similar manner to the phage derived lysins. We also cloned and expressed a 
spore cortex lytic enzyme (SleC) which targeted the cortex of C. difficile spores. 
Unfortunately this enzyme was inactive against intact spores, suggesting that the outer 
layers of the spore act as a permeability barrier. The results of this study showed in vitro 
the applicability of endolysins against the vegetative form of C. difficile and the activity 
of spore cortex lytic enzyme against coatless spores, offering interesting perspectives for 
evaluation of the antibacterial activity of a mixture of endolysin and spore cortex lytic 
enzyme.  
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1.1 Historical review 
 
The first mention of C. difficile in the literature was by Hall and O'Toole in 1935 when 
they considered it part of the normal body microbiota of the newborn (Brazier and 
Borriello, 2000). It was originally called Bacillus difficile due to it being difficult to 
isolate , however, as the organism is a strictly anaerobic, Gram-positive spore-forming 
bacillus, it was subsequently classified as a member of the Clostridium genus (Brazier 
and Borriello, 2000). Tedesco et al. (1974) found that pseudomembranous colitis (PMC) 
occurred in approximately 10% of clindamycin-treated patients. In 1977, Bartlett and his 
colleague described clindamycin-induced colitis in hamsters, and were able to isolate an 
unidentified Clostridium species which was subsequently identified as C. difficile and 
implicated as the causative agent of the condition (Bartlett, 2002). Subsequently Larson 
et al. (1977) identified the presence of cytotoxins in the stools of patients with PMC. C. 
difficile is now recognised as the causative agent of PMC and of 15% to 25% of cases of 
antibiotic-associated diarrhea (Gerding et al., 1995). 
 
1.2   Clostridium difficile characterisation  
C. difficile is ubiquitous in nature, being especially prevalent in humans. About 40-60% 
of neonates and 1-3% of healthy adults carry C. difficile asymptomatically (Kuijpers and 
Surawicz, 2008). 
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The bacterium is a Gram-positive, spore-forming, anaerobic bacillus (Brazier and 
Borriello, 2000). It's Gram stain is predominantly positive; however, some old colonies 
may exhibit Gram variability. Cells are between 3-5 µm in length and are usually round-
ended. Organisms produce large oval subterminal spores, usually in the stationary or 
decline phase (Brazier and Borriello, 2000). Colony morphology is variable depending on 
the strain, inoculation media and incubation time (Brazier and Borriello, 2000). However, 
colonies cultured on blood-based media following 24 to 48 hours incubation show 
irregular, lobate or rhizoid edges, are grey in colour and opaque with no haemolysis and a 
fried egg appearance can be seen due to spore formation (Brazier and Borriello, 2000). 
Colonies are between 4.5 mm (blood agar) to 7.5mm (cycloserine cefoxitin fructose agar 
(CCFA) in diameter (George et al., 1979). The vegetative form of the bacterium exhibits 
sluggish motility due to the presence of peritrichous flagellae. Some strains have multiple 
polar fimbriae which are up to 6 μm long and 4–9 nm in diameter (Hafiz and Oakley, 
1976; Borriello et al., 1988).  
In the presence of oxygen, the vegetative form of C. difficile can remain viable for up to 
15 minutes in a dry environment (Buggy et al., 1983) and for up to 3 hours in a moist 
environment (Jump et al., 2007).  
The first complete genome sequence of a C. difficile strain was published in 2006 by the 
Sanger Centre, UK (Sebaihia et al., 2006). This was of the C. difficile strain 
630(NAP1/027), a hypervirulent and multidrug-resistant strain which isolated from a 
patient with severe PMC in Zurich, Switzerland.  
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The genome of strain has a single circular chromosome of 4,290,252 bp (G+C = 
29.06%), and a circular plasmid of 7,881 bp (G+C = 27.9%). Analysis of the genome 
revealed that approximately 11% is comprised of mobile genetic elements, such as 
conjugative transposons, prophages, a skin element and other unknown mobile elements. 
These mobile elements could provide C. difficile 630 with the genes responsible for 
antimicrobial resistance and other virulence factors (Sebaihia et al., 2006). 
 
1.3   Spores of C. difficile 
Spores were first described in 1876 by Robert Koch and Ferdinand Cohn (Brock, 1975; 
Labbe, 2005). In 1933, Bayne-Jones and Petrilli produced pictures showing sporulation 
and different morphological changes (Bayne-Jones and Petrilli, 1933; Labbe, 2005). 
Spores are dormant with a non-reproductive structure which is formed following a 
multiphase process involving asymmetric cell division, followed by engulfment of the 
new small cell containing a single DNA chromosome by the mother cell (Errington, 
2003), and are normally surrounded by several envelope layers.  
Structurally, the bacterial spore contains a core, a cortex and inner and outer spore coats 
(Sousa et al., 1976). A loosely or closely fitting outermost structure has been observed 
around the spore in a number of species of Bacillus and Clostridium (Figure 1.1). This 
layer was given the name “exosporium” by Fluigge in 1886 (Gerhardt and Ribi, 1964).  
Furthermore, Koch (1877) described the exosporium as a “round transparent mass which 
appeared like a small, light ring surrounding the spore” (Gerhardt and Ribi, 1964), and 
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acting as the primary physiological barrier between the spore and the environment 
(Gerhardt and Ribi, 1964; Holt and Leadbetter, 1969; Ohye and Murrell, 1973). It was 
suggested that the exosporium may play a role in resistance to protease and lytic enzymes 
(Sousa et al., 1976) or may play role in spore attachment to surfaces and human gut 
epithelial cells (Joshi et al., 2012). In terms of the chemical composition of the spore 
layers, the outer and inner spore coats are mainly protein, while the cortex is mainly 
peptidoglycan; the core contains proteins, DNA, RNA and ribosomes (Lawley et al., 
2009). The exosporium layer is composed of phospholipid, lipid, protein and 
polysaccharide (Labbe, 2005).  
It has been found that C. difficile spores have extra germination activity in the presence of 
cholate derivatives, which are usually found in bile (Sorg and Sonenshein, 2008), which 
may explain why the spores undergo germination in the intestinal tract. However, spores 
do not possess a known germinant receptor such as those present in Bacilli and many 
Clostridia species and perhaps they employee a novel mechanisms for response to 
germinates (Lawley et al., 2009). Recently reported proteomic and genomic analysis of 
C. difficile spores has revealed that five spore genes unique to C. difficile (CD0939 , 
CD0940 , CD1898 ,CD2010 and CD2926)  are encoded within various mobile elements, 
including genomic islands , transposons and prophage 1 and 2 which may directly 
contribute to spore composition (Lawley et al., 2009).Clostridium difficile spores may 
survive on contaminated surfaces for an extended period of time and are resistant to many 
chemical and physical agents (Setlow, 2007). 
 Page | 6 
 
 It is this feature that makes C. difficile an enormous challenge for infection control 
systems in hospitals and health care facilities (Nerandzic and Donskey, 2010). 
 
Figure 1.1. Transmission electron microscopy of sectioned C. difficile DS1813 spores 
(ribotype 027), showing the spore’s ultrastructure including the core, cortex, coat and 
exosporium. Thin sections were double-stained with 2% uranyl acetate and 2% lead citrate and 
viewed on a Philips transmission electron microscope, EM 280, at 55,000x . 
 
1.4    Sporulation and germination of spores 
Sporulation is a multiphase process resulting in the development of a spore from a 
vegetative cell under conditions of environmental stress, such as a reduction in available 
nutrients. Germination is defined as the processes that result in the irreversible loss of 
spore-specific characteristics during the transition to a metabolically active vegetative 
cell following exposure to sense-specific effectors called germinants (Gould, 1970; 
Russell, 1990; Burns et al., 2010). 
Cortex Coat 
Core 
Exosporium 
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The vast majority of studies that have described the events of sporulation and 
germination have been performed on Bacillus species (especially Bacillus subtilis and 
Bacillus cereus). Little is known about Clostridium spore germination; however, Bacillus 
and Clostridium have some similarities in the sporulation process (Burns et al., 2010; 
Nerandzic and Donskey, 2010). 
 
Spore sporulation 
 
Sporulation is classically divided into seven distinct morphological stages (Gombas and 
Labbe, 1981; Russell, 1990; Labbe, 2005; McDonnell, 2007; De Hoon, et al., 2010). 
Stage 0 represents the vegetative cell, followed by stage I, the presporulation phase, 
where DNA is present as an axial filament rather than the normal spherical shape seen in 
normal cells (Figure 1.2). This is followed by stage II, where vegetative cells undergo 
septation in which asymmetric cell formation occurs. In stage III, the mother cell engulfs 
the new small cell containing a single DNA chromosome to form a forespore, which lies 
in the vegetative cell cytoplasm and is bounded by inner and outer forespore membranes. 
A thin layer of the vegetative cell wall lies between them, which is composed of 
peptidoglycan formed in stage IV; this layer is known as the cortex. The cortex is 
composed of modified peptidoglycan from the vegetative cell. This modification includes 
a repeating subunit of muramic lactam without any attached amino acids. Moreover, the 
alanine subunit is an L-alanyl residue that forms a tetrapeptide subunit with the sequence 
L-ala-D-glu-meso-DAP-D-ala with very little cross-linking between the tetrapeptide 
chains.  
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In stage V, the synthesis of spore coats and spore-specific molecule dipicolinic acid 
(DPA) occurs, followed by stage VI in which involves increase thickness of outer spore 
coat with further development of the cortex and loss of water from the core until a 
complete endospore is formed.  
In stage VII, degradation of the mother cell takes place by the activity of autolysin 
enzymes in order to release the mature endospore. The spore remains in the dormant 
stage until the external environment once more becomes favourable for growth. 
 
Figure 1.2.    Stages of the B. subtilis life cycle. Modified from De Hoon, et al. (2010). 
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Spore germination 
Spore germination in Clostridia sp. proceeds more slowly than in Bacillus sp. and often 
involves a mixture of germinants (Peck, 2009; Xiao et al., 2011). For example, C. 
perfringens spore germination can be triggered by a mixture of NaP and inorganic 
phosphate (NaPi) , a mixture of L-asparagine and KCl , and can also be triggered by L-
asparagine, KCl and Ca-DPA (Paredes-Sabja et al., 2008a; Xiao et al., 2011). In C. 
difficile, spores can be stimulated by cogerminants, cholate derivatives, and glycine in 
bile (Sorg and Sonenshein, 2008).  
During germination, dormant spores change to actively growing cells; this occurs in three 
stages (activation, germination and outgrowth), and occurs under favourable growth 
conditions that signal the process of germination (Russell, 1990). Germinants that trigger 
germination are thought to interact with specific receptors on spores (Burns et al., 2010). 
Activation is the process that prepares the dormant spore to enter germination and can be 
induced by metabolic and non-metabolic stimuli such as heat, acidity, ions and minerals. 
Activation is reversible and the spore retains most of its properties.  
This step is followed by germination, which involves the release of dipicolinic acid 
(DPA)  and calcium ions  and the core layer rehydration. Spore lytic enzymes such as 
CwlJ and SleB in B. subtilis (Popham et al., 1996), SleC (Miyata et al., 1995) and SleM 
(Chen et al., 1997) in C. perfringens and SleC in C. difficile (Burns et al., 2010 ), are 
activated and then cortex peptidoglycan degraded, leading to full spore rehydration. ATP 
synthesised and other enzymes are reactivated. Spores DNA are released after the small 
acid-soluble proteins (SASPs) are degraded by specific protease.  
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The outgrowth step follows germination, during which actively dividing cells are 
generated (Russell, 1990; Makino and Moriyama, 2002; Labbe, 2005; Moir, 2006; Burns 
et al., 2010). 
 
1.5   Pathogenesis 
 Healthy adults are protected from C. difficile colonisation and disease by the presence of 
the resident colonic microbiota, by a mechanism known as colonisation resistance 
(Gorbach et al., 1988). This mechanism is likely to involve a number of factors such as 
the production of hydrogen peroxide, lactic acid, short chain fatty acids and bacitracin by 
the resident microbiota in addition to competition for mucosal binding sites and nutrients 
(Payne et al., 2003; Naaber et al., 2004).  
However, administration of broad spectrum antibiotics disrupts this protective 
mechanism, allowing C. difficile spores acquired from either exogenous or endogenous 
sources to colonise and germinate in the small bowel upon exposure to bile acids (Kelly 
et al., 1994; Kelly and Lamont, 1998). The resulting vegetative bacteria adhere to the 
cells lining the gut with the aid of flagella and proteases, so that C. difficile can then 
adhere to enterocytes (Denève et al., 2009).  
Pathogenic strains of C. difficile produce two distinct toxins. Toxin A (tcdA), which 
consists of 2710 residues (308.0 kDa), is an enterotoxin, whereas toxin B (tcdB), 
containing 2366 residues (269.6 kDa), has been described as a cytotoxin (Taylor et al., 
1981). However, some virulent strains may only produce toxin B (Alfa et al., 2000). 
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These A
–
B
+
 strains are capable of causing disease and have been involved in outbreaks 
among hospitalised patients (Wren et al., 2009). These toxins are the principal virulence 
factors of the pathogen and act by glucosylating small Rho proteins using UDP-glucose 
as a sugar donor; this damages the human colonic mucosa (Jank et al., 2007). The actions 
of these toxins on gut cells result in the production of proinflammatory interleukins and 
tumour necrosis factor-α, which increase vascular permeability and cause the opening of 
epithelial cell junctions and epithelial cell apoptosis. PMC with watery diarrhea forms as 
a consequence of connective tissue degradation (Castgliuolo et al., 1998; Jank et al., 
2007). 
In terms of clinical presentation, a patient’s response will range from an asymptomatic 
carrier state to active infection depending on host-specific factors (Borriello, 1998). The 
major factors predisposing patients to the development of symptomatic C. difficile-
associated diarrhea are the type and duration of antibiotic therapy, the age of the patient 
and prolonged hospitalisation (Bignardi , 1998). Elderly patients in hospitals and nursing 
homes are at high risk of colonisation, with a rate of 73% having been reported (Denève 
et al., 2009). 
Other factors have been described, such as admission to intensive care units, the number 
and severity of underlying diseases and treatment with proton-pump inhibitors (Dial et 
al., 2005). Also at risk are patients who have recently received immunosuppressive 
therapy or undergone gastrointestinal surgery, have a nasogastric tube or are sharing a 
hospital room with a C. difficile-infected patient (McFarland, 1998; Greenstein et al., 
2008). 
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1.6   Incidence of C. difficile infection 
According to the health protection agency (HPA) report, dating 15
th
 February 2013, the 
number of laboratory reports in England, Wales and Northern Ireland mentioning  C. 
difficile infection decreased for the five consecutive year by 25 %  from 19807 in 2011 to 
14910 in 2012 after increasing every year since records began in 1999, as shown in 
Figure 1.3. 
According to the European Centre for Disease Prevention and Control (ECDPC), the cost 
of treating a single case of C. difficile infection in England is estimated at between €5,000 
and €15,000. The cost is expected to almost double over the next four decades. 
 
Figure 1.3.   Voluntary laboratory reports of  C. difficile positive faecal specimens: England, 
Wales and Northern Ireland ( 1990 – 2012). 
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317138039648, accessed on 10-06-
2013). 
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1.7    Treatment strategies 
The most important step is to discontinue offending agent, if possible, while giving fluids 
and electrolytes to maintain hydration. With this conservative strategy, up to 25% of 
patients with C. difficile-associated diarrhea (CDAD) recover without further therapy 
(Barbut et al., 2000). 
Metronidazole is recommended as a first-line treatment for CDAD, at a dose of 500 mg 
orally three or four times a day for up to 14 days, depending on the severity of the 
disease. Metronidazole is an inexpensive drug with a high positive response rate 
(Wenisch et al., 1996). Metronidazole is one of the most important drugs for the 
treatment of anaerobic infections. It has a low molecular weight that allows the drug to 
diffuse passively into bacterial cells and across cell membranes. The agent is then 
reduced by the pyruvate :ferredoxin oxidoreductase system of bacterial cells, resulting in 
the formation of a cytotoxic nitro radical anion which interacts with the host cell’s DNA, 
resulting in DNA strand breakage (Edwards, 1993; Cudmore et al., 2004). 
The antibiotic vancomycin is recommended as a second-line therapy. It is a glycopeptide 
that forms a complex with the D-Ala-D-Ala termini of peptidoglycan precursors in the 
outer surface of the bacterial membrane, and this complex results in cell wall synthesis 
inhibition (Nagarajan, 1991). The standard treatment with this drug is 125 to 500 mg 
orally four times a day for 10 to 14 days. It is also an effective treatment, with a response 
rate greater than 90% (Fekety et al., 1989; Bartlett, 2002). However, due to the higher 
cost of oral vancomycin therapy and increased concern about selection for vancomycin 
resistant Enterococcus (VRE), metronidazole is preferred as the initial agent of choice 
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(Bartlett, 2002). Despite this, a recent study has revealed that vancomycin gives a better 
therapeutic response than metronidazole with a lower relapse rate in patients with severe 
Clostridium difficile-associated infection (CDAI) (Bartlett, 2006). Alternative antibiotics 
have been described, including oral therapy with teicoplanin, bacitracin or fusidic acid 
(Bartlett, 2002). 
Resolution of fever, usually within the first two days, is a sign of a good response to 
therapy, and diarrhea should resolve within two to five days. Treatment should be 
continued for an average of 10 to 15 days, and at least five days are required to determine 
whether the treatment has failed or not (Florea et al., 2003). The use of antiperistaltic 
drugs to reduce diarrhea should be avoided as they can result in the loss of metronidazole 
(Fekety, 1997). 
Unfortunately, 15 to 25% of patients with C. difficile infection will suffer from recurrent 
infection following antibiotic treatment (Liang, 2003). This may be due to the 
germination of C. difficile spores which have survived the initial course of treatment 
(original organism) or as a result of reinfection by a new strain of the organism (Kelly et 
al., 1994). Metronidazole remains the drug of choice in cases of recurrent infection 
(Gerding, 2000).  
Concerns over the increased incidence of CDAD, the emergence of strains with enhanced 
virulence and an increase in the level of antibiotic resistance has prompted researchers to 
investigate the utility of employing bacteriophages (denoted as φ) to treat infections 
caused by this organism. Bacteriophages are viruses that only target bacterial cells and 
have been successfully used in the former Soviet Union and Eastern European countries 
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for many years to treat infectious diseases, often in preference to antibiotics 
(Sulakvelidze et al., 2001; Fortuna et al., 2008; Kutateladze and Adamia, 2008).  
A major advantage of their use in the context of C. difficile is their specificity; they are 
normally species-specific, meaning that other members of the bacterial microbiota of the 
gut are unaffected, in contrast to antibiotics. To date, several temperate bacteriophages 
have been shown to be active against C. difficile (Mayer et al., 2008; Meader et al., 2010 
Sekulovic et al., 2011). Indeed, the feasibility of employing bacteriophages to treat 
experimentally infected animals has been demonstrated in hamsters (Ramesh et al., 
1999). 
Endolysins, which are bacteriophage enzymes that degrade the bacterial peptidoglycan 
cell wall, resulting in lysis and death of the bacterial cell, have also been tested as 
antimicrobial agents against C. difficile. Endolysin, isolated from φCD27, was found to 
be active against 30 different C. difficile strains, including the major epidemic ribotype 
027(B1, NAP1) (Mayer et al., 2008; Mayer et al., 2011).  
In addition to approaches which directly target the bacteria, other potential therapies have 
been investigated as a means of treating the disease. Rectal infusions of faeces from a 
normal host have been investigated as means of restoring the normal microbiota of the 
colon in patients who suffer from recurrent C. difficile infection. Despite the good 
response rates which have been seen with this approach, there is a risk of transmitting 
retroviruses and other infectious agents from the donor to the recipient (Gustafsson et al., 
1999).  
 Page | 16 
 
A further live organism based approach which is being explored is the use of probiotic 
agents such as Saccharomyces boulardii (Surawicz et al., 1989) or Lactobacillus 
rhamnosus GG. Lactobacillus acidophilus, Lactobacillus bulgaricus and Lactobacillus 
plantarum 299v have also been found to be effective in patients with recurrent infections 
(Pochapin, 2000; Miller, 2007). In addition to directly targeting the bacteria, researchers 
have investigated the feasibility of inactivating the pathogen’s principle virulence factors, 
its two toxins. Anion resins, such as colestipol or cholestyramine, which bind the toxins 
of C. difficile, have been found to be effective in some patients with recurrent CDAD 
when used in combination with vancomycin (Poutanen and Simor, 2004). Tolevamer is 
another toxin sequestering compound which binds the toxins to a styrene sulphonate 
polymer. The polymer lacks antimicrobial activity and thus should permit the restoration 
of a normal gut microbiota and thereby prevent recurrent infections. However, this agent 
is still under investigation (Barker et al., 2006; Louie et al., 2006; Baines et al., 2009).  
 
1.8   Prevention 
The most important strategy for preventing C. difficile disease is the proper use of 
antibiotics. In hospital, most patients who develop CDAD have previously been exposed 
to antimicrobials. In addition, a decrease in CDAD cases in the hospital environment has 
been shown to be associated with judicious use of antibiotics (McNulty et al., 1997).  
According to the WHO Infection control measures, such as hand washing between 
patient contacts, environmental decontamination, and good hospital cleaning are the only 
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ways to reduce the spore burden (WHO, 2002). The use of disinfectants is controversial , 
although vegetative organisms might be killed, some spores will survive. Staff and 
patient education, as well as adequate nursing levels, are also vital. All of these measures, 
when correctly implemented, have proven to be effective at reducing the incidence of the 
disease (Vonberg et al., 2008). 
The use of probiotics containing live bacteria such as Lactobacillus casei, L. bulgaricus 
and Streptococcus thermophilus has been reported to reduce the incidence of
 
antibiotic-
associated diarrhea and C. difficile-associated diarrhea (Surawicz et al., 1989; Miller, 
2007). Hickson et al. (2007) stated that this approach has the potential to decrease 
healthcare costs,
 
morbidity, and mortality, if applied routinely in patients aged over 50. 
Vaccination is currently being investigated as a means of preventing infection (Kotloff et 
al., 2001 ; Aboudola et al., 2003). A C. difficile toxoid vaccine capable of inducing high-
level responses in the sera via anti-toxin A immunoglobulin G (IgG) has been developed 
and used in healthy volunteers (Aboudola et al., 2003). A vaccine containing formalin-
inactivated toxoid A and B has also been developed and has been shown to be highly 
immunogenic in healthy adults and may be capable of improving patient outcomes 
(Kotloff et al., 2001). Further testing will be required to validate the efficacy of this 
vaccine (Mattila et al., 2008). 
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Vaccination is not the only form of immunotherapy. Human monoclonal antibodies 
(HuMAbs), anti-toxin A HuMAb CDA1 and anti-toxin B HuMAb MDX-1388, which 
neutralise toxin A and toxin B, respectively, have been developed and have been shown 
in animal studies to prevent disease (Babcock et al., 2006). A further study in 2008 
showed that CDA1 was safe and well-tolerated at single doses after being used in healthy 
adults, suggesting that this intervention could be used to treat infected individuals (Taylor 
et al., 2008). 
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1.9   Bacteriophages 
1.9.1   Introduction 
Bacteriophages (or phages) are viruses that target and infect only bacterial cells. Phages 
are ubiquitous and can be found in all habitats populated by bacteria (Sherman, 2008). 
They are the most abundant life forms on Earth and approximately 5,100 phage types had 
been isolated and identified by the end of the last century (Ackermann, 2001).  
 
1.9.2   Structure 
A phage has an outer protein shell called the head or capsid, which can vary in size and 
shape (Guttman et al., 2005). Some are icosahedral and others are filamentous. The head, 
which is present in every phage, acts as a protective covering and encloses the phage's 
genetic material. The genetic material can be ssRNA, dsRNA, ssDNA or dsDNA, in 
either a circular or linear arrangement (Guttman et al., 2005). Some phage heads have 
tails attached to them, through which the nucleic acid passes during infection of the 
bacterial cell. The tail may be surrounded by a contractile sheath, as in the T4 phage. At 
the end of the tail, some phages have tail fibres and a base plate; these structures play a 
role in the attachment of the phage to the bacterial cell (Hanlon, 2007) (Figure 1.4). 
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Figure 1.4.   Illustration of the basic structural features of bacteriophages. Image is modified 
from Hanlon (2007). 
 
Phages can be classified based on their morphology, presence or absence of an envelope  
and type of nucleic acid . To date, phages have been classified into 13 families  (Parisien 
et al., 2008) (Figure 1.5). Approximately 96% of reported phages are “tailed phages”, 
which are composed of an icosahedral head and a tail, with double-stranded DNA 
(dsDNA), These phages are classified according to the morphological features of the tail 
into three families: Podoviridae (short tail; 13.9%) Myoviridae (contractile tail; 24.5%), 
and Siphoviridae (long non-contractile tail; 61.7%) (Ackermann, 1996).  
The remaining phage types, constituting only 186 (3.6%) of the 5,100 known phages, are 
cubic, filamentous or pleomorphic in shape with genomes comprising single or double-
Tail fibres 
Collar 
Nucleic acid 
Head 
Base plate 
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stranded DNA (ssDNA or dsDNA), or single or double-stranded RNA (ssRNA or 
dsRNA) (Ackermann, 2001).  
Phages can also be classified based on their way to escape from their host cell, i.e. 
filamentous phages and lytic phages (Young et al., 2000; Bernhardt et al., 2002). 
Filamentous phages (shaped like a rod filament) can, because of their unique morphology 
and morphogenesis, reproduce and disseminate without killing their host (Russel, 1995), 
whereas lytic phages lyse and destroy the bacterial cell wall, resulting in the death of the 
host (Borysowski et al., 2006). 
 Lytic phages can be further divided into two classes according to their  cell wall lytic 
mechanisms: phages which employ an endolysin-holin system to destroy the wall of the 
bacterial cell (this system is encoded in phages that have large double-stranded DNA) 
and phages that use a single lytic factor which inhibits peptidoglycan synthesis (these 
usually occur in phages having small single-stranded RNA or DNA) (Young et al., 2000). 
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Figure 1.5.  The basic structure of families of bacteriophages. Images are modified from 
Murphy et al. (1995). 
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1.9.3   Replication  
Phages have either a lytic or a lysogenic life cycle. Those with a lytic life cycle infect a 
host cell, resulting in lysis of the host cell, whereas phages with a lysogenic life cycle can 
either multiply via the lytic cycle or enter a dormant state inside the cell (Sulakvelidze et 
al., 2001). The life cycle starts with infection of the host cell. The bacteriophage binds to 
specific receptors, which may be present on the cell envelope, capsule, flagella or even 
conjugative pili, by their tail fibres or by some other structure in those phages that lack 
tail fibres (Young et al., 2000). However, this attachment is weak and needs to be 
supported by irreversible attachment via the base plate. 
The main reason for this process is to allow the phage to bind tightly to the bacterial cells 
Penetration then takes place by which the phage injects its genome into the cell 
cytoplasm (Guttman et al., 2005). 
 
The lytic life cycle  
As already stated, lytic or virulent phages multiply inside their bacterial victim and kill 
the cell by lysing its cell wall at the end of the reproductive cycle. The ability to 
specifically target and kill a particular species of bacteria has led to the development of 
phages as a treatment for infectious diseases. 
Following penetration of the bacterial cell wall, the genome of the phage circularises in 
the cytoplasm of the bacteria. The phage’s nucleic acid uses the host cell’s machinery to 
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synthesise large amounts of structural proteins and phage DNA. Progeny phages are 
formed by the self-assembly of these components which escape from the cell when the 
cell wall is lysed by the actions of a phage-encoded endolysin (Guttman et al., 2005).  
 
The lysogenic life cycle  
Temperate bacteriophage is one which is capable of undergoing a lysogenic life cycle. 
After infection the temperate phage can either integrate its genome into their host 
bacterium's and become a non-infectious prophage, or it can replicate using lytic life 
cycle which result in lysis of host cell  (Sulakvelidze et al., 2001).  
The insertion of phage DNA into the genome occurs at specific sites and is catalysed by a 
phage-encoded enzyme, such as att P in lambda phage, which reacts with the host 
integration site att B in E. coli which is catalysed by integrase (Int) and host integration 
factor (IHF) (Little, 2005). In order to maintain the lysogenic state, a phage-coded 
protein, called a repressor binds to an operator on the phage DNA and turns off 
transcription of phage genes. The result is a stable lysogenic phage genome which 
remains integrated into the host’s DNA (Little, 2005). As the bacterial cell replicates, the 
prophage replicates as part of the genome. When a prophage is induced, phage gene 
expression is no longer repressed and, as a consequence, viral proteins and copies of the 
viral genome are generated. Progeny virus particles are formed and released from the host 
cell  after completing the life cycle (Hanlon, 2007) (Figure 1.6). 
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Release   
Lytic phages produce an enzyme called an endolysin which disrupts the peptidoglycan 
structure of the bacterial cell wall and affects cross-linking. Peptidoglycan has a role to 
play in defining the structure of the bacteria and prevents the cell from bursting due to the 
osmotic pressure of the bacterial contents. Weakening of peptidoglycan means that the 
cell wall can no longer contain the pressure and the cell bursts (Fischetti, 2008). 
However, not all phages are lytic; filamentous phages replicate and escape from the 
bacteria cell without killing the organism (Russel, 1995). 
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Figure 1.6.   Bacteriophage life cycle (lytic and lysogenic cycles). Image is modified from 
Sulakvelidze et al. (2001) 
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1.10   Phage therapy 
1.10.1   Phage discovery and early therapeutic approaches 
The concept of using phages as antibacterial agents is not new. In 1896, a British 
bacteriologist, Ernest Hankin, reported that the water of the Ganges and Jumna rivers in 
India seemed to possess antibacterial capabilities against gastrointestinal infections, 
particularly cholera. He described a substance which was capable of passing through a 
fine porcelain filter and was heat labile, as an undefined substance (Sulakvelidze and 
Morris, 2001). Two years later, Gamaleya confirmed Hankin’s observation with Bacillus 
subtilis. In 1915, Frederick Twort isolated filterable entities that produced small cleared 
areas on bacterial lawns due to the destruction of bacterial cells (micrococci and intestinal 
bacilli). Furthermore, he found the same phenomenon with Staphylococcus aureus, which 
led him to suggest that this antibacterial activity could be due to the actions of a virus. 
However, Twort did not explore his findings further (Sulakvelidze and Morris, 2001).  
In 1917, Felix d’Herelle named these viruses bacteriophages (bacteria eaters) (Hanlon, 
2007) and realised their potential for the treatment of bacterial infections following an 
outbreak of severe haemorrhagic dysentery amongst troops stationed in Paris. At that 
time, he prepared filtrates from patients' stool samples and mixed and incubated these 
filtrates with Shigella strains isolated from the same patients. A portion of the mixtures 
was tested on experimental animals and a portion was spread on agar plates. The 
appearance of minor but clear lysis of bacterial cells was seen by d’Herelle on these 
plates and he later called these areas taches, and then plaques (Summers, 2001).  
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The first phage therapy experiments performed by D’Herelle, using a phage preparation 
against dysentery, gave extremely promising results with the elimination of infection 
(Sulakvelidze et al., 2001). However, the results of these studies were not published 
immediately, and so the use of bacteriophages to treat staphylococcal skin disease in 
1921, by Richard Bruynoghe and Joseph Maisin, was the first reported application of 
phages to treat infectious diseases in humans (Sulakvelidze et al., 2001).  
However, failures in phage therapy occurred in later years, which could be attributed to a 
variety of factors such as low quality of phage preparations, a lack of detailed 
understanding of phage biology and poor experimental methods (O'Flaherty et al., 2009). 
The commercialisation of antibiotics in the 1940s led to decline in the use of phages as 
therapeutic agent in Western civilisation; however, in the East, they continued to use 
phages as therapeutic agent either alone or in combination with antibiotics (O'Flaherty et 
al., 2009).  
 
1.10.2   Reappearance of interest in phage therapy in the west 
Bacteriophage therapy returned to the West in 1989 after the collapse of the Soviet 
Union. Despite some initial barriers, such as language problems and a lack of information 
in this field, the problems associated with increased levels of antibiotic resistance and 
advances in molecular techniques and purification methods encouraged scientists and 
clinicians in Europe and America to undertake clinical trials on phage therapy (Jonathan, 
2009). 
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One example was the treatment of infected leg ulcers by using a cocktail of eight 
bacteriophages: five against Pseudomonas aeruginosa, two against Staphylococcus 
aureus and one against E. coli. This was carried out in Texas, USA, in 2006 (Marza et 
al., 2006). Another example is the use of T4 bacteriophage by Nestlé (the Swiss 
multinational food corporation) in Bangladesh to treat E. coli-mediated diarrhea (Bruttin 
and Brüssow, 2005). Furthermore, a cocktail of six bacteriophages was used in 2007 at 
the Royal National Throat, Nose and Ear Hospital in London as a treatment for chronic 
inner ear infections caused by Pseudomonas aeruginosa with the phage cocktail being 
administered by aerosol (Jonathan, 2009). The use of a bacteriophage to treat cystic 
fibrosis patients infected with Burkholderia cepacia has recently been described 
(Golshahi et al., 2008). Bacteriophage therapies have been used against a range of 
infections such as otitis media and urinary tract infections, and against bacteria such as 
Pseudomonas aeruginosa, Klebsiella spp., Burkholderia, Group A Streptococcus and 
Bacillus anthracis (Jonathan, 2009). Phages have also been used in food 
decontamination; for instance, in 2006, the FDA approved the use of a cocktail of six 
bacteriophages in order to eradicate strains of L. monocytogenes from ready-to-eat meat 
and poultry products (Macgregor, 2006). While phages have a number of unique 
advantages over antibiotics, the approach is not without its disadvantages. Details of 
some of the possible advantages and disadvantages are given in table 1.1. 
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Table 1.1.  Advantages and disadvantages of phage therapy  
Advantages Disadvantages 
  Specific for a particular bacterial target, so 
phages will not harm the beneficial 
bacteria that are present in the body 
(Sulakvelidze et al., 2001). 
 Phages have a limited host range due to the 
specificity of phage attachment. Therefore, 
the disease-causing organism has to be 
identified prior to the commencement of 
phage therapy (O'Flaherty et al., 2009). 
 Phage therapy can be delivered via 
numerous methods such as injection, nasal 
sprays, etc. (Abhilash et al., 2009). 
 As a result of bacterial cell mutation, 
resistance can be developed against phages 
(Skurnik and Strauch, 2006). 
 
 Relatively simple and inexpensive to 
propagate compared with antibiotics 
manufacturing; therefore, treatment costs 
will be reduced (O'Flaherty et al., 2009). 
 The effectiveness of phage therapy against 
intracellular pathogens (e.g., Salmonella 
spp.) is unclear (Sulakvelidze et al., 2001). 
  Safe therapy; no serious adverse effects 
have been reported (Sulakvelidze and 
Morris, 2001). 
 Phages may swap genes with each other and 
other organisms, so there is a chance of 
spreading toxins or antibiotic resistance 
genes (Parisien et al., 2008). 
 Self-replicating at the site of infection, so 
the number will increase as long as there 
are bacteria present. There is often no need 
to carry out repeat dosing and phages will 
disappear once the target is destroyed 
(Alisky et al., 1998). 
 
 Lack of pharmacokinetic data, making 
phage therapy risky (Parisien et al., 2008). 
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1.11    Prophage induction 
Treatments that damage cellular DNA or inhibit DNA replication can switch the 
prophage from a highly stable lysogenic state to a lytic state; this is called prophage 
induction (Janion, 2001). 
1.11.1  The cellular response   
The SOS (save our souls) response can be triggered by ultraviolet (UV) light, mitomycin 
C or another inducing agent. This response is designed to cope with any DNA damage, 
including that which happens during prophage induction, in order to repair the DNA and 
restore normal replication (Little, 1991). Prophage induction can be highly efficient at 
generating a high level of DNA damage, which leads to switching on the SOS response in 
all cells in a culture (Janion, 2001). However, switching takes place at a low rate in the 
absence of the DNA damage, which usually happens with spontaneous induction (Little, 
1991). 
The SOS regulatory system is controlled by two important proteins: LexA and RecA. The 
LexA protein acts as a repressor of SOS genes (there are about 40 of these genes in 
E.coli) during normal cell growth. Inducing treatments activate RecA, the major bacterial 
recombinase (Little, 2005). Little (1991) stated that inducing agents damage dsDNA, 
leading to the production of ssDNA, which works as an inducing signal for RecA, which 
binds to ssDNA. Binding leads to activation of RecA as a co-protease which then cleaves 
and inactivates LexA.  
 Page | 32 
 
In the induced state, activated RecA continues to mediate LexA cleavage, and SOS genes 
are also expressed at a high level. If the prophage is present, the phage repressor gene is 
also cleaved, resulting in phage induction in a form that catalyses the specific proteolytic 
cleavage of LexA, which results in de-repression of SOS genes due to inactivation of the 
LexA repressor function. This mechanism usually happens in the λ phage and other 
related phages (Little, 2005). In addition, prophage 186 is known to be induced by 
treatment with UV light. In this phage, the tum gene is under the control of the LexA 
repressor. After the induction of the SOS system and inactivation of LexA, prophage 
induction is initiated by permitting expression of the tum protein product. This protein 
acts as an antirepressor, antagonising the repressor of 185 cI, which will result in phage 
release (Lamont et al., 1989; Little, 2005). Other alternative mechanisms are also used, 
although some of the induction pathways are not well-understood (Little, 2005). 
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1.12    C. difficile phages identified to date 
A number of bacteriophages have been used successfully in the typing of C. difficile 
strains (Sell et al., 1983). Recently, there have been successful isolations of whole phages 
and purified phage components, with a number of temperate C. difficile phages having 
been isolated and observed by the use of electron microscopy (EM). These phages are 
classified into two families. Those of the Myoviridae family have an isometric capsid and 
a contractile tail, for example φCD5, φCD52, φCD119, φCD2, φC2, φCD27, φCD8, 
φCD630-1 and φCD630-2. In addition, prophages belonging to the Siphoviridae family 
have been isolated, for example φCD8-1, φCD8-2, φCD24, φCD38-1, φCD38-2, 
φCD6356 and φCD6365. This family has an isometric capsid and a long non-contractile 
tail (Table 1.2). 
However, only seven phages have been fully sequenced and annotated, these being 
φCD119, φCD2 , φCD27 , φMMP03 and φMMP04 from the Myoviridae family (Govind 
et al., 2006; Goh et al., 2007; Mayer et al., 2008; Meessen-Pinard et al., 2012 ) and two 
phages from the Siphoviridae family, namely φCD6356 (Horgan et al., 2010) and 
φCD38-2 (Sekulovic, et al., 2011).  
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Table 1.2. C. difficile phages identified so far. 
Phage Host 
strain 
Indicator 
strain(s) 
Family EM image Reference 
φCD119 CD119 C. difficile 
strains 602, 
660 and 460 
Myoviridae  
 
 
(Govind et al., 
2006; Govind et 
al., 2009) 
φCD27 NCTC 
12727 
NCTC 11204, 
11205, 11207 
and 11209 
Myoviridae 
 
 
(Mayer et al., 
2008)  
 
φCD630 1 
& 2 
 
 
CD630 
  
Myoviridae 
 
 
(Goh et al., 2007) 
 
φ56 
  
79 
 
Myoviridae 
 
 
(Mahony et al., 
1985) 
 
φCld 1 
   
Myoviridae 
 
 
(Sell et al., 1983) 
 
φ41 
  
36 
 
Siphoviridae 
 
 
 
(Mahony et al., 
1985) 
 
φC6 
 
CD371 
 
CD60 
 
Siphoviridae 
 
 
 
(Goh et al., 2005b ) 
   1                          2 
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Phage Host 
strain 
Indicator 
strain(s) 
Family EM image Reference 
 
φCD5  
 
φCD8-1  
 
φCD8-2  
 
 
φCD24  
 
φCD38-1  
 
φCD38-2  
 
φCD52  
 
CD5 
 
CD8 
 
CD8 
 
 
CD24 
 
CD38 
 
CD38 
 
CD52 
 
 
 
 
 
 
 
 
 
 
 
 
CD274 
 
Myoviridae  
 
Siphoviridae  
 
Siphoviridae 
 
 
Siphoviridae 
 
Siphoviridae 
 
Siphoviridae 
 
Myoviridae 
 
 
 
 
 
 
(Fortier and 
Moineau, 2007) 
 
 
 
 
 
(Sekulovic et al., 
2011) 
 
φC8 
 
CD371 
 
CD843 
 
Myoviridae 
 
 
(Goh et al., 2005b ) 
 
φC2 
 
CD242 
 
CD062 
 
Myoviridae 
 
 
(Goh et al., 2005b ) 
 
φC5 
 
CD578 
 
CD062 
 
Myoviridae 
 
 
(Goh et al., 2005b ) 
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Phage Host 
strain 
Indicator 
strain(s) 
Family EM image Reference 
 
φCD6356  
 
DPC6356 
 
DPC6365 
 
Siphoviridae 
 
(Horgan et al., 
2010) 
 
φCD6365 
 
DPC6365 
 
DPC6356 
 
Siphoviridae 
 
(Horgan et al., 
2010) 
φ001   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ002   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ013   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ014   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ015   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ020   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ027-1   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
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Phage Host 
strain 
Indicator 
strain(s) 
Family EM image Reference 
φ076   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ078   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ087-1   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ087-2   Siphoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ107   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ220-1   Myoviridae 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φ220-1   Siphoviridae 
 
 
(Nale et al., 2012 ; 
Shan et al.,2012) 
φMMP01 CD407 
 
CD19 Myoviridae 
 
(Meessen-Pinard et 
al., 2012) 
φMMP02 CD408 
 
CD117 Myoviridae 
 
(Meessen-Pinard et 
al., 2012) 
φMMP03 CD411 
CD368 
CD117 Myoviridae 
 
(Meessen-Pinard et 
al., 2012) 
φMMP04 CD412 
CD380 
CD73 Myoviridae 
 
(Meessen-Pinard et 
al., 2012) 
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1.13    Phages and their relation to hosts 
Phages may play an important role in infectious diseases. As a consequence of lysogenic 
infection, phages may add new properties to lysogen, especially with phages that carry a 
toxin gene or a drug resistance gene which may convert normally harmless bacteria into 
pathogens or make sensitive bacteria resistant (Grabow, 2001). Examples include 
pyrogenic exotoxin A production in group A streptococci (Johnson et al., 1986), cholera 
toxin production in Vibrio cholerae (Waldor and Mekalanos, 1996) and shiga toxin-
converting phages involved in the pathogenicity of enterohaemorrhagic Escherichia coli 
(Muniesa and Jofre, 1998). 
 
In terms of C. difficile, temperate phages have been induced, isolated and characterised 
from different C. difficile isolates with different ribotypes, including the hypervirulent 
strain 027 (Fortier and Moineau, 2007; Nale et al., 2012; Shan et al., 2012). Furthermore, 
the complete genome sequence of C. difficile strain CD630 has revealed that up to about 
11% of the genome is composed of mobile genetic elements including two highly related 
prophages (Sebaihia et al., 2006; Goh et al., 2007). These results have revealed that C. 
difficile strains often harbour lysogenic phages in their genome (Govind et al., 2009). 
However, to date, production of toxins in C. difficile has not been shown to be encoded or 
regulated by temperate phages. Furthermore, according to several studies, temperate 
phages have no ability to convert non-toxigenic strains to those capable of toxin 
production (Mahony et al., 1985; Goh et al., 2005a).  
 Page | 39 
 
However, preliminary results have shown that infection of toxigenic strains by some 
phages could modulate toxin A and/or toxin B production (Goh et al., 2005a; Govind et 
al., 2009). 
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1.14   Bacteriophage endolysins 
1.14.1   Introduction 
To date, lytic phages have not been isolated from C. difficile, although temperate phages 
have been isolated and characterised as described before (Table 1.2) .One of the major 
challenges faced by researchers seeking to isolate temperate phages is highlighted by the 
narrow host range of the phages which have been isolated from C. difficile, possibly due 
to high-frequency carriage of prophages (Mayer et al., 2008; Fortier and Moineau, 2007; 
Horgan et al., 2010; Nale et al., 2012) which can be attributed to the role of the system of 
clustered regularly interspaced short palindromic repeats (CRISPR) within these hosts     
(Deveau et al., 2008), which may be problematic for therapeutic applications (Mayer et 
al., 2008)  
This highlights the need to investigate the potential of bacteriophage endolysins as 
antimicrobial agents. This has been done by Mayer and his group, who managed to 
sequence the φCD27 genome, identify the gene code for its endolysin and sub-clone this 
gene into E. coli. This endolysin was found to be active against 30 different C. difficile 
strains, including the major epidemic ribotype 027(B1, NAP1). It has a broader host 
range than the phage itself (Mayer et al., 2008). 
Endolysins are dsDNA bacteriophage-encoded enzymes that are designed to attack the 
peptidoglycan bonds in the bacterial cell wall. They accumulate in the bacterial 
cytoplasm during a lytic infection cycle. At the terminal stage of the phage life cycle, 
lysins undergo holin-mediated translocation, which results in the cleavage of one of the 
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five major peptidoglycan bonds, thereby allowing progeny phage release after lysis of the 
cell wall (Fischetti, 2008). Muralytic or mureolytic enzymes, lysins, lysozymes or 
virolysins are the alternative names of these enzymes (Loessner, 2005; Courchesne et al., 
2009). Their lytic action is regulated by small hydrophobic proteins called holins. These 
proteins which are encoded by the phage target the cytoplasmic membrane and produce 
patches, allowing the endolysins to pass through these patches to access the 
peptidoglycan (Young and Bläsi, 1995). 
The most important thing that makes endolysins promising as potential antibacterial 
agents is their ability to act as exolysins that target and damage the cell wall rapidly when 
added exogenously (Borysowski et al., 2006). Current data shows that these kinds of 
enzyme only work with Gram-positive bacteria in vitro, since the outer membrane does 
not exist, as it does in Gram-negative bacteria, thus enabling them to directly target cell 
wall compounds. However, in Gram-negative bacteria, when the outer membrane is 
disrupted by, for example, detergents, cells immediately become sensitive to endolysins 
(Loessner, 2005). 
 
1.14.2   Structure 
Endolysins from Gram-positive bacteria bacteriophages usually have a classically 
modular structure (250–400 amino acids, 25-40 kDa) with an N-terminal enzymatic 
domain which encodes for peptidoglycan hydrolase activity and C-terminal binding 
responsible for the species specificity of the molecule, separated by a short linker 
(Fischetti, 2008; Loessner, 2005) (Figure 1.7). 
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The catalytic domain encodes the catalytic activity of the enzyme that can cleave one of 
the five major bonds in the bacterial cell wall peptidoglycan. These catalytic domains fall 
into one of five classes: Muramidase (lysozyme), Transglycosylase, Glucosaminidase, 
Endopeptidase and Amidase. For all endolysins reported to date, the majority appear to 
be amidases or muramidases (Fischetti, 2005). However, in rare cases, endolysins might 
have two or three different catalytic domains that link to one cell binding domain 
(Navarre et al., 1999).  
 
The cell wall binding domain at the C-terminus is responsible for binding species-specific 
carbohydrate epitopes in the cell wall, which offers a high degree of specificity. Catalytic 
domains in the lysin can be swapped, resulting in new activity against new targets 
(Fischetti, 2005). However, not all Gram-positive endolysins conform to this standard 
structure; for example, Gram-positive endolysins have been identified with only an N-
terminal enzymatic domain, such as T4 lysozyme (Matthews & Remington, 1974).  
 
  
N terminus 
Binding a species-
specific receptor in the 
cell wall 
Muramidase (lysozyme), 
Transglycosylase, 
Glucosaminidase, 
Endopeptidase and 
Amidase 
 
C terminus 
Catalytic domain Cell wall binding domain L 
Figure 1.7.   Modular structure of phage lytic enzymes. Image modified from Fischetti 
(2008). 
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Some possess two enzymatic domains, such as a pneumococcal phage Cpl-1 lytic enzyme 
which contains both muramidase and endopeptidase activity (Hermoso et al., 2003). 
Furthermore, an endolysin with three enzymatic domains has been described, 
staphylococcal phage187 lysin (Ply187), which contains an endopeptidase, an amidase 
and a glucosaminidase module (Cheng et al., 2005). 
  
In contrast Gram-negative endolysins are smaller as they only possess the N-terminal 
enzymatic domain. However, a few endolysins with a modular structure have been 
identified and all have inverted molecular orientations compared to Gram-positive 
endolysins, such as the KZ144 endolysin of the Pseudomonas aeruginosa bacteriophage 
phiKZ which has an enzymatic domain at the C-terminal and the binding domain at the 
N-terminal (Briers et al., 2007). Another type of inverted endolysin with two C-terminal 
binding domains has been identified, i.e. OBPgp279 endolysin of Pseudomonas putida 
phage OBP (Cornelissen et al., 2011). 
 
1.14.3   Mode of action 
The bacterial cell wall is essential to bacterial viability since it protects the cell from 
mechanical damage and lysis. In Gram-negative bacteria cell wall is relatively thin about 
10 nm and is composed of a single layer of peptidoglycan covered from the outside by 
the outer membrane. In contrast, Gram-positive bacteria, the cell wall is thick about 15-
80 nm and consist of several layers of peptidoglycan (Winn et al., 2006 Borysowski et 
al., 2006) (Figure 1.8). 
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The main building block in the cell wall is peptidoglycan, which is formed from linear 
chains of two alternating amino sugars, namely N-acetylglucosamine (GlcNAc or NAG) 
and N-acetylmuramic acid (MurNAc or NAM). These amino sugars are connected 
alternately by a β-(1,4)-glycosidic bond. Each N-acetylmuramic acid unit is attached to a 
short amino acid chain (four to five residues), usually consisting of L-alanine, D-glutamic 
acid, either meso-diaminopimelic acid in Gram-negative bacteria or L-lysine in Gram-
positive bacteria, and D-alanine (Barer, 2007). Adjacent tetrapeptides are cross-linked by 
interpeptide bridges in Gram-positive bacteria or by interpeptide bonds in Gram-negative 
bacteria (Figure 1.9). 
Holins target the cytoplasm by making pores that allow endolysin to pass through 
peptidoglycan (Loessner, 2005). According to the catalytic domain structure, endolysin 
will target a specific bond in the cell wall. As can be seen in Figure 1.9, N-acetyl-β-D-
muramidase (or lysozyme) targets the β-1,4-O-glycosidic bond between C1 of N-
acetylmuramic acid (MurNAc) and C4 of N-acetylglucosamine (GlcNAc), whereas N-
acetyl-β-D-glucosaminidase cleaves the β-1,4-O-glycosidic bond C1 of GlcNAc and C4 
of MurNAc. N-acetylmuramoyl-L-alanine amidases cleave the amine bond between L-
alanine in the peptide chain and MurNAc. Endopeptidases cleave the peptide moiety 
(Borysowski et al., 2006). 
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 Figure 1.8.   Schematic representation of the cell wall of Gram-positive and Gram-
negative bacteria. Picture modified from Barer (2007). 
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  GlcNAc   MurNAc   GlcNAc   MurNAc 
  GlcNAc   MurNAc   GlcNAc   MurNAc 
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Figure 1.9. Bacterial cell wall peptidoglycan structure and sites of cleavage by various 
endolysins: N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), L-alanine (L-
Ala), D-glutamic acid (D-Glu), meso-diaminopimelic acid (m-DAP), L-lysine (L-Lys) and D-
alanine (D-Ala). Picture is modified from Borysowski et al. (2006) 
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1.14.4   Therapeutic applications 
Examples of the basic applications of endolysins as therapeutic agents include the 
elimination of bacterial colonisation of mucous membranes, for example the elimination 
of upper respiratory colonisation in mice by group A. streptococci (Nelson et al., 2001) or 
S. agalactiae, which colonises the human genitourinary tract and lower gastrointestinal 
tract (Cheng et al., 2005; Borysowski et al., 2006). 
 In terms of the treatment of bacterial infections, the first attempt was made by using B. 
anthracis phage γPlyG amidases which were found to lyse B. anthracis, and a single 
strain of B. cereus that is closely related to B. anthracis (Schuch et al., 2002). Another 
example of a medical lysin application is the treatment of pneumococcal bacteraemia in 
mice by Cpl-1 and Pal endolysins (Jado, 2003). In addition, a recent study showed that 
the lysin of bacteriophage CD27 has the ability to lyse C. difficile cells in vitro,  also, the 
host range of the endolysins is significantly broader than that of the phage itself (Mayer 
et al., 2008). Furthermore, lysins can be used for biocontrol of bacteria in food and feed, 
as well as in the protection of plants against phytopathogenic bacteria (Loessner, 2005). 
There are several unique features that make endolysins very promising antibacterial 
agents, including their specificity for pathogens without affecting normal microbiota, 
relatively easy manufacturing and modification by genetic engineering, the low chance of 
developing resistance and the fact that they can be identified and isolated from both lytic 
and temperate phages (Borysowski et al., 2006). However, endolysin therapy is not 
without disadvantages, especially since their actions have only been described against 
Gram-positive bacteria. Also, since they are proteins, they have short half-lives and are 
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susceptible to inactivation (Fischetti, 2008). Research into lysin dosage will be required 
in the future because they are not self-replicating (O'Flaherty et al., 2009). Furthermore, 
it is unlikely that they can be used against intracellular bacteria that require entrance to 
the cells, since they are proteins (Fischetti, 2008).  
 
1.15   Holins 
In phage λ, which presents the best characterised example of a holin-endolysin system, 
the holin gene (S) and the endolysin gene (R) are located at the beginning of the late 
transcriptional unit (Young et al., 2000). During late gene expression, holins are believed 
to accumulate in the cytoplasmic membrane as oligomers until a trigging event occurs 
that results in membrane lesions (Gründling et al., 2001; Wang et al., 2003). 
 
Holins are small phage proteins. Most holin sequences are short (about 160-145 amino 
acid residues) with a highly hydrophilic carboxyl terminal domain (Young et al., 2000). 
Holins are classified into three classes based on their membrane topology. Class І holins, 
such as the holin S of λ phage, (about 95 residues or longer) have three potential 
transmembrane domains (TMDs), while class ІІ holins are usually small (about 65-95 
residues) with two TMDs and class ІІІ holins have only one TMD (Young, 2002). 
 
Holins can be regulated by inhibitors, known as antiholin, which usually transcribed from 
the same reading frame as holin (Loessner, 2005). After lysis, antiholin which exist in the 
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cytoplasm (as in T4) or bound to the inner membrane (as with λ) or); binds and 
inactivates the holin, producing an inactive holin-antiholin dimer (Young et al., 2000). 
In all phages tested to date, endolysin needs holin, except in some phages of Gram-
positive bacteria where the endolysins use the host sec system to achieve their goals. For 
example, the endolysin of fOg44, a phage of the Gram-positive bacteria Oenococcus 
oeni, causes lysis of the host without a holin when endolysin undergoes leader peptidase 
cleavage of its signal sequence (Sao-Jose et al., 2000). The endolysin of Lactobacillus 
plantarum phage φg1e (Kakikawa et al., 2002) works in a similar fashion. Furthermore, 
some phage sequences have revealed that no holin encoding genes are located upstream 
of endolysin genes; therefore, these lysins may pass through the cytoplasmic membrane 
via a holin-less mechanism, such as in the B. cereus phages Bastille, TP21 and 12826 
(Loessner et al., 1997 ; Borysowski et al., 2006) and the Listeria monocytogenes phage 
A511 (Loessner et al., 1995 ; Borysowski et al., 2006). 
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1.6   The Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) System  
1.16.1   Introduction 
Various strategies have been developed by different microbial species to tackle exposure 
to different viruses and other foreign DNA and to allow cells to differentiate between the 
host genome and foreign genomes. These systems maintain genetic integrity and allow 
foreign DNA to be taken and used in ways that will help the organism to adapt to the 
environment and gain resistance to these elements (Horvath and Barrangou, 2010). 
Strategies such as prevention of adsorption, blocking of injection and aborting infection 
are effective against viruses, and restriction modification systems (R-M) and the use of 
sugar non-specific nucleases are also effective defence systems against invading nucleic 
acids (Karginov and Hannon, 2010). 
 An adaptive microbial immune system has recently been described that provides 
acquired immunity against viruses and plasmids. This system is known as the clustered 
regularly
 
interspaced short palindromic repeats (CRISPR) system (Barrangou et al., 
2007). These repeats are a diverse family of DNA repeat sequences found in the DNA of 
many Bacteria (about 40%) and Archaea (about 90%) (Kunin et al., 2007). The first 
description was provided in 1987 by Ishino and colleagues, who found 14 repeats of 29 
base pairs (bp), interspersed by 32-33 bp non-repeating spacer sequences, in E. coli. 
Subsequently, similar CRISPR arrays have been found in Mycobacterium tuberculosis 
(Hermans et al., 1991) and other bacteria. Mojica and colleagues were the first group to 
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describe the presence of short regularly spaced repeats in prokaryotes (Mojica et al., 
2000), which was subsequently incorporated into the CRISPR name (Jansen et al., 2002). 
 
1.16.2   Structure 
The CRISPR system is formed from CRISPR arrays and CRISPR-associated sequences 
(CAS). As can be seen in figure 1.10, the CRISPR system consists of repeats, spacers, a 
leader and CAS genes. 
 
 
 
Repeats 
The size of a repeat can vary between 24 and 47 bp. The number of repeats per array can 
vary from 2 to 249. Within a single array, the repeat sequences are highly conserved in 
terms of size and sequence (Jansen et al., 2002). 
 
Repeats 
Spacers 
Leader 
CAS genes 
Figure 1.10.  Typical structure of a CRISPR locus. Image modified from Sorek et 
al. (2008). 
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Spacers  
 Spacers usually have a size between 26 and 72 bp. Mojica et al. (2005) showed that 
CRISPR spacer sequences derive either from mobile genetic elements  such as 
conjugative plasmids and bacteriophages or chromosomal sequence  
Leader  
The leader is the sequence that is located between the repeats and CAS genes. This 
sequence is usually up to 550 bp long (Jansen et al., 2002). The leader sequence seems to 
be conserved between several CRISPR loci in the same chromosome; however, it is not 
conserved between species (Sorek et al., 2008). The leader could function as a 
recognition sequence since a new repeat-spacer unit is always added between the leader 
and the previous unit in a CRISPR array (Sorek et al., 2008) and likely acts as the 
promoter for the transcription of CRISPER array since it is found directly upstream of the 
first repeat (Lillestøl et al., 2006; van der Oost et al., 2009). 
CRISPR-Associated Sequence (CAS) Genes 
These are a large set of gene families that are always found adjacent to the leader 
sequence. Six “core” CAS genes have been identified, including cas1, which is regarded 
as a universal marker of the CRISPR/CAS system. Furthermore, six or fewer CAS genes 
are usually present in a CRISPR system, but some may have up to 20 CAS genes (Haft et 
al., 2005; Sorek et al., 2008). CAS genes encode for proteins that carry nucleic acid-
related domains such as nucleases and helicases, and are involved in nucleotide binding 
(Barrangou and Horvath, 2009).  
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In general, single CRISPR loci are usually present in one genome; however, some 
organisms may have more than one, such as Methanococcus jannaschii which has 18 loci 
(Bult et al., 1996; Sorek et al., 2008). 
Mobile genetic elements, such as plasmids, skin mobile elements and prophages, have 
been found to carry CRISPR and CAS elements, which may suggest the role of these 
elements in the distribution of this mechanism (Godde and Bickerton, 2006). Regarding 
the roles of CRISPRs, several hypotheses have been suggested, such as the role of 
CRISPRs in DNA repair, since DNA manipulating domains are found in many CAS gene 
contents (Makarova et al., 2002). It has been suggested that the CRISPR-CAS system 
mediates immunity against foreign genomes by means of an RNA interference-like 
mechanism, since there are many similarities between the spacer and extrachromosomal 
DNA, such as phage or plasmid DNA (Mojica et al., 2005; Pourcel et al., 2005 ; Bolotin 
et al., 2005; Sorek et al., 2008). 
Barrangou and colleagues (2007) recently showed that CRISPRs provide acquired 
resistance against viruses in prokaryotes, after showing that new spacers that were 
acquired after phage infection give resistance against the phage (Barrangou et al., 2007; 
Kunin et al., 2007). Furthermore, in 2008, Marraffini and Sontheimer showed a CRISPR 
system that prevented conjugation and plasmid transformation in S. spidermidis 
(Marraffini and Sontheimer, 2008). 
A CRISPR-CAS mechanism that provides immunity against foreign genetic elements 
after acquisition of the novel spacer that is derived from these elements is not fully 
characterised. As can be seen in figure 1.11, in a sensitive cell following plasmid 
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transformation or infection by a phage, exogenous DNA proliferates in the cell and either 
new phage particles are produced, leading to the death of the bacterial cell, or there is 
production of a new cell that carries the plasmid DNA. However, bacterial cells become 
resistant after integration of a novel spacer unit, from the exogenous DNA, at the leader 
end of the CRISPR locus. In this immunisation process, the repeat-spacer array is 
transcribed into a poly-spacer precursor crRNA (pre-crRNA), then pre-crRNA sequences 
are recognised and processed by the CAS complex to produce mono-spacer crRNAs 
which contain a spacer and two half repeats. Mature crRNA is used by the CAS complex 
to base pair with invading nucleic acids, leading to their inactivation and degradation 
(Sorek et al., 2008; Horvath and Barrangou, 2010). 
It has been reported recently that the proto-spacer adjacent motif (PAM) sequence plays a 
role in CRISPR-encoded resistance. Previously, this motif was proposed as playing a role 
in the recognition or cleavage of a phage sequence by the CRISPR system (Sorek et al., 
2008). This motif sequence is a short sequence found in the phage genome located 
downstream of the proto-spacer. A mutation in either the proto-spacer or the adjacent 
motif allows a phage to bypass the CRISPR-CAS defence mechanism, which strongly 
indicates the involvement of the motif in resistance (Deveau et al., 2008). 
CRISPR loci provide useful applications that include strain typing, such as the 
Spoligotyping  method (Kamerbeek et al., 1997), and engineering of industrial bacteria 
for resistance to phage infection, by inserting a known sequence from a phage into a 
CRISPR array as a spacer (Sturino and Klaenhammer, 2006; Sorek et al., 2008). 
However, phages can circumvent CRISPR-encoded immunity and continue to infect host 
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cells. This happens when the phage develops mutations either in the proto-spacer 
(mutation, insertion or deletion) or in the CRISPR motif (point mutation), or there is 
large-scale deletion of both the proto-spacer and CRISPR motif (Barrangou and Horvath, 
2009). 
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Figure 1.11. Putative  model for CRISPR action ; CRISPR structure (A), normal 
mechanism without the CRISPR system (B) and an overview of the CRISPR/CAS 
mechanism of action (C). Diagram is modified from Sorek et al., (2008) and Horvath and 
Barrangou (2010).  
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                 1.16.3   CRISPR sequences in the C. difficile 
Sebaihia et al. (2006) identified a number of CRISPR sequences in the C. difficile 630 
genome. Table 1.3 presents these sequences and their positions. Furthermore, some of 
these sequences were also found within a C. difficile 630 prophage, which may explain 
the role of phages in using CRISPR to prevent super-infection by other phages (Sebaihia 
et al., 2006). In addition, this may explain the rarity of C. difficile as a strain that is 
sensitive to the temperate phages that have been isolated so far (Mayer et al., 2008). 
Interestingly, the sequences from different CRISPR regions have homology with some 
sequences from C. difficile φC2, φCD119 and φCD27, as shown in table 1.3. 
Table 1.3. The different CRISPR sequences in C. difficile 630 
 
CRISPR Coordinates Number 
of repeats 
Genomic 
location 
*Homology with C. difficile 
phages 
CRISPR1 1124036-1125688 9 Prophage 1 φC2 & ΦCD119 
CRISPR2 1433859-1435639 14 Mobile element φCD119 
CRISPR3 1644671-1645952 12 Mobile element φC2 
CRISPR4 1756116-1756833 9 Chromosome φCD119 
CRISPR5 1935320-1936495 16 Chromosome φCD27 
CRISPR6 2298609-2298929 3 Chromosome  
CRISPR7 2662916-2665492 15 Mobile element φC2, φCD119 & φCD27 
CRISPR8 2907464-2908427 7 Mobile element φC2 & φCD119 
CRISPR9 3396953-3398605 10 Prophage 2  
CRISPR10 3455612-3456944 18 Chromosome φCD27 
*all the information in the table was taken from Sebaihia et al. (2006), except for this column 
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      1.17   Aims and objectives 
The aims of this research are as follows:  
 To isolate lytic phages which could be used for the treatment of C. difficile 
 To isolate phage lysins which could be used for the treatment of C. difficile 
 To understand the role of phages in the evolution of C. difficile 
 To isolate the spore lysins that can target C. difficile spores 
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Chapter Two 
 
General materials and methods 
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2.1   Microbiological materials and methods 
2.1.1   Growth and sporulation media 
Cycloserine-Cefoxitin-Fructose Agar (CCFA), Clostridium difficile Moxalactam 
Norfloxacin (CDMN) agar and Brain Heart Infusion (BHI) media were purchased from 
Oxoid (Basingstoke, UK). Luria-Bertani (LB) agar and broth were purchased from Fisher 
Scientific (Leicestershire, UK), while Listeria selective agar was obtained from Sigma-
Aldrich (Gillingham, UK). Culture media were prepared according to the manufacturer’s 
instructions and sterilised by autoclaving at 121°C for 15 minutes (Prestige Medical, 
UK). To make up CCFA and CDMN agar plates, the  media was cooled to 50°C prior to 
the addition of  Clostridium difficile supplement antibiotic (Oxoid, Basingstoke, UK) and 
7% (v/v) Defibrinated Horse Blood (Oxoid, Basingstoke, UK).  Prior to culture, agar 
plates and broth were incubated at 37°C for 24 hours in an anaerobic cabinet (Ruskinn 
Technology Ltd) containing an anaerobic environment, consisting of 85% N2, 10% CO2, 
and 5% H2 to facilitate the removal of dissolved oxygen. Inoculated cultures were 
incubated at 37°C for 48 hours in an anaerobic workstation (Ruskinn Technology Ltd).  
 
2.1.2   Bacterial strains 
Ninety four isolates of Clostridium difficile, eleven isolates of Clostridium perfringens 
and individual strains of diverse clostridia species and aerobic strains were kindly 
donated by the Anaerobe Reference Laboratory, University Hospital of Wales, Cardiff.  
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National Collection of Type Culture (NCTC) strains were purchased from the Health 
Protection Agency Culture Collection (Health Protection Agency, Colindale). E. coli 
recombinant protein host strains M15[pREP4] and SG13009[pREP4] were supplied by 
QIAexpress Type IV Kit (Qiagen Ltd, Crawley, UK). Details of these strains are noted in 
table 2.1 and 2.2. 
Table 2.1: The C. difficile isolates used in this study  (Appendix 1) 
C. difficile ribotypes Strain 
001 DS1759 - DS1747- R8652- DS1750-  R17752 
027 DS1813- DS1801- R20291 -DS1807-R24626 
106 R10459 -DS1798 -DS1787- DS1771 -R28614 
014 DS1742 -R30061- R22537 -R31755-R31757 
002 DS1748 -R25577 -R27039 -R31760-R31763 
005 DS1721 -R27038 -R25028- R31762- R31778 
012 DS1752-R31771-R31080-R30904-NCTC 13307 (CD630) 
078 DS1723-R19058-R31710-R31708-R31777 
020 DS1724-R31774-R31550-R31464-R31502 
010 DS1684-R31750-R31722-R30762-R30327 
023 DS1665- R15552-R31377-R31148-R31314 
017 R9557 -R13695 –R18091- R2139- R19222 
047 R10542- R18045-R25961-R17732-R10543 
056 R24498- DS2008 -R26796-R31312-R31229 
110 R7771- R17978-R30967-R18040-R17985 
046 R19168-R31583-R31263-R30869-R30870 
045 R20408-R30776-R28450-R30072-R27086 
NCTC (001) NCTC 11204 - NCTC 12727-  NCTC 11209 
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Table 2.2: The bacterial isolates used in this study 
Bacterial species Strain 
C. perfringens R31707,R31837,R31599,R31737,R31745,R31885,R31973,R31782,R
31936, R31972- NCTC 8359 (ATCC 12915) 
Other Clostridium strains Clostridium sordellii  R20453,   Clostridium septicum R22030, 
Clostridium novyi  R14479   
Aerobic species Listeria monocytogenes (NCTC 5412), Micrococcus luteus NCTC 
2665 (ATCC 4698), Bacillus subtilis NCTC 10400 (ATCC 6633 ), 
Staphylococcus aureus NCIMB 9518 (  NCTC 10788) , E. coli 
strains M15(pREP4) and SG13009 (pREP4) 
 
 
2.1.3   Culture and growth conditions of anaerobic bacterial strains 
Individual C. difficile isolates were recovered from spore stocks and introduced to pre-
reduced BHI and CDMN agar plates using the direct streak method, in which 10 μl of 
spore suspension was streaked across the surface of an agar plate using a sterile loop 
(Fisher Scientific, Leicestershire, UK). The inoculated plate was incubated anaerobically 
for 48 hours at 37°C.  
Freeze-dried NCTC bacterial strains were recovered using the method recommended by 
NCTC (How to Handle Bacteria and Fungi on Receipt at 
http://hpacultures.org.uk/technical/Howto Handle Bacteria.jsp; accessed on 05-2009).  
Between 0.3 and 0.4 ml of pre-reduced BHI broth was added aseptically to the freeze-
dried material, using a Pasteur pipette, and mixed. The mixture was transferred to a 5 ml 
pre-reduced BHI broth and an aliquot was subsequently spread across a BHI agar plate. 
All cultures were incubated at 37°C anaerobically for 48 hours. 
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To recover cultures of non-difficile anaerobic strains, protect beads were passed over the 
surface of a pre-reduced BHI agar (enriched with 5% w/v Defibrinated horse blood). 
Plates were incubated anaerobically for 24-48h at 37°C. 
All anaerobic cultures were performed  in a gloveport Bugbox Plus anaerobic workstation 
(Ruskinn Technology Ltd). The anaerobic environment consisted of 85% N2, 10% CO2, 
and 5% H2.  Disposable anaerobic indicator strips (Oxoid, UK) were replaced daily to 
ensure that a strict anaerobic environment was maintained. The temperature of the 
workstation was set at 37°C.  
 
2.1.4   Culture and growth conditions of aerobic bacterial strains  
E. coli host strains M15 and SG13009 were grown on Luria-Bertani (LB) agar 
supplemented with ampicillin (100 μg/ml) at 37°C for 24h; subsequently distinct colonies 
were re-suspended  and stored frozen at -80°C  using Protect™ vials (Technical Service 
Consultants, Heywood, UK)  
Transformed E. coli M15 and SG3009, which was used throughout as a cloning host, 
were routinely cultured using (LB) broth or agar, as appropriate, at 37°C, with 300 rpm 
shaking for liquid cultures. Media was supplemented as appropriate with kanamycin (25 
μg/ml) and ampicillin (100 μg/ml) (Sigma-Aldrich, Gillingham, UK). Listeria 
monocytogenes (NCTC 5412) was cultured aerobically on Listeria selective agar at 37°C 
for 48h. Micrococcus luteus (NCTC 2665), Staphylococcus aureus (NCTC 10788) and 
Bacillus subtilis (NCTC 10400) were grown in BHI agar aerobically at 37°C for 24 h.  
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2.1.5   Freezer cultures 
Freezer cultures of all strains were prepared as follows: 850 µl of a 48 h. broth culture 
was added to 1.5 ml cryogenic vials (Fisher Scientific, Leicestershire, UK) along with 
150 µl of glycerol. The vials were vortexed and stored at -80°C. 
Freezer cultures of all strains were also prepared by using Protect™ vials containing 
cryopreservative fluid and porous beads. One ml of the 48 h broth culture was added to 
each of the vials, which were vigorously shaken; the residual liquid was removed using a 
sterile Pasteur pipette, after which the vials were stored at -80°C. 
 
2.1.6   C. difficile spore production 
 A single colony from a 48 h BHI agar plate culture was sub-cultured into 45 ml of pre-
reduced BHI broth (50ml Falcon tube) and incubated anaerobically for 10 days at 37°C. 
At the end of this period, spores were extracted using two modified methods. 
 In the first method, the  broth was centrifuged at 4,000xg for 15 minutes at room 
temperature (Heraeus Primo, Thermo Scientific, UK). The supernatant was discarded and 
the pellet was washed twice with 10 ml of chilled sterile deionised water (SDW). The 
washed pellet was re-suspended in 1 ml of SDW and heated for 10 minutes at 80°C in a 
water bath (Fisher Scientific, Leicestershire, UK) to inactivate any vegetative cells. The 
spore suspension was then centrifuged at 4,000xg for a further 5 minutes at room 
temperature and finally re-suspended in 1 ml of SDW and stored at 4°C until needed.  
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To confirm purity, spore suspensions were cultured on the pre-reduced BHI plate to 
assess purity. This method was modified from that described by Perez et al. (2005).   
The second spore preparation method is based on a technique for purifying C. difficile 
630 spores that was originally described by Lawley et al. (2009). The spores were 
harvested by centrifugation at 5,000xg for 15 minutes (Heraeus Primo, Thermo 
Scientific, UK) and were re-suspended in 10 ml of sterile water. The samples were then 
washed four to six times in water, during which the supernatant became clear. The 
samples were then pelleted and re-suspended in 30 ml of PBS (Fisher Scientific, 
Leicestershire, UK) prior to sonication (four times) with second 30  bursts at an 
amplitude of 12 using a Soniprep 150 ultrasonic disintegrator (Sanyo, Leicester, UK). 
Following sonication, 3 ml of 10% Sarkosyl (Fisher Scientific, Leicestershire, UK) was 
added to the sample, which was then incubated at 37°C for 1 hour. The samples were 
then pelleted by centrifugation at 4,000xg for 10 minutes, after which the pellet was re-
suspended in 10 ml of PBS containing 0.125 M Tris buffer pH 8 (Fisher Scientific, 
Leicestershire, UK) and 10 mg/ml lysozyme (Roche, Germany) before being incubated 
overnight at 37°C. The samples were then sonicated as described above, and 3ml of 1% 
Sarkosyl was added to the sample prior to incubation for 1 hour at 37°C.  The samples 
were then layered on to 50% sucrose (Fisher Scientific, Leicestershire, UK) and 
centrifuged for 20 minutes at 4,000xg. The pellets were re-suspended in 2 ml of PBS 
containing 200mM EDTA, 300 ng/ml Proteinase K (recombinant PCR grade; Roche,  
Germany), and 3 ml of 1% Sarkosyl, before being incubated for 1 to 2 hours at 37°C until 
the samples cleared. The samples were then layered on to sucrose as described above.  
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The pellets were re-suspended in water and were washed twice prior to re-suspension in 
sterile water. The resulting spore suspensions were plated on the pre-reduced BHI plate to 
assess purity, and then stored at 4°C until needed. 
 
2.1.7   Viable count for spores and bacterial cells 
 The spore/bacterial cell suspensions were diluted by adding 100 µl of the stock 
suspension to 900 µl of BHI broth, creating a 10
-1
 dilution. Five further 10 – fold serial 
dilutions were made i.e. to a 10
-6
 dilution. The dilutions were then used to perform viable 
counts using a drop count method (Miles and Misra, 1938), in which three 10 µl drops of 
each dilution were applied to pre-reduced BHI agars, three plates being prepared for each 
dilution. The plates were left to dry and then inverted and incubated anaerobically at 37°C 
for 48 hours. The colony forming units (CFUs) present in dilution, which contained 
between 3 and 30 CFUs, were counted after 48 hours and used to calculate the number of 
CFU/ml, using the following formulae: 
Mean number of colonies x dilution factor = CFU/10µl 
CFU/10µl x 100 = CFU/ml 
This technique was validated by performing 10 separate dilution series, as described 
above, and statistically analysing the results using a one-way ANOVA in the Minitab 
Statistical Software Package (release 14 software, Minitab Inc., PA, USA) to ensure that 
there were no statistically significant differences in the results. Validation was deemed 
successful when the p-value ≥0.05. 
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2.1.8   Identification of C.difficle 
 
2.1.8.1  Colony morphology 
On media colonies are typically cream in colour, irregular, lobate or rhizoid edges, a fried 
egg appearance can be seen due to spore formation (Figure 2.1). Furthermore, the horse 
manure odour that is associated with C. difficile colonies is very distinctive and may give 
a quick and easy aid to identification. In addition, the ability of colonies to give a golden-
yellow fluorescence under long-wave ultraviolet light is a very useful and recommended 
approach for C. difficile detection (Aspinall and Hutchinson, 1992 ; Brazier and 
Borriello, 2000). 
Figure 2.1 shows the colony morphology of C.difficile NCTC 12727 on BHI agar and 
CDMN agar plates after 48 hours incubation  
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Figure 2.1.  Colony morphology of C.difficile NCTC 12727 on BHI agar (A,B) and CDMN 
(C,D) agar plates, incubated anaerobically for 48 hours at 37°C 
 
 
2.1.8 .2 Gram stain 
All Gram stain dyes were supplied by Fisher Scientific, Leicestershire, UK. 
The Gram stain technique, which was developed by Hans Christian Gram in 1884, is used 
to classify bacteria on the basis of their forms, sizes, cellular morphologies, and Gram 
reactions (Winn et al., 2006).  
A B 
C D 
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A drop of suspended culture was transferred on to a glass slide using an inoculation loop. 
If the culture was from a Petri dish, a minute amount of a colony was smeared with a 
drop of water and allowed to air dry; the slide was then flooded with crystal violet for 1 
minute and washed with distilled water. Gram’s iodine was then added for 1 minute and 
the slide was washed again with distilled water. The slide was then decolorised with 95% 
ethanol for 10 seconds and washed with distilled water. Finally the slide was 
counterstained with safranin for 1 minute and rinsed with water (Winn et al., 2006). To 
remove excess fluid, the slides were blotted with a disposable towel and examined under 
the 100x oil immersion objective of an Olympus DX-50 microscope, the images being 
captured on an Olympus DP10 camera.  
C. difficile is a Gram-positive bacillus with rounded or sometimes pointed ends, as can be 
seen in figure 2.2.    
 
Figure 2.2.  Gram stain of C. difficile showing Gram-positive bacilli often arranged in pairs 
or short chains 
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2.1.8 .3   Spore stain  
Spore stain solutions were supplied by Fisher Scientific, Leicestershire, UK. 
A one  colony (~ 2-3mm) was smeared onto a microscope slide with a drop of water and 
allowed to air dry, and the slides were then flooded with malachite green. The slides were 
heated from below with a Bunsen flame until steam was seen to rise from the stain, then the 
slides were left for 1 minute before being washed with distilled water and counterstained 
with safranin dye for 15-30 seconds (Schaeffer and Fulton, 1933) and washed with distilled 
water. The slides were blotted dry and examined under the 100x oil immersion objective of 
an Olympus DX-50 microscope, with the images being captured on an Olympus DP10 
camera. 
The Spore stain of C. difficile illustrates the brownish red vegetative cells with a few 
interspersed green spores (Figure 2.4). Spores are usually detected after 48 hours of 
incubation.  
 
Figure 2.3.  Spore stain of C. difficile illustrating the brownish red vegetative cells with a 
few interspersed green spores 
 
 
VG VG +green spores 
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2.1.8.5   Latex agglutination 
The latex agglutination test is rapid and easy to perform, but the test detects only bacterial 
antigens such as glutamate dehydrogenase (GDH) by using latex particles coated with 
antibody. However, this test detects both toxigenic and nontoxigenic strains of C. difficile 
(DiPersio et al., 1991). In this study latex agglutination test (Oxoid, Hampshire, UK) 
were used. 
 
2.2   Molecular biological materials and methods 
2.2.1   Identification of restriction enzyme sites in primary gene sequence 
The NEBcutter v2.0 program (http://tools.neb.com/NEBcutter2 ) was used to determine 
the presence of restriction enzyme sites in a particular nucleotide sequence. The gene 
sequences of all of the genes which were cloned and expressed as recombinant proteins 
were analysed against all commercially available restriction enzymes (single, double and 
triple cutter enzymes).  Restriction enzyme sites which were also present in the cloning 
vector pQE30 were identified and removed. To facilitate cloning into the vector, BamH1 
(GGATCC) and SalI (GTCGAC) sites were incorporated into the 5’ and 3’ primer ends 
of the gene insert 
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2.2.2   Codon optimisation  
The genetic code employs 61 nucleotide triplets (codons) to represent 20 amino acids and 
three codons for translation termination, meaning that a single amino acid can be encoded 
by more than one codon, with alternate codons for the same amino acid being referred to 
as synonyms or synonymous (Swartz, 2001; Gustafsson et al., 2004).  Synonymous 
codons frequently vary at the third codon position by one nucleotide, and a subset of the 
cell’s transfer ribonucleotide acid molecules (tRNA) are able to recognise each of these 
codons.  
Indeed, according to Zdanovsky and Zdanovskaia (2000), many clostridial proteins are 
poorly expressed in E. coli because the codons that are commonly used in clostridial 
coding sequences are rarely used in E. coli, and the quantities of the corresponding 
tRNAs in E. coli are not sufficient to support efficient translation.    
Fortunately, with modern molecular biology methods it is now possible to modify the 
codon composition of a gene so that it more closely matches that of the host bacteria, 
resulting in an increased level of expression of the protein of interest (Makoff et al., 
1989).  
To enhance expression from E. coli the nucleotide sequence of each endolysin codon was 
optimised using a commercial algorithm (Genscript Inc., USA). Optimised sequences 
were then chemically synthesised and cloned into the vector pUC57, after which they 
were sub-cloned into the QIAgen high level inducible protein expression system (pQE 
30)  using the BamHI and Sa1I sites so that expression of the insert was placed under the 
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control of the T5 promoter and so that each endolysin sequence was fused to an N-
terminal  histidine tag (Figure 2.4). The correct orientation and fidelity of each coding 
sequence following insertion was confirmed by DNA sequencing.  
 
Figure 2.4.  pQE 30 vectors for N-terminal 6xHis tag constructs  
PT5: T5 promoter - Optimised promoter/operator element consists of the phage T5 promoter and 
two lac operator sequences, which increase the probability of lac repressor binding and ensure 
efficient repression of the powerful T5 promoter; RBS: Ribosome-binding site -  Synthetic 
ribosomal binding site RBSII for efficient translation; Stop Codons: Translational stop codons in 
all three reading frames for convenient preparation of expression constructs; Ampicillin 
resistance: beta-lactamase gene (bla) confers ampicillin resistance; 6xHis tag sequence: 6xHis-
tag coding sequence either 5' or 3' to the poly-linker cloning region; Col E1: Col E1 origin of 
replication from pBR322 - Two strong transcriptional terminators from phage lambda, and 
T1from the rrnB operon of E. coli, to prevent read-through transcription and ensure stability of 
the expression construct; lac O: lac operator; ATG: Start codon; MCS: Multiple cloning site 
(Qiagen Ltd, Crawley, UK). 
pQE 30 
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An aliquot of 4 μg of each construct was provided by Genscript in a lyophilised form 
which was stored at -20°C. To reconstitute this sample, the tube was centrifuged at 
6,000xg for 1 minute (Eppendorf 5417R centrifuge, fixed angle rotor F45-30-11, UK). A 
20 μl aliquot of sterilised distilled water was added and the vials were vortex mixed for 1 
minute. 
 
2.2.3   Preparation of competent cells 
The QIA express system provides two strains of E. coli: M15, which supports high-level 
expression and is easy to handle, and SG13009 (Gottesman et al., 1981), which can be 
used to express proteins that are poorly expressed in M15.  
Both the M15 and SG13009 strains are derived from E. coli K12 (DH5α strain) and have 
the phenotype NaIS, StrS, RifS, Thi–, Lac–, Ara+, Gal+, Mtl–, F–, RecA+, Uvr+, Lon+. 
The E. coli host strains M15and SG13009 were grown on LB agar supplemented with 
ampicillin (100 μg/ml) at 37°C for 24h; subsequently, distinct colonies were re-
suspended and stored frozen at -80°C in the Protect™ microbial preservation kit.  
An aliquot of M15 or SG13009 cells from a Protect™ vial was taken with a sterile 
toothpick or inoculating loop and streaked out on an LB agar plate containing 25 μg/ml 
kanamycin and incubated at 37°C overnight, aerobically. A single colony of M15 or 
SG13009 was  subsequently inoculated into 10 ml LB broth containing kanamycin (25 
μg/ml) and grown overnight at 37°C and 300 rpm (Max 4450, Thermo Scientific, UK). 
One ml of  this culture was then added to 100 ml of pre-warmed LB-kanamycin and  
incubated at 37°C and 300 rpm until an absorbance  of OD600 0.5 (Ultra spec 3100 pro, 
GE Healthcare) was achieved.  
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The culture was cooled on ice for 5 minutes prior to centrifugation at 4,000xg for 5 
minutes at 4°C (Heraus Primo R, Thermo Scientific, UK). The cells were gently re-
suspended in cold TFB1 buffer (100 mM RbCl, 50 mM MnCl2, 30 mM potassium 
acetate, 10 mM CaCl2, 15% glycerol, pH 5.8, sterile filter), and placed on ice for 90 
minutes. The cells were centrifuged as above, the supernatant was discarded, and then the 
pellet was gently re-suspended in ice-cold TFB2 (10 mM MOPS, 10 mM RbCl, 75 mM 
CaCl2, 15% glycerol, adjusted to pH 6.8 with KOH, sterile filter) buffer. Aliquots of 100–
200 μl were prepared in sterile microcentrifuge tubes, frozen in liquid nitrogen and stored 
at -80°C. 
 
2.2.4   Transformation of competent E. coli cells  
Chemically competent cells of E. coli M15 and SG13009 were thawed on ice for 
approximately 5 min, after which 100 μl of cells were gently transferred into a cold 
microcentrifuge tube. An aliquot containing 10 ng of the pQE30 plasmid construct was 
then added to the cells and mixed, after which the tubes were incubated on ice for 20 
minutes. 
Following incubation, cells were heat shocked for 90 s in a water bath (Fisher Scientific, 
Leicestershire, UK) at exactly 42°C, after which they were placed on ice for 2–3 minutes. 
Five hundred microliters of ice-cold SOC medium (Super Optimal broth with Catabolite 
repression) (2% tryptone, 0.5% yeast extract, 0.05 % NACL, 250mM KCl, 2M MgCl2, 
and 1M sterile glucose) was added to the tube, which was then incubated at 37°C for 90 
min, with shaking at 300 rpm (Max 4450, Thermo Scientific, UK). Following incubation, 
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5, 10, 50 and 100 μl aliquots of the culture were plated out on LB-agar plates containing 
25 μg/ml kanamycin and 100 μg/ml ampicillin. Following inoculation, the plates were 
incubated overnight at 37°C, after which the number of positive transformations were 
enumerated and individual colonies were picked off and stored at −80°C using Protect™ 
storage vials. 
Transformation efficiency was compared to that achieved when competent cells were 
transformed with 1 ng of pQE-40 (Qiagen Ltd, Crawley, UK) control plasmid in 20 μl of 
Tris-EDTA buffer (pH 8.0) (Sigma-Aldrich, Gillingham, UK). Transformation efficiency 
was determined using the following calculation:  
Transformation efficiency = Total number of cells growing on the agar plate / 
Amount of DNA spread on the agar plate (in μg). 
 
2.2.5   Recombinant protein expression 
An individual protect bead containing a specific E. coli recombinant expression system 
was  recovered from -80°C storage and inoculated into 10ml of LB broth containing 25 
μg/ml kanamycin and 100 μg/ml ampicillin,  and was incubated for 14 h in an orbital 
shaker at 37°C and 300 rpm (Max 4450, Thermo Scientific, UK). Following incubation, 
5ml of this culture was transferred into a further 100 ml of pre-warmed antibiotic 
supplemented LB broth (100 μg/ml ampicillin and 25 μg/ml kanamycin). The resulting 
culture was incubated at 37°C and 300 rpm until it achieved an OD600 of 0.6.  At this 
point, recombinant protein expression was induced by the addition of 100 μl of 1mM 
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Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Invitrogen, Paisley, UK). Following the 
addition of IPTG, cultures were incubated with shaking (300 rpm) for a further 4 h at 
27°C to reduce the formation of inclusion bodies.  
To optimise recombinant protein induction conditions for each recombinant protein, 1 ml 
aliquots of cultures were collected prior to induction, at the commencement of induction 
and each hour post-induction until the end of the induction period (4 h). As a control, 
samples were collected from cultures to which IPTG had not been added. Samples were 
harvested by centrifugation at 15,000 g for 3 min at 4°C (Eppendorf 5417R centrifuge, 
fixed angle rotor F45-30-11, UK), after which recombinant protein was visualised on 
SDS-PAGE using a ChemiDoc XRS equipped with a 12-bit CCD (charge-coupled 
device) camera (Bio-Rad).  
Once the optimal induction conditions had been identified, the bacteria were harvested by 
centrifugation at 5,000 xg for 20 min at 4°C (Heraeus Primo, Thermo Scientific, UK) and 
the cell  pellet was retained and stored at -20°C prior to purification. 
 
2.2.6   Recombinant protein purification 
Recombinant proteins were extracted from the induced bacterial cell pellet using the 
procedure described in the QIAexpressionist kit instructions (Qiagen, Crawley, UK). 
Frozen cell pellets were thawed for 15 min on ice and resuspended in a  lysis solution 
containing 10ml 1X Ni-NTA Bind Buffer (50 mM NaH2PO4, pH 8.0; 300 mM NaCl; 10 
mM imidazole) (Ni-NTA buffer  kit; Novagen, USA), lysozyme (1 mg/ml) (Roche, 
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Germany) RNase A (10 μg/ml) (Sigma-Aldrich, Gillingham, UK) and DNase I (5 μg/ml) 
(Sigma-Aldrich, Gillingham, UK), which was then incubated on ice for 30 min. The cell 
suspension was then subjected to sonication (five 40 second bursts at 14 am with a 30 
second cooling period between each burst) using a Soniprep 150 ultrasonic disintegrator 
(Sanyo, Leicester, UK).   
The resulting lysates were then centrifuged at 10,000g for 30 min at 4°C (Beckman 
Coulter Optima L-100K centrifuge, rotor 14) to pellet cellular debris. The His-tagged 
recombinant proteins were recovered from the clear lysate under native conditions by 
affinity chromatography using a Nickel-nitrilotriacetic acid (Ni-NTA) Buffer Kit 
(Novagen, USA), in accordance with the manufacturer’s instructions. 
Briefly, 12 ml of 50% Ni-NTA Agarose (Qiagen, Crawley, UK) was added to the 
cleared lysate and gently mixed by shaking at 30 rpm on a Stuart SSL 3 Gyro Rocker 
(Sigma-Aldrich, Gillingham, UK) at room temperature for 60 min. Following mixing, the 
lysate–Ni-NTA mixture was loaded into a 10 ml polypropylene disposable column 
(Fisher Scientific, Leicestershire, UK) and washed twice with 4 ml 1X Ni-NTA Wash 
Buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 20 mM imidazole). The bound 
recombinant protein was eluted from the column using 0.5 ml 1X Ni-NTA Elution Buffer 
(50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 250 mM imidazole). This elution step was 
repeated four times. Eluted proteins were immediately buffer-exchanged into 20 mM 
sodium phosphate buffer (pH 6) using a 10 ml Zeba Spin Desalting Column (Thermo 
Scientific, UK). Purified recombinant protein was stored at 4°C until required. 
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To monitor the efficiency of the purification process 50 μl aliquots were collected at the 
following stages during the process: culture lysate supernatant, column wash flow-
through (wash fractions 1 and 2)  and elution fractions 1, 2, 3 and 4.  Samples were 
analysed by SDS-PAGE. 
 
2.2.7   Protein quantification 
Protein quantification of purification fractions was determined using the Bicinchoninic 
acid (BCA) assay using the method described in Pierce BCA protein assay kit 
instructions (Thermo Scientific, at http://www.piercenet.com/instructions/2161296.pdf . 
accessed on 5-2011)  with the following modifications. 
A series of bovine serum albumin (BSA, Fisher Scientific, Leicestershire, UK) standards 
ranging from 0.05 to 1.0 mg/ml were prepared in PBS in order to construct a standard 
curve. To determine the protein concentration of a sample, 10 μl of the sample was mixed 
with 190 μl of PBS buffer and all test samples were prepared in triplicate. The BCA 
working solution was prepared by mixing 50 parts BCA (Sigma-Aldrich, Gillingham, 
UK) solution with 1 part 4% (w/v) copper sulphate (CuSO4) (Fisher Scientific, 
Leicestershire, UK). One ml of this BCA solution was added to each standard and protein 
sample and vortex mixed, after which they were incubated at 37°C for 15 minutes. At the 
end of this period, samples were immediately placed on ice and the absorbance of each 
sample was determined at 562nm (Ultra space 3100pro, GE Healthcare), using a sample 
comprising PBS as the blank. 
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Using the results, a Beer’s law plot was constructed by plotting the mean absorbance at 
562 nm of the protein standards against their concentration to produce a straight line, 
from which the protein concentration of the unknown samples could be determined. The 
final concentration of the sample was corrected for the dilution factor by multiplying by 
20. 
 
2.2.8  Sodium dodecyl sulfate polyacrylamide gel electrophoresis and protein 
gel staining  
Proteins were visualised by SDS-PAGE using 4–20% pre-cast gels Mini-PROTEAN® 
TGX™ Precast Gel (Bio-Rad). Samples were resuspended in 50 μl of 2x SDS-PAGE 
sample buffer (0.09M Tris-Cl pH 6.8, 20% (w/v) glycerol, 2 % (w/v) SDS, 0.02% (w/v) 
bromophenol blue, 0.1 M DTT) and stored at -20°C prior to analysis. Following removal 
from storage, samples were denatured using a dry block heater (Techne DB-3D, Bibby 
Scientific Ltd, Staffordshire, UK) at 95°C for 5 minutes, after which 10 μl volumes were 
loaded onto the PAGE gel. To determine the migration distance of recombinant proteins, 
a Molecular weight standard (Sigma Marker wide Range: 6,500-200,000 Da, Sigma-
Aldrich, Gillingham, UK) was run on each gel. Following sample loading, gels were 
placed in a tank (Bio-Rad) and overlaid with 1X SDS-PAGE running buffer (10x running 
buffer contains: 250 mM Tris base, 1.92 M glycine, 1% SDS, pH 8.3; Fisher Scientific, 
Leicestershire, UK). Gels were then subjected to electrophoresis for 45 minutes at 150 V 
(400 mA). 
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On completion of electrophoresis, the SDS-PAGE gel was then washed twice, for five 
minutes each time, in sterile distilled water. The gel was then fixed in 100 ml of fixing 
solution (40% (v/v) methanol, 10% (v/v) glacial acetic acid in diH2O, 10 ml methanol, 7 
ml glacial acetic acid and 83 ml water) for 1 hour. A 1x working solution of Brilliant 
Blue G-Colloidal concentrate (Sigma-Aldrich, Gillingham, UK) solution was prepared 
and stored at 4°C. Prior to staining, 4 parts of working solution were mixed with 1 part 
methanol. Staining was carried out for 2 hours and the gel was de-stained with 25% 
methanol, continuously changing the methanol until the stain had been removed from the 
gel and the gel was ready for imaging. On completion of staining, gels were imaged on 
the ChemiDoc XRS equipped with a 12-bit CCD (charge-coupled device) camera (Bio-
Rad). 
 
2.2.9  Western blot  
Prior to antibody probing, proteins were separated by SDS-PAGE as described above. A 
6x His Protein Ladder (Qiagen Ltd, Crawley, UK) was included as a positive control with 
a culture of E. coli M15 serving as a negative control. All incubations were carried out at 
room temperature on a Stuart SSL 3 Gyro Rocker. Upon completion of electrophoresis, 
proteins were transferred from the polyacrylamide gel to a nitrocellulose membrane (0.2 
μM pore size, Bio-Rad) using the Bio-Rad Trans-Blot® Turbo™ System at 25 volts, 
1.0A for 30 h.  
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Detection of histidine-tagged proteins was achieved using a histidine-specific murine 
antibody, as described in the QIAexpress® Detection and Assay Handbook. Tween 20 
was purchased from Sigma-Aldrich and all other reagents were purchased from Fisher 
Scientific. All steps were carried out at room temperature on a Stuart SSL 3 Gyro Rocker. 
The membrane was washed twice for 10 minutes with PBS and 0.1 % (v/v) Tween 20 
(PBST) and thereafter incubated in blocking buffer (3% non-fat dried milk (w/v) in PBST 
buffer) for 1 hour. Membranes were then washed twice for 10 minutes in PBST. The 
detection antibody, Penta-His Antibody (Qiagen Ltd, Crawley, UK) was diluted 1:10,000 
in blocking buffer and then incubated with the membrane for 1 h.   
Prior to the addition of the secondary antibody, the membranes were washed four times 
for 10 min with PBST. The secondary anti–mouse IgG/HRP conjugate antibody (Thermo 
Scientific, UK) was diluted 1:10,000 in blocking buffer and then incubated with the 
membrane for 1h, after which the membrane was washed four times for 10 min with 
PBST. Immobilon Western chemiluminescent HRP substrate (Millipore; Billerica, MA, 
USA) was used to detect the presence of bound antibody complexes which we 
subsequently visualised using a ChemiDoc XRS with a CCD camera (Bio-Rad) detection 
system. 
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2.3    Statistical analysis  
 
 
The results were compared using one-way ANOVA in the Minitab Statistical Software 
Package (release 14 software, Minitab Inc., PA, USA) and means results were compared 
using the TukeyHSD method. Two-group comparisons were analyzed by Student's t test 
with the statistical function of excel (Microsoft Office 2010) 
 
 
2.4   Bioinformatics analysis 
 
Nucleotide sequences were analysed using the Basic Local Alignment Search Tool 
(BLASTn) to identify homologous regions to sequences deposited in the NCBI database 
(http://www.ncbi.nlm.nih.gov). The presence of restriction enzyme sites in a nucleotide 
sequence was determined using NEBcutter v2.0 program 
(http://tools.neb.com/NEBcutter2/). 
BLASTp (Altschul et al., 1997) was used to compare protein sequences to the non-
redundant protein sequence database in the NCBI database. Multiple sequence 
alignments were performed using either Clustal W2 (available at 
http://www.ebi.ac.uk/Tools/msa/clustalw2/) or T-Coffee (Notredame et al., 2000), and 
the creation of phylogenetic trees using the average distance method was performed using 
Clustal W2. 
The prediction of protein functional domains was made using Pfam 
(http://pfam.janelia.org/search). The isoelectric point (pI) and molecular weight (Mw) of 
protein sequences were calculated using Compute pI/Mw tool in ExPASy 
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(http://www.expasy.org/tools/pi_tool.html). Signal peptide predictions were performed 
using SignalP 4.0 Server (Petersen et al., 2011; Gram-positive organism group), while the 
solubility of recombinant proteins in E. coli were predicted using Recombinant Protein 
Solubility Prediction at http://www.biotech.ou.edu/. 
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Chapter Three 
 
Isolation of bacteriophages infecting Clostridium 
difficile 
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3.1   Introduction 
3.1.1   Isolation of temperate bacteriophages  
The induction of phages from C. difficile by treatment with mitomycin C (MMC) has 
previously been described (Sell et al., 1983; Nagy et al., 1991; Goh et al., 2005b, 2007; 
Govind et al., 2006; Fortier and Moineau, 2007; Mayer et al., 2008; Horgan et al., 2010; 
Meader et al., 2010; Sekulovic, et al., 2011; Meessen-Pinard et al., 2012; Nale et al., 
2012; Shan et al., 2012). Recently, there have been successful isolations of whole phages 
and purified phage components, with a number of temperate C. difficile phages having 
been isolated and observed by the use of electron microscopy (EM). These phages have 
been classified into two families. The first family are the Myoviridae which have an 
isometric capsid and a contractile tail and comprise of 
φMMP01,φMMP02,φMMP03,φMMP04, φC2, φCD27, φCD8, φCD630-1 and φCD630-
2;the second family consists of a number of prophages belonging to the Siphoviridae 
family, such as φ 41, φCD8-2, φC6, φCD38-1, φCD38-2, φCD6356 and φCD6365. This 
family has an isometric capsid and a long non-contractile tail (Chapter 1, table 1.2). 
Mitomycin C is an alkylating agent which has been used as an anti-tumour antibiotic 
since the 1950s. Mitomycin C is a natural product isolated from Streptomyces caespitosus 
and was discovered by a Japanese microbiologist in the 1950s (Tomasz, 1995). Its mode 
of action involves cross-linking DNA bases, which leads to cell death (Tomasz, 1995).  
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The DNA damage to the bacterial cell appears to be the trigger that stimulates the 
production of RecA via the SOS repair system, which induces prophages in the lytic 
cycle (Kuzminov, 1999).  
The antibiotic norfloxacin has also been used as a phage induction agent; it is a specific 
inhibitor of the A subunit of DNA gyrase which inhibits DNA synthesis, resulting in the 
accumulation of single-stranded DNA fragments. This results in the activation of the 
RecA protein, facilitating the cleavage of a phage repressor, thus allowing prophage 
induction (Matsushiro et al., 1999).   Norfloxacin has been used successfully in the 
induction of phages from E. coli O157:H7 and Shiga toxin (Stx)-producing E. coli 
(STEC) strains (Matsushiro et al., 1999; McDonald et al., 2010). In addition, it has also 
been used to induce the expression of prophages from examples of the C. difficile 027 
ribotype (Nale et al., 2012; Shan et al., 2012). Moreover other quinolones such as 
Ciprofloxacin, Moxifloxacin, and Levofloxacin have recently been used at sub-MIC 
concentrations to stimulate the expression of C. difficile prophages (Meessen-Pinard et 
al., 2012). 
Other induction methods such as UV light treatment have been used to induce the 
expression of C. difficile prophages (Mahony et al., 1985; Sekulovic, et al., 2011). 
 It is interesting to note that C. difficile prophages can enter the lytic cycle in the absence 
of inducing agents by a process known as spontaneous phage induction (Little, 2005; 
Govind et al., 2006). The C. difficile temperate phages φ41 and φ56 were spontaneously 
released and detected using a direct agar plating technique similar to the method 
employed in this chapter (Mahony et al., 1985, 1991; Ramesh et al., 1999; Govind et al., 
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2006). Spontaneous C. difficile temperate phages φMMP03 and φMMP04 have also been 
identified using a method known as host adsorption, which is also employed in this 
chapter in an attempt to isolate phages from environmental samples (Grabow, 2001; 
Meessen-Pinard et al., 2012 ). 
 
 
3.1.2   Isolation of virulent bacteriophages  
Bacteriophages are widely distributed in the environment and can be isolated from 
seawater, soil, fresh water and sewage ecosystems (Jensen et al., 1998). Indeed, sewage 
represents a particularly rich source of phages as it contains a large diversity of coliforms 
due to faecal contamination (Sundar et al., 2009). 
 
Bacteriophages have been isolated from drinking water (Grabow and Coubrough, 1986), 
fresh water (Goyal, 1987; Grabow, 2001) and seawater (Tartera and Jofre, 1987). Wiebe 
and Liston (1968) isolated a bacteriophage that was active against a marine Aeromonas 
species from surface sediments of the North Pacific Ocean. Baross et al. (1978) reported 
the isolation of bacteriophages active against Vibrio from marine water and sediments. 
 
Phage recovery methods should ideally be rapid, cheap and easy to perform. They should 
be applicable to a wide range of samples and should give high efficiency in recovery 
(Grabow, 2001). Several methods have been used to isolate phages from environmental 
samples. These consist of direct culture methods, enrichment methods, adsorption-elution  
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methods using negatively or positively charged filters or glass powder, precipitation 
using polyethylene glycol (PEG), and ultrafiltration (Goyal, 1987; Grabow, 2001). 
However, in this study, direct culture methods and host adsorption methods were used, 
since these methods are easy to use, inexpensive, suitable for a large amount of samples 
and have been used before for C. difficile lytic phage isolation (Seeley and Primrose, 
1982; Grabow, 2001; Goh et al., 2005b). 
 
 
 
3.1.3   Aim of this study  
The aims of this chapter are: 
 To isolate phages from twenty-three clinical isolates of C. difficile, representing a 
range of ribotypes using mitomycin C and norfloxacin.  
 To isolate phages from environmental samples those are lytic for C. difficile. 
 To determine the physical characteristics of phages isolated during this study.  
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3.2   Materials and Methods 
3.2.1   Isolation of temperate bacteriophages from clinical isolates  
Unless indicated otherwise, all centrifugations were performed using a Heraeus Primo 
centrifuge (Thermo Scientific, UK) and all anaerobic work was performed in a gloveport 
Bugbox Plus anaerobic workstation (Ruskinn Technology Ltd). The Optical density 
(OD600) of bacterial cultures was determined using an Ultra spec 3100 pro 
spectrophotometer (GE Healthcare, Piscataway, NJ, USA). 
 
3.2.2   Strains of C. difficile used to isolate and propagate bacteriophages  
The ribotypes of the twenty clinical isolates and three NCTC reference strains of C. 
difficile used in this phage study are shown in table 3.1. C.difficile NCTC 12727 is of 
particular note, as it has been shown to contain a phage whose expression is inducible by 
treatment with mitomycin C and which is able to infect C.difficile NCTC 11204 (Mayer 
et al., 2008).  
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Table 3.1: C. difficile strains that were used in phage induction studies described in this 
Chapter  (Appendix 1) 
Ribotype Strain 
 
001 R8562 –DS1747-DS1750-DS1759, NCTC 12727, NCTC 11209, NCTC 11204 
023 DS1665 
027 DS1801-DS1807 -R20291-DS1813 
106 R10459-DS1798- DS1771 
002 DS1748 
078 DS1723 
012 DS1752 
014 DS1742 
005 DS1721 
010 DS1684 
017 R22660 
020 DS1724 
 
For this reason, these two strains, NCTC 12727 and NCTC 11204, were used to optimise 
culture conditions, to establish the most appropriate plaque assay and to identify the 
optimal phage induction conditions for mitomycin C and norfloxacin. 
 
3.2.3   Optimisation of C. difficile culture conditions prior to phage induction.  
The manner in which a bacterial culture is grown and its stage of growth is known to 
influence the efficacy of phage induction (Gill and Hyman, 2010). To identify the 
optimal culture conditions for our collection of C. difficile isolates, the following methods 
were assessed: static tube culture and Bioscreen microtiter plate.  
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3.2.3.1   Tube method 
Individual isolates were cultured on pre-reduced BHI agar plates for 48 hours at 37ºC 
under anaerobic conditions, after which a single colony was harvested and used to 
inoculate 5 ml of pre-reduced BHI broth; this was subsequently incubated for 24 hours at 
37ºC.  At the end of this period, 1.25 ml (adjusted volume) of cell suspension was 
transferred into 8.75 ml of fresh pre-reduced BHI broth and incubated for a further 48 
hours in an anaerobic environment. Aliquots (1ml) were removed at different time points 
and the optical density (OD600) was determined. 
3.2.3.2   Bioscreen microtiter plate method 
 Individual isolates were cultured on pre-reduced BHI agar plates for 48 hours at 37ºC 
under anaerobic conditions, after which a single colony was harvested and used to 
inoculate 5 ml of pre-reduced BHI broth; this was subsequently incubated for 24 hours at 
37ºC. Following this period, 50 μl of cell suspension was transferred into a microtiter 
plate well, where it was mixed with 350 μl of the pre-reduced BHI broth. For each strain, 
a total of four wells were inoculated on each plate. Negative control wells contained 
culture media only. To maintain anaerobic conditions, individual wells were sealed with 
either  silicone glue, sterile immersion oil or adhesive tape. The inoculated plate was then 
loaded on to the Bioscreen-C system (Lab Systems, Helsinki, Finland) and incubated at 
37ºC for 48 h. The optical density (OD600) of each well was measured every 15 minutes. 
The resulting data was analysed using spread sheet software (Excel 97) and the mean of 
the quadruplicate values for each isolate were calculated and used to generate a growth 
curve. 
 Page | 93 
 
3.2.4   Phage induction using mitomycin C and norfloxacin 
The ability of different concentrations of mitomycin C and norfloxacin (3 or 5 µg/ml) to 
induce the production of lytic phages by bacterial cultures at different stages of 
physiological development (mid log and stationary phase) was determined using the 
methods described elsewhere (Sell et al., 1983; Nagy et al., 1991; Fortier and Moineau, 
2007; 2012; Nale et al., 2012; Shan et al., 2012) with following modifications.  
The test strain C.difficile NCTC 12727 was initially cultured on degassed BHI agar for 48 
hours at 37°C under anaerobic conditions. A single colony was harvested and transferred 
into 5 ml of BHI broth and grown at 37°C under anaerobic conditions for 24 h. A 5 ml 
inoculum from this culture was then transferred into  45 ml of fresh degassed BHI 
medium, and growth was monitored until the optical density (OD600) reached the required 
values.  In the case of mid log phase cultures this was OD600= 0.4-0.6, while for 
stationary phase cultures the values were OD600 =1.0-1.2. 
Once the desired OD600 was achieved, 10 ml aliquots were pipetted into individual 50 ml 
Falcon tubes where the cultures were mixed with either mitomycin C (Arcos Organics, 
Geel, Belgium) or norfloxacin (Sigma-Aldrich, UK) to achieve a final concentration of 3 
or 5 µg/ml , reference control cultures were left untreated. Following treatment, cultures 
were incubated at 37°C under anaerobic conditions and OD600 was monitored. A 
significant decrease (>60% of initial OD) in cell density compared to the untreated 
control at 3 to 5 hours post-induction was taken to indicate the induction of phage 
expression (Fortier and Moineau, 2007) . Induced broth cultures were centrifuged at 
5,000xg for 10 minutes; the supernatant was collected and filtered through a 0.45 μm 
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membrane filter (Millipore, Massachusetts, US) to remove bacterial debris. The 
subsequent filtrates were stored at 4°C prior to further analysis. 
3.2.5   Plaque assay development: Optimisation of C. difficile inoculum  
Two assay formats were assessed for their suitability as a means of determining the phage 
susceptibility of C. difficile isolates; direct plating (Mazzocco et al., 2009) and agar 
overlay (Adams, 1959; Sell et al., 1983; Mahony et al., 1985 ; Govind et al., 2006 ; 
Fortier and Moineau, 2007, Fortier and Moineau, 2009; Sekulovic, et al., 2011) . The 
optimum bacterial inoculum was determined for each assay. 
3.2.5.1   Direct plating plaque assay 
A 1ml culture of NCTC 11204 in BHI broth, which was incubated at 37ºC until the 
culture reached an OD600 of 0.4 to 0.6 (mid log phase), was spread over the surface of a 
pre-reduced BHI agar plate. The number of viable bacteria in the culture was also 
determined using the method described in section 2.1.7. Excess liquid was removed by 
Pasteur pipettes, the plate was allowed to dry and was then incubated anaerobically at 
37ºC for 24 and 48 hours, in order to assess the method’s ability to produce a confluent 
lawn of bacteria growth.  
3.2.5.2   Agar overlay plaque assay 
 A single colony of a 48 h culture of C.difficile NCTC 11204 on BHI agar  was harvested 
and inoculated into 5 ml of  pre-reduced BHI broth and incubated at 37ºC for 24 h. 
Following incubation, 1.25 ml of  cell suspension was added to 8.75  ml of pre-reduced 
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BHI broth and the mixture was subsequently incubated until  the culture reached an 
OD600 0.4 to 0.6 (mid log phase). Volumes of 25 μl, 100 μl, 200 μl, 300 μl, 400 μl, 500 μl 
and 1 ml of this culture were seeded into molten agar (0.75% BHI agar -cooled to 45°C) 
supplemented with MgCl2 (0.1- 0.4 M) and CaCl2 (0.1- 0.4 M) as the overlay. Once 
inoculated the agar/ bacterial mixture was spread over the surface of a BHI agar plate and 
allowed to solidify. The plates were then incubated at 37ºC for 48 h under anaerobic 
conditions and the subsequent degree of growth was assessed. In the two methods, 
samples were assayed for the presence of phage by spotting 10 μl of filtered phage extract 
onto the surface of the solidified agar. 
3.2.6   Concentration and purification of phage 
Broth cultures were induced and centrifuged in a 45 ml volume, as previously described 
in prophage induction (section 3.2.4) .The phage concentration and purification method 
was performed based on the method described elsewhere (Fortier and Moineau, 2007; 
Nale et al., 2012) with following modifications The supernatants were transferred to a 
sterile conical flask (500ml) that contains 1M sodium chloride (NaCl) (Fisher Scientific, 
UK). The suspensions were mixed and incubated on ice for 1 h with continuous stirring, 
then 10% (w/v) of polyethylene glycol (PEG) 8000 (Fisher Scientific, UK) was slowly 
added with continuous mixing until completely dissolved. The mixtures were left 
overnight at 4°C with constant mixing. The solutions were then centrifuged at 11,000xg 
at 4°C for 30 minutes (Beckman Coulter Optima L-100K centrifuge, rotor 14). The 
supernatants were discarded and the pellets re-suspended in 3 ml of SM buffer (50 mM 
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Tris-HCl, pH 7.5, 100 mM NaCl, 8 mM MgSO4, 0.002% gelatine, Fisher Scientific, 
Leicestershire, UK). After this, each mixture was vortexed and left at room temperature 
for one hour. The solution was then centrifuged at 5,000xg at 4°C for 20 minutes and the 
supernatant containing the phage was filtered through 0.22 mm filters and stored at 4ºC. 
 
3.2.7   Transmission Electron Microscopy (TEM) 
All TEM materials and chemicals were purchased from Agar Scientific (Essex, UK) 
unless otherwise stated in the text.  A 5 μl drop of purified concentrated phage suspension 
was added to carbon coated Formvar grids (400 mesh), which were dried at room 
temperature for 2 minutes, with any excess fluid being removed using filter paper. The 
samples were subsequently negatively stained with 5 µl of 2% uranyl acetate and dried at 
room temperature for 2 minutes. The samples were imaged using a Phillips CM12 
transmission electron microscope with an accelerating voltage of 80 kilovolts (kV); 
magnifications between 25,000x and 63,000x were used. Digital images were captured 
with a Megaview III digital TEM camera and iTEM software (Soft Imaging System 
GmbH, Münster, Germany). Representative images were taken using 30 to 40 fields of 
vision. Morphology was assigned by using figure 1.8 (Chapter 1) after measuring the 
dimensions of the phages’ capsids and tails (Murphy et al., 1995). 
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3.2.8   Isolation of virulent bacteriophages from environmental samples  
Eighteen water samples were collected in 1 litre Sterile Duran bottles from the following 
locations around Cardiff: three from the River Taff, three from the River Ely, five from 
Cardiff Bay, and seven from Roath Park Lake. Each sample was  centrifuged at 2100xg 
for 30 minutes at 4°C and then filtered through a  0.22 μm-pore-size filters (Millipore, 
Massachusetts, US) in order to remove bacterial and other suspended material.  
 
 
3.2.8.1   Direct culture method  
The direct culture method includes direct plating and agar overlay technique as follows: 
 
Isolation of bacteriophages using the direct plating plaque assay 
The test strains of C. difficile were cultured in pre-reduced BHI agar for 48 hours under 
anaerobic conditions at 37°C.  Subsequently, the direct plating plaque technique was 
performed as described before in section 3.2.5.1. A 10 μl aliquot of the filtrated 
environmental sample was then spotted on top of the streak and left to dry. The plates 
were transferred to an anaerobic cabinet, incubated for 48 hours at 37°C and examined 
for the presence of plaques. 
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 Isolation of bacteriophages using the agar overlay plaque assay  
Cultures of C. difficile were prepared as described above. A total of 3ml of molten BHI 
overlay agar (0.75% supplemented with 0.4 M MgCl2) was seeded with 1ml of culture 
(OD600, 0.4 to 0.6) and allowed to set. Samples were assayed for the presence of phage by 
spotting 10 μl of filtered environmental sample onto the surface of the solidified agar. 
The plates were left to dry and then incubated overnight anaerobically and examined for 
the presence of plaques. 
 
 
3.2.8.2   Host adsorption method (enrichment method) 
A single colony of a 48 h culture on BHI agar was harvested and inoculated into 5 ml of 
pre-reduced BHI broth, before being incubated at 37ºC for 24 h. Following incubation, 
the entire culture was added to 15 ml of pre-reduced BHI broth in a Falcon tube (50 ml). 
The tube was incubated at 37ºC until the culture reached an OD600 of 0.4 to 0.6, at which 
point 20 ml of filtered environmental sample was added.  The mixture was incubated 
overnight anaerobically at 37°C and centrifuged at 2100xg for 30 minutes, after which 
the culture supernatant was passed through a 0.45μm filter. To screen for the presence of 
lytic phages, 10 μl aliquots were assayed using the agar overlay assay. This method was 
modified and simplified from methods described by Purdy et al. (1984) and Grabow 
(2001). 
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3.3   Results 
3.3.1   Optimisation of C. difficile broth growth conditions 
The Bioscreen microtiter plate system allows a large number of samples to be screened 
over time and thus represents an ideal system with which to screen the growth 
characteristics of multiple   bacterial isolates. We attempted to develop an approach 
which would allow us to monitor the growth of C. difficile. Unfortunately, the system 
lacks an anaerobic culture capacity and none of the sealing methods employed were able 
to achieve an effective oxygen seal. 
In contrast, the tube method was able to support anaerobic growth, as can be seen for the 
growth curves of C. difficile NCTC 11204 and 12727 presented in figure 3.1. The growth 
kinetics of each strain was similar, with a peak in cell density at 24 hours. As one would 
expect, the production of spores was detected at 48 hours. For this reason, the tube 
method was employed to support phage induction studies.  
 
 Page | 100 
 
 
Figure 3.1: Growth curves of C. difficile strains NCTC 11204 and 12727. Strains were grown 
anaerobically in BHI medium and aliquots were removed for OD600 readings. Data represent 
mean ± S.D from triplicate assays 
 
 
3.3.2   Optimisation of C. difficile agar culture conditions   
The method we employed to plate C. difficile directly onto the surface of BHI agar 
produced a thick, non-confluent growth and bacteria colonies are discrete on the plate 
when repeated on four separate occasions. In contrast, the agar overlay method using 400 
µl of culture at an OD600 (0.4-0.6) in 3 ml of overlay agar was reproducible (repeated 4 
times) and gave confluent growth of C.difficile NCTC 11204. Therefore, agar overlay 
method was used for further phage propagation methods. Furthermore, due to a lack of 
positive phage controls that can be used to optimise MgCl2 and CaCl2 concentrations, we 
decided to use 0.4 M MgCl2, since this concentration had been previously proven to be 
the optimum concentration for propagation of C. difficile phages (Mahony et al., 1985). 
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3.3.3   Phage induction  
 
We determined the optimal phage induction conditions using C.difficile NCTC 12727. 
Mid-log phase and stationary phase cultures of the organism were exposed to 3 or 5 
μg/ml or mitomycin C and norfloxacin. As determined by a reduction in culture optical 
density, we failed to observe any evidence of phage induction in stationary phase cultures 
of C.difficile NCTC 12727 following treatment with either concentration of mitomycin C 
or norfloxacin. These results suggested that there was no cell lysis and no release of viral 
particles, a hypothesis which was confirmed by TEM. 
However, mid-log phase cultures of C.difficile NCTC 12727 (OD600~0.4-0.6) with 3 and 
5 μg/ml of mitomycin C resulted in a marked reduction in optical density suggestive of 
phage mediated cell lysis. The presence of phages in the culture supernatant following 
induction was confirmed by TEM. However, prophage expression was not induced from 
this strain of C. difficile by treatment with norfloxacin (Figure 3.2).  
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Figure 3.2.  Growth curves of the induced C. difficile strain NCTC12727. Strain  was grown 
anaerobically in BHI medium and induced at the mid-log phase (4h) using mitomycin C and 
norfloxacin (3 μg/ml each); aliquots were removed for OD600 readings every 2 h. Results are the 
means ±standard deviations (SD) from triplicate assay. 
 
3.3.4   Phage propagation 
The purified and concentrated phage preparation isolated from C.difficile NCTC 12727 
following mitomycin C induction produced a hazy plaque when plated on a lawn of 
C.difficile NCTC 11204 on agar supplemented with 0.4 M MgCl2 following 24 h of 
incubation (Figure 3.3). However, it failed to produce plaques upon a second passage.  
We tried to identify a phage indicator strain that could be used to propagate newly 
induced prophages from our collection of clinical isolates. Unfortunately, none of the 23 
C. difficile isolates examined proved to be susceptible to any of the phage extracts 
produced in this study, including that of C.difficile NCTC 12727. This failure could 
reflect our failure to efficiently induce the expression of lytic phages from these isolates 
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or may reflect the inherent resistance of C. difficile isolates to phage infection. The 
difficulty in finding suitable sensitive strains has been reported before (Fortier and 
Moineau, 2007; Nale et al., 2012).  
 
 
Figure 3.3.  A & C) Plaque assay of phages isolated from C. difficile NCTC 12727 following 
mitomycin C induction on a culture of C. difficile NCTC 11204. B) An inoculated control 
culture of C. difficile NCTC 11204. 
Hazy plaques 
A B 
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3.3.5   Electron microscopy studies of mitomycin C treated cultures  
The presence of viral particles in culture supernatant of induced cultures was confirmed 
by electron microscopy (Figure 3.4).   
 
Figure 3.4.  TEM results of phage induction method of C. difficile NCTC 12727, showing that 
the phage belongs to the Myoviridae family. Bar represents 50nm; the size of the phage was 
determined by measuring 3 phages. Representation from 30 fields of view. 
 
Using the optimised phage induction method at the mid log phase, we were able to induce 
the expression of a phage from C. difficile NCTC 12727, which showed a clear 
resemblance by electron microscopy to the φCD27 bacteriophage isolated from C. 
difficile NCTC 12727 by Mayer and colleagues using mitomycin C (Mayer et al., 2008). 
However, the phage was induced at a low level, since a low number of phages was seen 
per grid (one in 30 fields). 
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Of the twenty-two clinical isolates of C. difficile exposed to mitomycin C, twelve strains, 
representing nine different ribotypes, underwent lysis when exposed to mitomycin C. 
 Electron microscopy studies of the culture supernatant of these induced cultures revealed 
the presence of twelve phages, eleven of which were morphologically identical with an 
icosahedral head measuring ~35-75 nm and contractile tails between ~90-170 nm in 
length (Table 3.2). Measurement was estimated by measuring 3 phages in each sample. 
The presence of a tail sheath suggests that these phages belong to the family Myoviridae. 
These phages show a clear resemblance to other C. difficile bacteriophages (Chapter 1, 
table 1.2).  Defective phage particles were also seen in some of the samples. However, 
these phages were also induced at low levels, since a low number of phages were seen 
per grid (one in 40 fields). 
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Table 3.2. TEM results of phages induced using mitomycin C. All phages belong to the 
Myoviridae family. Bar represents 50 nm. Measurements were estimated by measuring 3 phages 
of each sample .Representation from 40 fields of view. 
 
 
Ribotype Strain TEM 
 
001 
 
DS1750 
 
 
001 
 
DS1759 
 
 
001 
 
R8562 
 
 
001 
 
DS1747 
 
 
014 
 
DS1742 
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Table 3.2 ( continued) 
Ribotype Strain TEM 
 
002 
 
DS1748 
 
 
106 
 
DS1771 
 
 
027 
 
DS20291 
 
 
010 
 
DS1665 
 
 
023 
 
DS1684 
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Table 3.2 ( continued) 
Ribotype Strain TEM 
 
005 
 
DS1721 
 
 
 
 
Interestingly, one of the induced phages (Figure 3.5) induced from C. difficile R22660 
(ribotype 017) belonged to the Siphoviridae family, with an isometric capsid (~92 nm) 
and a long non-contractile tail (~211 nm).  
 
 
 Figure 3.5.  TEM results of phages induced from C. difficile R22660 using mitomycin C. 
The morphology of the phages shows that they belong to the Siphoviridae family. Bar represents 
50nm; Measurements were estimated by measuring 3 phages. Representation from 40 fields of 
view. 
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The presence of phage tail-like particles (PT-LPs) were observed in some of our induced 
lysates (strains DS1750, DS1665, DS1747, NCTC12727 and DS1684) and these particles 
were morphologically similar to those previously described (Nagy and Foidas, 1991; 
Fortier and Moineau, 2007; Nale et al., 2012) (Figure 3.6). These can be classified as R-
type bacteriocins, which resemble the structures of Myoviridae phage tails (contractile, 
nonflexible tails) (Gebhart et al., 2012). Similar PT-LPs were also observed in Vibrio, 
Budvicia aquatica and Pragia fontium cultures (Smarda and Benada, 2005; Gnezda-
Meijer et al., 2006). 
Interestingly, some of these PT-LPs possess flower-like appendages similar to those 
observed before (Fortier and Moineau, 2007; Nale et al., 2012; Gebhart et al., 2012), 
which were proven experimentally to have bactericidal activity against strains of C. 
difficile (Gebhart et al., 2012). 
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Figure 3.6.   Phage tail-like particles (PT-LPs) induced in the culture supernatant of 
mitomycin C treated cultures of  C. difficile DS1747, 1665, 1750, NCTC 12727 and DS1684; 
bar represents 50 nm. Representation from 30 fields of view. 
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3.3.6    Isolation of bacteriophages from environmental samples  
 
Eighteen environmental samples (water samples) were collected from areas around 
Cardiff. These samples were centrifuged at 2100xg for 30 minutes at 4°C and filtered 
through 0.22 μm pore size filters. Two methods, direct culture (with and without agar 
overlay) and host adsorption were used in an attempt to isolate virulent phages from these 
samples. 
 
We failed to isolate any environmental phages with activity against the 23 C. difficile 
isolates included in this study. Although this method is easy and fast, the volume of the 
test sample is generally limited and is only suitable when the phages are present in high 
numbers, which is unlikely in most situations (Goyal, 1987). Also, it may be the case that 
the strains used in this study are inherently resistant to phage infection or that there were 
no phages present in the original samples. 
The enrichment method principle is to increase the number of phages that are present in 
the environmental sample by mixing it with an appropriate host. This method is sensitive, 
simple and easy to perform; however, it is not suitable for the detection of a wide 
spectrum of phages and the correct host has to be chosen (Goyal, 1987). Again, we failed 
to isolate any lytic phages. 
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3.4   Discussion  
3.4.1   Optimisation of C. difficile growth conditions 
C. difficile is an obligate anaerobic organism, which means that the total exclusion of 
oxygen is an important element of any attempt to culture the organism. Our attempts to 
employ a screening method based on the Bioscreen system were unsuccessful due to the 
fact that we were unable to house the system inside the anaerobic cabinet for technical 
reasons. For this reason, three different methods were investigated as means of achieving 
a suitable anaerobic environment, namely oil, silicon glue and adhesive tape. None of 
these approaches supported active growth, and for this reason the tube method was 
adopted. This method has been used successfully by other groups to induce the 
expression of significant quantities of lysogenic phages (Brüssow et al., 2004). 
In addition to optimising culture conditions, we also tried to develop a plaque assay to 
enable us to identify the presence of induced phages.  In our hands, the double-agar-layer 
plaque technique
 
proved to be the most reproducible approach (Santos et al., 2009). 
Phages can diffuse through the agar gel to form plaques . The concentration of the gel has 
an effect on the size of the plaque; if the concentration of gel increases, the plaque size 
will decrease, and so on (Douglas, 1975). However, the recommended concentration is 
0.75% of agar (Sell et al., 1983). Standardisation of inoculum is of prime importance in 
ensuring reproducible and accurate results in plaque assay.  Despite confluent growth 
being difficult to assess, 400 μl of the sensitive bacterial strain which was grown until the 
mid-log phase (OD600 ~0.4-0.6), provides the ideal confluent growth in 3 ml of overlay 
agar.  
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3.4.2   Phage induction 
Examination of the mitomycin C induced supernatant from 22 strains of C. difficile by 
electron microscopy identified the presence of twelve distinct phages from different C. 
difficile ribotypes.  
 
These results were encouraging given that attempts to isolate C. difficile specific phages 
with mitomycin C has previously met with little success (Sell et al., 1983; Goh et al., 
2005b; Mayer et al., 2008; Horgan et al., 2010). The major difference between our 
studies and these earlier attempts to recover phage was the fact that the mitogen was 
added to actively growing cells rather than to cells which had reached the stationary 
phase (Sell et al., 1983). 
Phage induction in the early (Fortier and Moineau, 2007), mid-log (Shan et al., 2012) and 
stationary (Sell et al., 1983; Goh et al., 2005b; Mayer et al., 2008; Horgan et al., 2010) 
phases suggest that there is no one period of growth when phage induction is likely to be 
more successful. Furthermore, some induced C. difficile strains were found to release 
phages only following sporulation or after 72 h of incubation (Nale et al., 2012).   
Interestingly, we were unable to isolate prophages from any of our C. difficile strains 
using norfloxacin, even though this approach has been successfully employed by others 
(Nale et al., 2012). It could be the case that our cultures were static rather than moving, 
as was the case in the studies by Nale et al. (2012). The fact that we saw phage induction 
with mitomycin C under the same conditions would suggest that it is a more efficient  
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mitogen, possibly due to its different mechanism of action as described in the 
introduction of this chapter (Ingrey et al., 2003; Shan et al., 2012; Meessen-Pinard et al., 
2012). 
Our ability to detect the presence of phages was greatly hindered by our inability to 
identify a suitably susceptible indicator strain that could be used to propagate newly 
induced prophages.  We attempted to employ C.difficile NCTC 11204, a susceptible 
strain previously identified by Meyer and colleagues, but met with little success (Meyer 
et al., 2008). This failure could be due to the fact that insufficient quantities of phages 
were released following mitomycin C induction, as shown by our EM studies. 
 
The same was true for all of the twenty-two C. difficile isolates included in this study; as 
a consequence we were compelled to employ electron microscopy as a means of 
screening for the presence of phages. Perhaps we should not have been surprised as the 
difficulty of finding suitable sensitive strains has been reported by others (Fortier and 
Moineau, 2007; Nale et al., 2012). One possible explanation could be that the induced 
phages had undergone proteolytic degradation during storage, as was evidenced by the 
presence of defective phage particles in some of the samples. Alternatively, these phages 
may have been released at a low frequency due to inefficient induction and as a 
consequence we were unable to detect their presence due to the  way in which the plaque 
assay had been configured (Hayes, 1968 ; Grabow, 2001; Clokie et al., 2011).  
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Another possible contributory factor is the presence of the CRISPR system (as described 
in the introduction, Chapter 1, section 1.16 ). This system is thought to confer immunity 
to infection with phages which the bacterial cell has encountered in the past (Barrangou 
et al., 2007; Deveau et al., 2008 ) . To date, a number of CRISPR sequences have been 
identified in the C. difficile 630 genome and some of these sequences have also been 
found within a C. difficile 630 prophage (Sebaihia et al., 2006). This could have resulted 
in our inability to detect an indicator strain or isolate lytic bacteriophages.  
The phages isolated in this study showed a clear resemblance to previously isolated C. 
difficile bacteriophages (Chapter 1, table 1.2). Our results supported by previous results 
of phage isolation (Sell et al., 1983; Mahony et al., 1985 ; Nagy et al., 1991; Goh et al., 
2005b, 2007; Govind et al., 2006; Fortier and Moineau, 2007; Mayer et al., 2008; Horgan 
et al., 2010; Meader et al., 2010; Sekulovic, et al., 2011; Meessen-Pinard et al., 2012; 
Nale et al., 2012; Shan et al., 2012) seem to suggest that particular phage families 
(Myoviridae and Siphoviridae) are associated with C. difficile strains.  
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3.4.3   Isolation of phages from environmental samples 
We were unable to detect the presence of lytic phages with activity against C. difficile in 
any of our environmental samples. This is consistent with other studies attempts to detect 
and isolate lytic phage against C. difficile phages (Goh et al., 2005b; Horgan et al., 2010) 
and to date, no lytic C. difficile phages have been isolated. It may be the case that C. 
difficile is a strict anaerobe that exists only as spores in the environment and these spores 
lack receptors which are essential in phage infection; this may explain the absence or 
rarity of C. difficile-specific lytic phages in the environment (Goh et al., 2005b). A 
lysogenic state for phages of spore-forming anaerobic bacteria is convenient, as in this 
case phages are not affected by the availability of metabolically active anaerobic cells 
(Stewart and Levin, 1984). 
 
 
3.5   Conclusions 
We were able to induce the expression of C. difficile specific lysogenic phages using 
mitomycin C, but only at low levels. The phages which were isolated were 
morphologically similar to those reported by others. Our inability to efficiently propagate 
phages represents a major obstacle to our attempts to develop lytic phages as a potential 
therapeutic. For this reason, we adopted an alternative strategy, which is described in the 
next chapter. 
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Chapter Four 
 
The cloning and expression of the lysin genes of 
Clostridium difficile and its bacteriophages 
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4.1   Introduction 
4.1.1   Endolysin  
Endolysins (Lysins for short) are bacteriophage-encoded lytic enzymes that are designed 
to break down the peptidoglycan bonds in the bacterial cell wall during the terminal stage 
of the phage life cycle. These enzymes attack the cell wall that is needed to maintain the 
internal cytoplasmic pressure, which results in the lysis of cell, thereby allowing progeny 
phage release (Fischetti, 2008). 
Endolysins are also capable of causing rapid cell lysis when applied externally to the 
bacterial cell wall as purified recombinant proteins. This unique ability, along with their 
species specificity, makes them interesting antibacterial agents, particularly with 
increasing bacterial drug resistance (Borysowski et al., 2006). 
In terms of structure, endolysins from Gram-positive bacteria classically have a modular 
structure (250–400 amino acids) with an N-terminal domain which encodes 
peptidoglycan hydrolase activity and C-terminal binding responsible for the species 
specificity of the molecule (Fischetti, 2008). Gram-negative lysins are smaller as they 
only have the N-terminal enzymatic domain. However, not all lysins conform to this 
standard structure; for example Gram-positive lysins have been identified which 
comprise multiple enzymatic domains (Baker et al., 2006), while  Gram-negative lysins 
with an N-terminal binding domain  have been discovered (Briers et al., 2007; Schmitz et 
al., 2010). 
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Interestingly, although the C-terminal domain is responsible for recognising specific cell 
wall components, is not always essential for the activity of endolysin. This property was 
shown in a number of bacterial endolysins including C. difficile φCD27 endolysin 
(Borysowski et al., 2006; Mayer et al., 2011). 
To date, several temperate bacteriophages with activity against C. difficile have been 
identified and described in detail (Chapter1, table 1.2). However, only seven phages have 
been studied at the molecular level, these being φCD119, φCD2 ,φCD27, φMMP03 and 
φMMP04 from the Myoviridae family (Govind et al., 2006; Goh et al., 2007; Mayer et 
al., 2008; Meessen-Pinard et al., 2012 ) and two phages from the Siphoviridae family, 
namely φCD6356 (Horgan et al., 2010) and φCD38-2 (Sekulovic, et al., 2011). In 
addition, most C. difficile strains sequenced to date were found to carry a prophage in 
their genome. In recent studies, prophages have been identified in a large number of 
clinical isolates of C. difficile (Fortier and Moineau, 2007; He et al., 2010; Nale et al., 
2012; Shan et al., 2012) 
To date, a single enzymatic class of phage lysin for C. difficile has been subject to 
recombinant expression and analysis. Mayer et al. (2008) induced and sequenced φCD27 
from C. difficile NCTC12727. The gene encoding the lytic enzyme (cd27l) was 
subsequently identified by sequence homology and PCR-cloned into E. coli and 
Lactococcus lactis expression plasmids (Mayer et al., 2008). The authors demonstrated 
that LysCD27 was capable of lysing viable suspensions of all of the C. difficile strains 
tested, with a significantly broader host range than the phage itself, and had no activity 
against clostridium-like members that are part of the gastrointestinal (GI) tract of 
organisms. 
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The majority of phage lysins characterised to date have been identified using the method 
adopted by Meyer and colleagues (2008). While it is an effective approach, it is time-
consuming and dependent on the isolation of sufficient quantities of phage particles to 
enable subsequent sequencing (Schmitz et al., 2010). 
Due to our failure to induce and propagate sufficient quantities of C. difficile phage, as 
described in Chapter 3, we were compelled to adopt an alternative bioinformatics-based 
approach in which we identified potential lysin genes by screening published C. difficile 
genome and bacteriophage sequences for homologues to known lysins. Using this 
approach we identified, cloned and expressed a 789bp open reading frame (ORF) 
encoding a putative phage endolysin from the genome of C. difficile 630, based on its 
similarity to previously characterised C. difficile phage lysins and its presence in all C. 
difficile strains that have been tested by PCR (Chapter 5) and furthermore five endolysin 
genes from the following published bacteriophage nucleotide sequences: φCD27, φC2, 
φCD119, φCD6356 and φCD38-2.  
 
Furthermore, we report the cloning and expression of mutated endolysin sequences, 
namely LysCD227, which was generated from φCD27 endolysin sequences, in order to 
investigate the effect of sequence modification on the activity of endolysin. 
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4.1.2     Aim of this study  
The aims of this chapter are: 
 To clone and express endolysins from C. difficile phage and to determine their 
ability to lyse vegetative C. difficile.  
 To clone and express potential lysins from the C. difficile genome and to 
determine their ability to lyse vegetative C. difficile and assess the utility of 
bacterial genomic sequencing in the identification of non-phage origin endolysins. 
 To investigate the effect of cell wall binding domain-based modifications on the 
activity and specificity of endolysin. 
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4.2    Materials and methods 
This project was approved as a Containment Level 1 study by Cardiff University’s 
Genetic Modification Safety Committee (GMSC) and the Health and Safety Executive 
(HSE). 
4.2.1    Bioinformatics methods 
4.2.1.1    Bioinformatic analysis of C. difficile phage-encoded endolysin 
sequences 
The nucleotide sequences of the endolysin-encoding genes were identified from the 
National Center for Biotechnology Information (NCBI) database-by employing several 
database search strategies (Table 4.1). The protein sequences of each endolysin were 
subject to multiple sequence alignment using T-Coffee (Notredame et al., 2000), and 
functional domains of each endolysin were searched against the Pfam database 
(http://pfam.sanger.ac.uk/search) (Finn et al., 2010). Signal peptide predictions were 
made using SignalP v4.0 (Petersen et al., 2011; Gram-positive organism group) and 
SOSUIsignal, (Gomi et al., 2004). The  predicted molecular weight (MW) of each 
endolysin protein was determined using ExPASy tools (http://web.expasy.org/compute_pi/) 
(Gasteiger et al., 2003) and protein solubility was estimated according to Wilkinson-
Harrison (Wilkinson and Harrison, 1991; Davis et al., 1999; Harrison, 2000) using their 
web-server (http://www.biotech.ou.edu/). 
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Bacteriophage Endolysin Locus Gene length (bp) References 
φCD119 LysCD119 AAZ32275 816 (Govind et al., 2006) 
φC2 LysC2 ABE99499 813 (Goh et al., 2005) 
φCD27 LysCD27 ACH91325 812 (Mayer et al., 2008) 
φCD6356 LysCD6356 ADK37890 807 (Horgan et al., 2010)   
φCD38-2 LysCD38-2 AEF56898 807 (Sekulovic et al., 2011) 
            
Table 4.1.  The endolysin gene nucleotide sequences used in this study 
 
 
 
4.2.1.2   Bioinformatic analysis of C. difficile genome-encoded lysin sequences 
In the current study, the genomes of the following sequenced strains of C. difficile were 
analysed for the presence of endolysins: 
 630 (#NC_009089) 
 NAP08 (#NZ_GG770710) 
 QCD-97b34 (#NZ_ABHF02000060)  
 QCD76w55 (#NZ_CM000661)  
 CIP107932 (#NZ_CM000659) 
 QCD-66c26 (#NZ_CM000441)  
 ATCC43255 (#NZ_CM000604) 
 QCD-23m63 (#NZ_CM000660)   
 NAP07 (#NZ_GG770749  
 QCD-63q42 (#NZ_ABHD02000060) 
 002-P50-2011 (#NZ_JH379598) 
 QCD37x79(#NZ_ABHG02000042) 
 70-100-2010 (#AGAC01000002) 
 CD196 (#NC_013315) 
 R20291 (#NC_013316) 
 BI1 (#NC_017179) 
 QCD-32g58 (#NZ_CM000287) 
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The protein sequences were chosen and analysed using the following criteria: 
 The proteins that were designated as endolysin or lysin by the GenBank 
database (Benson et al., 2012). Following identification, each sequence was 
run against BLASTp (Altschul et al., 1990) to identify further potential lysin 
homologues.  
 The proteins that were designated as lysin for germination or cell surface 
protein were eliminated.  
 All protein sequences were subject to Pfam domain analysis (Finn et al., 
2010). 
 Signal peptides at the N-terminal region of each lysin were predicted using 
SignalP v4.0 (Petersen et al., 2011; Gram-positive organism group) and 
SOSUIsignal, (Gomi et al., 2004). 
 Any newly identified homologues were added to the original list until 
September 2012. 
 Phylogenetic analyses of lysin amino acid sequences was performed using  
Molecular Evolutionary Genetics Analysis (MEGA) software MEGA5 
(Tamura et al.,2011) utilising the ClustalW2 program from EBI 
(http://www.ebi.ac.uk/Tools/msa/clustalw2; Larkin et al., 2007; Goujon et al., 
2010). 
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4.2.1.3   Bioinformatic analysis of lysin sequences derived from mutated CD27 
endolysin  
 
 
A mutated version of LysCD27 called LysCD227 was generated by introducing a single 
point mutation to the nucleotide sequence of the C-terminal domain at nucleotide 768 
where an aspartic acid was substituted for a glutamic acid. The LysCD27 endolysin was 
chosen to perform this study on the basis that its activity has been well characterised 
(Mayer et al., 2008).  
To model the potential effect of this mutation on the tertiary structure of the protein, we 
constructed an in silico predictive structural model using Molecular Operating 
Environment (MOE) (Chemical Computing Group Inc., Montreal, Canada) software 
( www.chemcomp.com). The models were built by using homology modelling using the 
structures of the φCD27 endolysin (Protein Data Bank (PDB) code 3QAY ( at 
http://www.pdb.org) (10.1128/JB.00439-11) and Listeria monocytogenes phage PSA 
endolysin (PlyPSA)(PDB code: 1XOV) (10.1016/j.jmb.2006.08.069) as templates. The 
sequences were aligned and the φCD27 endolysin was used to model the catalytic 
domain, while the PlyPSA was only used to model the binding domain. The final model 
was then energy minimized using the Amber 99 force field, until a RMSD gradient of 
0.05 Kcal mol
-1 
was reached. 
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4.2.2   Molecular biological materials and methods  
 
Individual endolysin sequences used in this study were codon optimised to enhance 
expression from E. coli using a commercial algorithm (Genscript Inc.). Sequences were 
then chemically synthesised and cloned into pUC57, after which they were sub-cloned 
into pQE30 (QIAgen Inc.) to generate N terminal histidine-tagged fusion proteins. 
The constructed plasmids were subsequently transformed into chemically competent E. 
coli M15 [pREP4] and SG13009 [pREP4] as described in Chapter 2 (2.2.4) 
Recombinant proteins were then expressed, analysed, and purified under native 
conditions, as described in Chapter 2 (2.2.5 and 2.2.6). 
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4.2.3   Microbiological materials and methods 
4.2.3.1   Bacterial strain and growth conditions   
The bacterial strains employed in this study were described in Chapter 2 (Table 2.1 and 
table 2.2).  
4.2.3.2   Biochemical properties of endolysins 
To characterise the activity of each recombinant lysin, a range of biochemical properties 
were determined using the Bioscreen method, which included the effect of suspension 
media, pH, heat, concentration and thermostability on activity and stability. 
To determine the effect of bacterial suspension media on the enzymatic activity, cells of 
C. difficile were suspended in PBS, BHI broth and 20mM sodium phosphate buffer and 
treated with 7.0μg/ml of recombinant lysin at 37°C for 1 h.  
To determine the effect of different concentrations of purified lysin on cell lysis, the 
following concentrations were tested: 0.875, 1.75, 3.5 and 7.0 µg/ml. 
The activity profile under different pH conditions was examined in PBS buffer adjusted 
to pH between 4 and 9 and suspensions were treated with 7.0μg/ml protein concentration 
at 37°C.The sensitivity to heat of each lysin was also assessed by  pre-incubation of the 
enzyme for 30 min at a range of temperatures (37,45,50,60,70°C) prior to mixing with a 
cell suspension of C. difficile cells in 20mM sodium phosphate at pH7. 
The thermostability of the recombinant lysins stored at 37°C and room temperature for a 
period of 2 weeks was also determined.  
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4.2.3.3   Biological activity of endolysins  
 
The lytic activity of each endolysin was determined by measuring the decrease in optical 
density of a C. difficile cell suspension following the addition of the endolysin using a 
method based on that previously described by Mayer and colleagues (2008). Briefly, 
cultures of selected isolates of C. difficile  and other Gram positive strains were grown 
anaerobically-aerobically as appropriate at 37°C to mid-log phase (OD600 0.4-0.6) in 45 
ml of BHI broth and were then harvested by centrifugation (5,000xg for 5 min); pellets 
were then resuspended in 20mM sodium phosphate buffer (pH 7) to an OD600 of 0.8–1.2.   
A 270 μL aliquot of bacterial cell suspension was then added to the well of a Bioscreen 
plate (Honeycomb Bioscreen plates: Thermo Scientific, UK) and mixed with 20 μL of 
recombinant lysin (∼7 μg). Negative controls comprised of cell suspensions mixed with 
20 μL of buffer. Following inoculation, the Bioscreen plates were incubated aerobically 
at 37°C  with shaking for 2 sec on a Bioscreen C (Labsystems, Helsinki, Finland), and 
monitored for changes in Optical density OD600 at 2 min intervals over a 1 h period. 
 
Lytic activity was calculated using the following equation: 100 x (OD600nm of control 
without lysin - OD600nm of reaction mixture)/OD600nm of control without enzyme. 
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The activity of lysins against C. difficile cells on CDMN plates were also determined, 
using a method described previously by Simmons and co-workers (2010), with slight 
modifications. Plates were prepared as follows: 1 ml of C. difficile BHI broth, which was 
left to grow to the mid-log phase (OD600 0.4 to 0.6), was poured directly on to the pre-
reduced CDMN agar. Excess liquid was removed and the plate was allowed to dry; then, 
20 μL of recombinant lysin (7 μg) was added. Subsequently, plates were incubated 
anaerobically at 37°C for 24 h and then checked for lysis zones. PBS buffer was also 
spotted onto plates as a negative control.  
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4.3   Results 
4.3.1  Bioinformatic analysis of C. difficile phage-encoded endolysin sequences  
The amino acid sequences of the endolysins from the published C. difficile-specific phage 
φCD119, φC2, φCD27, φCD6356 and φCD38-2 were downloaded from the NCBI 
database and subjected to bioinformatic analysis. 
All had a similar modular structure composed of a single enzymatically-active domain 
(EAD) and the cell-wall binding domain (CBD). Structural analysis using Pfam domain 
analysis showed that all of the phage endolysins belonged to the amidase-3 (N-
acetylmuramoyl-L-alanine amidase) family. Surprisingly, comparison of the amino acid 
sequence of the N -terminal regions found that rather than being highly conserved, as one 
might expect given that they all belonged to the same functional group, they showed a 
greater degree of diversity than the C terminal domain (Figure 4.1). 
 
Interestingly, although CBD is designed to act on the same bacterial cell wall, each 
endolysin appears to carry a distinct CBD, suggesting that several different ligands of that 
cell compartment might be targeted by the endolysins. However, Pfam analysis failed to 
recognise any known CBD in their C-terminal regions (Figure 4.1). 
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Figure 4.1.  Domain architecture of endolysins (A) Schematic representation of endolysin 
domain organisation. The blue rectangle delimits the enzymatically-active domain (EAD) of N-
acetylmuramoyl-L-alanine amidase (amidase3) and the yellow rectangle denotes the cell-wall 
binding domain (CBD), using previously characterised endolysin (Mayer et al., 2011). 
(B)Alignment of the endolysin sequences taken from NCBI was conducted using T-Coffee. All 
endolysins carry N-acetylmuramoyl-L-alanine amidase (amidase3) at their N-terminal region. 
Regions of sequence homology are indicated by (*) and similar amino acids (:). 
 
 
 
 
 
 
LysCD27         1 MKICITVGHSILKSGACTSADGVVNEYQYNKSLAPVLADTFRKEGHKVDVIICPEKQFKTKNEEKSYKI   69  
LysC2           1 MKICITVGHSILKSGACTSADGVVNEYQYNKSLAPVLADTFRKEGHKVDVIICPEKQFKTKNEEKSYKI   69  
LysCD119        1 MKIGVNCGHTK--TGAGSGAIGKINESIETRNVGYKVIDKLKTLGNNV--VDCTIDKASTQSECLSKIA   65  
LysCD6356       1 MKVVLTAGHTL--TGKGTGATGYINEGKENRILMDLVVKWLKKGGATV--YSGKVDKS---NNYLSEQC   62  
LysCD38-2       1 MRVALTAGHTL--TGKGTGATGYINEGTENRILMDLVVKWLKKGGATV--YSGKVDKS---NNYLAEQC   62  
                  *:: :. **:   :*  :.* * :**   .: :   : . ::. * .*       .:    .:  :       
 
LysCD27        70 PRVNSGGYDLLIELHLNASNGQ--GKGSEVLYYSNKGLEYATRICDKLGTV-FKNRGAKLDK-RLYILN  134  
LysC2          70 PRVNSGGYDLLIELHLNASNGQ--GKGSEVLYYSNKGLEYATRICDKLGTV-FKNRGAKLDK-RLYILN  134  
LysCD119       66 TQANRQDLDWFISIHFNAGK----GRGCEVYTYKGKQYQDAIDVCKKISDLGFTNRGVKDGS-GLYVVK  129  
LysCD6356      63 QIANKRNVDLAVQIHFNANKTTINPMGTETIYKTNNGKVYAERVNEKLATV-FENRGAKSDARGLYWLR  130  
LysCD38-2      63 QIANKQNVDVAVQIHFNADHTTLNVMGTETIYKTNNGKVYAERVNEKLATI-FKNRGAKSDARGLYWLS  130  
                    .*  . *  :.:*:**.:      * *.   ..:    *  : .*:. : * ***.* .   ** :    
 
LysCD27       135 SSKPTAVLIESFFCDNKEDYDKAKKLGHEGIAKLIVEGVLNKNINN-EG---VKQMYKHTIVYDGEVDK  199  
LysC2         135 SSKPTAVLIESFFCDNKEDYDKAKKLGHEGIAKLIVEGVLNKNINN-EG---VKQMYKHTIVYDGEVDK  199  
LysCD119      130 KTKAKSMLIEVCFVDSEDA-NKYLSLGADKLATAIVEAIT-KHISSAEEN--NYNRYKHTIVYSGD-DK  193  
LysCD6356     131 HTKAPAILIEVCFVDSKADTDYY-IRHKDIVAKLIAEGILNKNIDN-KENGEDKKMYKHTIVYDGEVDK  197  
LysCD38-2     131 HTKAPAILIEVCFVDSKADTDYY-IRHKDIVAKLIAEGILNKTIDN-KENSEDKKMYKHTIVYDGEVDK  197  
                   :*. ::***  * *.:   :       : :*. *.*.:  * *.. :      : *******.*: **   
 
LysCD27       200 ISATVVGWGYNDGK--ILICDIKDYVPGQTQNLYVVGGGACEKISSI---TKEKFIMIKGNDRFDTLYK  263  
LysC2         200 ILANVLSWGYSPSK--VLVCDIKDYVPGQTENLYVVGGGACEKISSI---TKEKFIMIKGNDRFDTLYK  263  
LysCD119      194 VSADILGLYYKRKKESYLVTDIKDYKPHRTQNLYVIGGVTCNKMKEMSKTTGEKFTQLYGNDVWSTMDK  262  
LysCD6356     198 ILATVLGWGYSSSK--VLVCDIKDYIPGQTQNLYVVGGGACEKIGSI---TKEHYTTIKGNDRFDTLHK  261  
LysCD38-2     198 IPATVVGWGYNDGK--ILICDIKDYVPGQTQNLYVVGGGACEKIGSM---TKEKFTMIKGNDRFDTLYK  261  
                  : * ::.  *.  *   *: ***** * :*:****:** :*:*: .:   * *::  : *** :.*: *   
 
LysCD27       264 ALDFIN--R  270  
LysC2         264 ALDFIN--R  270  
LysCD119      263 AIEFVKEKL  271  
LysCD6356     262 VLDFIK--K  268  
LysCD38-2     262 ALDFID--R  268  
                  .::*:.      
A 
 
B 
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4.3.2   Bioinformatic analysis of C. difficile genome-encoded lysin sequences 
Putative lysin sequences located within the genome sequences of the C. difficile isolates 
deposited in GenBank were screened for the presence of putative proteins with the 
following properties: 
 (A) A N-terminal enzymatic domain and a C-terminal binding region with the absence of 
additional domains which may encode non-lysis function (Schmitz et al., 2010). 
 (B) A N-terminal sequence lacking a signal peptide which is often present in cell 
autolysins (Blackman et al., 1998; Vollmer et al., 2008; Schmitz et al., 2010). 
In total, 87 proteins were identified from 17 C.difficile genomes which fit the above 
criteria (Table 4.2). Of this total, 52 were predicted to possess an N-acetylmuramoyl-L 
alanine amidase at the N-terminal. This enzyme cleaves the amine bond between the L-
alanine of the peptide chain and N-Acetylmuramic acid (MurNAc). The majority (51) 
belonged to the N-acetylmuramoyl-L-alanine amidase family 3 (PF01520), while the 
remaining protein was from the N-acetylmuramoyl-L-alanine amidase family 2 
(PF01510).  
 The remaining 35 proteins were predicted to carry an Mannosyl-glycoprotein endo-beta-
N-acetylglucosaminidases (Glucosaminidase) (PF01832), which hydrolyses 
peptidoglycan bonds between N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc). Interestingly, Pfam failed to identify any conserved domains in the C terminal 
region of all of the proteins. 
 Page | 133 
 
Source Gene accession no Domains  Source Gene accession no Domains 
 BI1 YP_006198983 
YP_006199265 
YP_006198983 
YP_006198687 
YP_006198091 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase 
 QCD-37x79  
 
 
ZP_05399195 
ZP_05399316 
ZP_05399324   
Amidase_3 
Amidase_3 
Amidase_3 
ATCC43255 ZP_05351369  
ZP_05350750 
ZP_05350132 
ZP_05352351 
ZP_05351060 
ZP_05350856 
 ZP_05351372 
Amidase_3 
Amidase_3 
Glucosaminidase  
Amidase_2 
Amidase_3 
Amidase_3 
Glucosaminidase 
QCD-97b34 ZP_05386798 
ZP_05384969 
ZP_05385260 
ZP_05384675 
ZP_05385264 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase 
R20291 YP_003218580 
YP_003218307 
YP_003218576 
YP_003217960 
YP_003217390 
Glucosaminidase 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase 
NAP08 ZP_06892601 
 ZP_06892148 
EFH07492 
ZP_06891530 
EFH08309   
Amidase_3 
Glucosaminidase 
Glucosaminidase 
Glucosaminidase 
Glucosaminidase 
CD196 YP_003215071 
YP_003214798 
YP_003215067 
YP_003214516 
YP_003213943 
Glucosaminidase 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase 
NAP07 ZP_06903479 
ZP_06901942 
EFH15484 
EFH16819 
ZP_06903476 
Glucosaminidase 
Glucosaminidase 
Glucosaminidase 
Glucosaminidase 
Amidase_3 
050-P50-2011 ZP_17072773 
EHJ24718 
EHJ26281 
EHJ25719 
EHJ26800  
EHJ31012 
EHJ31282 
ZP_17076819 
ZP_17075489 
ZP_17074811 
EHJ29023 
EHJ25043 
EHJ27323 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase 
Glucosaminidase 
Glucosaminidase 
Glucosaminidase 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
70-100-2010 EHJ38445 
EHJ40888  
ZP_17077665 
EHJ39933 
 
Glucosaminidase 
Glucosaminidase 
Amidase_3 
Amidase_3 
 
630 YP_001087453 
YP_001089407              
YP_001088405  
CAJ67875 
CAJ69071 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase  
Glucosaminidase 
QCD-63q42 ZP_05332329 
ZP_05331981 
ZP_05331962 
ZP_05331929 
ZP_05331399 
ZP_05330908 
ZP_05330302 
ZP_05329048 
ZP_05330299 
ZP_05330002   
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Amidase_3 
Glucosaminidase 
Glucosaminidase 
 Amidase_3 
Amidase_3 
CIP107932 ZP_05322060 
ZP_05322650 
ZP_05321453 
Amidase_3 
Glucosaminidase 
Glucosaminidase 
QCD-66c26 ZP_05271664 
ZP_05271057 
ZP_05272257 
Amidase_3 
Glucosaminidase 
Glucosaminidase 
QCD-23m63 ZP_05402087 
ZP_05400420 
ZP_05401584 
Amidase_3 
Glucosaminidase 
Glucosaminidase 
QCD-76w55 ZP_05355902 
ZP_05356497 
ZP_05355293 
Amidase_3 
Glucosaminidase 
Glucosaminidase 
QCD-32g58 ZP_07406968 
ZP_07406964 
ZP_07406453 
ZP_07406726 
Glucosaminidase 
Amidase_3 
Amidase_3 
Amidase_3 
Table 4.2. Domain structure of 87 endolysin and lysin-like proteins from the 17 C. difficile strains. The 87 protein sequences were 
identified representing two classes of endolysin: Amidase and Glucosaminidase.
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Subsequently, we decided to focus on protein sequences which carried amidase lysin 
class 3 domains, since all of the C. difficile phages isolated to date also carried this type 
of endolysin at their N-terminal region. 
The evolutionary analysis was conducted by MEGA5  and constructed using the 
Neighbor-Joining method (Figure 4.2) and Maximum Likelihood method (Appendix 2) 
.The evolutionary history showed that all C. difficile amidase lysin amino acid sequences 
clustered in two groups: group 1, which  contains endolysin sequences from Siphoviridae 
phages, including those from C. perfringens phages φ39-O, φCP13O, φCP26F, φCP34O 
and φCP9O, and from a C. sporogenes phage φ8074-B1 (Oakley et al.,  2011; Mayer et 
al., 2012). Interestingly, the endolysin sequence of C. difficile phage CD119, which 
belongs to the Myoviridae group, is also present in this group. 
 
Group 2 comprises sequences derived from phages belonging to the Myoviridae family. 
 Many of the proteins identified by this process were encoded in regions of the genome 
thought to correspond to prophages or prophage remnants. In addition, some of these 
sequences showed considerable homology to previously described phage endolysins. For 
example, the genome of C. difficile QCD-63q42 contains two protein sequences 
(ZP_05331399 and ZP_05331929) which share 100% amino acid identity with the 
endolysins φCD27 and φCD38-2, respectively. Furthermore, the lysin sequence from C. 
difficile QCD-37x79 (ZP_05399316) shares 100% amino acid identity with the φCD38-2 
endolysin sequence (Figure 4.2). Interestingly, these genes are located in a region of the 
genome which does not contain other putative phage-derived genes. 
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Figure 4.2.  Evolutionary relationship of lysin sequences encoded peptidoglycan hydrolase, 
N-acetylmuramoyl-L-alanine amidase from C. difficile genomes and phages. 
The evolutionary history was inferred using the Neighbor-Joining method. The percentage of 
replicate trees in which the associated taxa clustered together in the bootstrap test (1000 
replicates) is shown next to the branches. The evolutionary distances were computed using the 
Poisson correction method based on their amino acid sequences. The analysis involved 65 amino 
acid sequences including C. difficile phage endolysins (φCD119, φCD2, φCD27, 
φMMP03,φMMP04, φCD6356 and φCD38-2), C. perfringens phage endolysin (φ39-O, φCP13O, 
φCP26F, φCP34O, φCP9O) and C. sporogenes phage (φ8074-B1). All positions containing gaps 
and missing data were eliminated. There were a total of 180 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA5.      
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This is not always the case; for example, ZP_05352351, the lysin carried by C. difficile 
ATCC43255 contains an amidase class 2 domain which was followed by a gene 
predicted to encode a holin, suggestive of the fact that this strain had previously been  
infected by a class of phage ,which has not been previously described in C. difficile. The 
presence of  numerous lysins in the genome of multiple C. difficile strains located in 
regions lacking any other phage-related sequences suggests that these genes may 
represent evolutionary  relic of past phage infection. 
 
C. difficile strain 630 contains three putative endolysin sequences located in locus 
(YP_001087453, YP_001089407 and YP_001088405), which are homologous to 
previously described phage endolysins. Two of these genes (YP_001087453 and 
YP_001089407) are identical and share 97% amino acid identity with the endolysin from 
φCD119. They are located in a region of the genome of 630 which has been annotated as 
prophage 1 and 2 (prophage 1 CD0904-0979 and prophage 2 CD2889-2952 (Sebaihia et 
al., 2006; Goh et al., 2007; Monot et al., 2011).  
The remaining sequence (YP_001088405) is located outside of these prophage regions 
and was found to have the greatest homology (62% amino acid identity) with the 
endolysin from φCD6356.  
Interestingly , BLASTn searches revealed that the nucleotide sequence of this gene 
appears to be highly conserved in that a   homology (96% homology or higher) has been 
found in all nine strains of C. difficile  sequenced to date (Sebaihia et al., 2006; Stabler et 
al., 2009; He et al., 2010; Monot et al., 2011).  
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We further confirmed the universal nature of this gene using a PCR based approach, 
which identified the presence of a homologous gene in 85 isolates of C. difficile (Chapter 
5). For this reason, the lysin encoded by YP_001088405 was selected and expressed as a 
recombinant protein. 
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4.3.3   Bioinformatic analysis of the mutated endolysin (LysCD227) 
During the course of this study, we generated a mutated version of the LysCD27 lysin 
called LysCD227, which differed from LysCD27 due to a single point deletion in the 
nucleotide sequence at the C-terminal domain (T at position 768). This mutation resulted 
in two endolysins which shared 100% homology in their enzymatically-active domain 
(EAD), but only 84% homology within the cell-wall binding domain (CBD) (fig 4.3).  
 
LysCD27         MKICITVGHSILKSGACTSADGVVNEYQYNKSLAPVLADTFRKEGHKVDVIICPEKQFKT 60 
LysCD227        MKICITVGHSILKSGACTSADGVVNEYQYNKSLAPVLADTFRKEGHKVDVIICPEKQFKT 60 
                ************************************************************ 
 
LysCD27         KNEEKSYKIPRVNSGGYDLLIELHLNASNGQGKGSEVLYYSNKGLEYATRICDKLGTVFK 120 
LysCD227        KNEEKSYKIPRVNSGGYDLLIELHLNASNGQGKGSEVLYYSNKGLEYATRICDKLGTVFK 120 
                ************************************************************ 
 
LysCD27         NRGAKLDKRLYILNSSKPTAVLIESFFCDNKEDYDKAKKLGHEGIAKLIVEGVLNKNINN 180 
LysCD227        NRGAKLDKRLYILNSSKPTAVLIESFFCDNKEDYDKAKKLGHEGIAKLIVEGVLNKNINN 180 
                ************************************************************ 
 
LysCD27         EGVKQMYKHTIVYDGEVDKISATVVGWGYNDGKILICDIKDYVPGQTQNLYVVGGGACEK 240 
LysCD227        EGVKQMYKHTIVYDGEVDKISATVVGWGYNDGKILICDIKDYVPGQTQNLYVVGGGACEK 240 
                ************************************************************ 
LysCD27         ISSITKEKFIMIKGNDRFDTLYKALDFINR 270 
LysCD227        ISSITKEKFIMIKGNEDLIHFIKHWILLID 270 
                ***************: :  : *   ::   
 
Figure 4.3. Comparison of the endolysin sequences of LysCD27 (from φCD27), and 
mutated LysCD227. The enzymatically-active domain (EAD) and the cell-wall binding domain 
(CBD) are marked with blue and yellow colour, respectively. Regions of sequence homology are 
indicated by (*). EAD regions are identical (100% homology), CBD regions are only 84%. The 
sequences were aligned using ClustalW2. 
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In an attempt to predict the effect of this mutation on the structure of the endolysin, we 
constructed a 3D in silico model for these endolysins (Figure 4.4).    
Our modelling, based on previously published crystal structure data, revealed that the 
enzymatic domain consisted of five helices flanked by six-twisted β-sheets connected to 
the cell wall binding domain, which is formed by 7 β-sheets (Mayer et al., 2011) . As can 
be seen from the model, the single point mutation in LysCD27 was predicted to cause a 
structural change to make the protein more lipophilic. 
 Page | 140 
 
 
Figure 4.4.  Structural comparison of endolysins (LysCD27 and LysCD227 .  A: Alignment of  endolysins showing the enzymatically-
active domain (EAD) and the cell-wall binding domain (CBD). LysCD27 is purple and LysCD227 is blue. The dashed circle highlights the 
area containing the difference. 
 
B: Showing the 3D structure of endolysins displaying the hydrophilic (purple), lipophilic (green) and neutrophilic (white) residues.
 EAD 
LysCD27  LyCD227 
A 
B 
CBD EAD 
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4.3.4   Cloning and expression of lysins of E. coli 
4.3.4.1   DNA Manipulation  
Individual protein sequences were codon optimised for expression in E. coli by Genscript 
Inc.  Gene sequences were synthesised and cloned into pUC57 and then sub-cloned into 
the QIAgen expression vector pQE30, where they were placed downstream of a histidine 
affinity tag and under the control of an inducible T5 promoter. Following insertion, 
plasmids were sequenced to ensure the correct orientation of the gene, after which the 
recombinant plasmid was transformed into competent cells of E. coli M15[pREP4] and 
SG13009[pREP4] for protein expression.  Positive transformants were identified by 
culture on LB agar plates containing ampicillin (100 μg/ml) and kanamycin (25 μg/ml). 
 
Endolysin Gene 
length (bp) 
Protein 
length (aa) 
Predicted 
MW (kDa) 
Protein Solubility 
prediction 
LysCD119 816 271 30.16 81.0% insolubility 
LysC2 813 270 30.16 86.7% insolubility 
LysCD27 813 270 30.14 85.9% insolubility 
LysCD6356 807 268  29.9 79.5% insolubility 
LysCD38-2 807 268 29.84 69.7% insolubility 
*LysCD227 812 270 30.12  81.8% insolubility 
**LysCD630  789 263  28.57 72.5% insolubility 
 
Table 4.3.  Showing the details of endolysin sequences used in this study, and the predicted 
MW which was generated using ExPASy tools (http://web.expasy.org/compute_pi/). *LysCD227 
is the modified endolysin generated from phage CD27 endolysin, as described before in the 
methods section. **LysCD630 is the putative endolysin from C. difficile 630. 
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While the transformation efficiency of the pQE30 plasmid containing the endolysin genes 
was lower than that seen for the positive control plasmid (pQE-40), it was still efficient 
enough to yield the desired transformants (Table 4.4). M15 seems to provide a 
statistically significantly better transformation ratio than SG13009; therefore, E. coli M15 
was select for further work. 
 
Endolysin construct 
Transformants /µg of plasmid DNA 
M15 SG13009 
LysCD27 167.5±11X10
3
 150.8±6.9X10
3
 
LysC2 192.3±5X10
3
 214.4±2.2X10
3
 
LysCD119 321.4±24X10
3
 498.8±22X10
3
 
LysCD630 385.5±20.6X10
3
 229.8±8X10
3
 
LysCD6356 305.5±4.2X10
3
 266.4±2.7X10
3
 
LysCD38-2 267.6±7.8X10
3
 251.6±4.1X10
3
 
LysCD227 279.9±8.1X10
3
 222.3±2.5X10
3
 
pQE40 341.5±459X10
3
 286±232X10
3
 
 
Table 4.4. Transformation efficacy in E. coli M15 and SG13009  ,using 100 μl of the 
overnight culture plated out on LB-agar plates for 24h (readings represent the mean of three 
results± sd). pQE-40 control plasmid, which expresses 6xHis-tagged DHFR, is optimised for a 
high-level of transformation and expression into these E.coli strains. 
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4.3.4.2  Optimisation of recombinant protein expression, analysis and 
purification 
 
As described in Chapter 2, expression cultures were grown in LB broth containing 
ampicillin (100 μg/ml) and kanamycin (25 μg/ml) at 37°C and 300 rpm to an OD600nm of 
0.6. Cultures were induced by the addition of IPTG to a final concentration of 1 mM. 
Under these conditions, the recombinant proteins formed insoluble inclusion bodies, so 
the culture temperature was reduced to 27°C, which is a temperature that has been 
reported to reduce the formation of inclusion bodies (Zimmer et al., 2002; Dhalluin et al., 
2005). 
The expression of recombinant proteins following induction was monitored over time and 
the results revealed that approximately 4 h of incubation was required for sufficient 
protein production (Figure. 4.5 B, 4.6 B). Following 4h of incubation, expression cultures 
were harvested and the recombinant proteins were purified under native conditions using 
Nickel–nitrilotriacetic acid (Ni–NTA) affinity chromatography. 
 
Protein bands with a molecular weight of approximately (~30 kDa), the expected size 
range of the recombinant lysins (as described in table 4.3), were visualised in SDS-PAGE 
gels stained with Coomassie blue stain following induction. Protein purification was also 
performed with cells harbouring the empty vector (pQE40), with the eluate serving as a 
negative control in the subsequent activity assays. 
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Typically, the protein yields obtained from 100 ml cultures of E. coli M15 were 
approximately 3, 2.5, 4, 1.5, 3.5, and 2 mg for endolysins of LysCD119, LysC2, 
LysCD27, LysCD6356, LysCD630, LysCD227 and LysCD38-2, respectively, as 
determined using the BCA protein assay (section 2.2.7).   
 In figures 4.5 and 4.6 we compare recombinant protein induction and purification from 
phage origin endolysin (LysC2) and non-phage origin endolysin LysCD630; it can be 
seen that LysCD630 was induced and extracted in the same way as other phage 
endolysins extracted with almost the same yield. 
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Figure 4.5.  LysC2 endolysin extraction ,  ( predicted size 30 kDa) 
A) Time-course analysis of LysC2 at 37°C. Aliquots were removed post-induction at the time indicated 
and analysed by SDS-PAGE and Coomassie blue stain. 1: Molecular weight marker. NI: non-induced 
control, N0:0 hour induced, C: crude, INS: insoluble, SO: soluble.  
B) Time-course analysis of LysC2 at 27°C. Aliquots were removed post-induction at the time indicated 
and analysed by SDS-PAGE and stained with Coomassie blue stain. 1: Molecular weight marker. NI: non-
induced control, N0: 0 hour induced, C: crude, INS: insoluble, SO: soluble.  
C) LysC2 protein extraction: Lanes: 1, marker; 2, non-induced culture; 3, 1h  induced culture; 4, total 
protein extracts after  4 h  of induction with IPTG; 5, column flow-through; 6, primary wash effluent; 7, 
secondary wash effluent; 8, 1
st
 eluate (E1); 9, 2
nd
 eluate (E2); 10, 3
rd 
eluate (E3); 11, 4
th
 eluate (E4); 12,  
buffer exchange 20mM NaPhos pH 6; 13, marker. 
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Figure 4.6.  LysCD630 putative endolysin extraction ,  ( predicted size 28 kDa) 
A) Time-course analysis of LysCD630 protein at 37°C. Aliquots were removed post-induction at the time 
indicated and analysed by SDS-PAGE and Coomassie blue stain. 1: Molecular weight marker, NI: non-
induced control, N0: 0 hour induced, C: crude, INS: insoluble, SO: soluble.  
B) Time-course analysis of LysCD630 protein at 27°C. Aliquots were removed post-induction at the time 
indicated and analysed by SDS-PAGE and stained with Coomassie blue stain. 1: Molecular weight 
marker .NI: non-induced control, N0: 0 hour induced, C: crude, INS: insoluble, SO: soluble.  
C) LysCD630 protein  extraction: Lanes: 1, marker; 2, non-induced culture; 3, 1h induced culture; 4, total 
protein extracts after 4 h of induction with IPTG; 5, column flow-through; 6, primary wash effluent; 7, 
secondary wash effluent; 8, 1
st
 eluate (E1); 9, 2
nd
 eluate (E2); 10, 3
rd 
eluate (E3); 11 , 4
th
 eluate (E4); 12,  
buffer exchange 20mM NaPhos pH 6; 13, marker. 
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4.3.4.3   Protein detection: Western blot 
The identity of the recombinant endolysin proteins was confirmed by probing western 
blots (as described in Chapter 2 section 2.2.9). Probing was accomplished with an 
antibody, Penta-His, which recognised the N-terminal histidine tag antibody and the 
secondary antibody, which detected the reciprocal proteins on the nitrocellulose 
membrane by producing the dark band signal, as shown in figure 4.7 .The signals were 
seen at the membrane region corresponding to a molecular weight of ~30 kDa. A protein 
marker (6x His-protein ladder) confirmed the size of the signals.  
 
 
Figure 4.7.  Western blot analysis of purified endolysin: (1) LysCD27 (30kDa), (2) 
LysCD227 (30kDa), (3) LysC2 (30kDa), (4) LysCD119 (30kDa), (5) LysCD6356 (29.9kDa), (6) 
LysCD38-2 (29.4kDa) and (7) LysCD630 (28.5kDa) by western blot technique. M: Pre-stained 
protein marker (6x His-protein ladder 100-15 kDa); C: Negative control. 
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4.3.5   Biochemical properties of lysins 
To determine the pH optimum, the lytic activity of recombinant endolysins was assayed 
at pH values ranging from 4 - 9 in sodium phosphate (Na3PO4). All of the endolysins 
showed their greatest lytic activity at pH5. An example of a typical activity profile is 
shown in figure 4.8, which depicts the activity of the LysCD6356 endolysin against C. 
difficile NCTC11204 across a range of pH values. Lytic activity decreased  at higher pHs, 
resulting in near inactivation at pH 9, a profile that is common amongst phage lysins 
(Loeffler et al., 2003; Yoong et al., 2004; Gu et al., 2011). While activity was greatest at 
pH 5, all subsequent assays were performed at pH 7 to determine the activity of lysins 
under conditions similar to physiological conditions.  
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Figure 4.8.   pH profile of LysCD6356 activity. LysCD6356 (7µg) activity against the C. difficile 
strain NCTC 11204 was tested at pHs 4, 5, 6, 7, 8, and 9 at 37
0
C. Lysin activity was measured by an 
OD assay and plotted as the percentage decrease in OD600 in 30 min. Each column represents the 
mean of results from triplicate assays, and error bars indicate the standard deviation. 
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Temperature stability of the lysins was also determined by incubating the recombinant 
protein at a range of temperatures (37, 45, 50, 60, and 70°C) for 30 min prior to 
determining their lytic activity. An example of a typical temperature stability profile is 
shown in figure 4.9, which depicts the activity of the LysCD6356 endolysin against C. 
difficile NCTC11204. As can be seen from the results presented in figure 4.9, the lytic 
activity of LysCD6356 was lost following incubation at  60°C and 70°C.  
 
 
Figure 4.9.  Temperature stability profile of LysCD6356, purified LysCD6356 lysin was 
incubated for 30 min at the indicated temperatures, followed by the addition of 7µg of lysin to a 
buffered suspension of C. difficile NCTC 11204 in 20mM sodium phosphate ( pH 7) at 37
0
C for 1 
h. The figure reports the treated/untreated OD-ratio for each temperature at 10, 30 and 60 min 
intervals.  Each column represents the mean of results from triplicate assays, and error bars 
indicate the standard deviation 
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To determine the effect of the suspension media on lysin activity, cells of C. difficile 
NCTC 11204 at pH7 were suspended in either 20mM Sodium Phosphate buffer, BHI 
broth or PBS and treated with the LysCD6356 lysin. As can be seen in figure 4.10, lytic 
activity was greatest when the cells were suspended in either PBS or sodium phosphate 
buffer. In contrast, BHI appeared to inhibit lytic activity. 
 
 
 
 
 
We next determined the effect of concentration on the activity of the LysCD6356 lysin 
when suspended in PBS at pH 7. As expected, lytic activity was proportional to the 
concentration of the lysin employed (Figure 4.11).  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
O
D
6
0
0
 
Time (hr) 
A
B
C
D
Figure 4.10.  Lysis activity of LysCD6356 (7µg) with C. difficile NCTC 11204 at pH7 with 
different buffers, assays were performed at 37
0
C for 1h. 
 A - cells  with  PBS only, B - cells in BHI broth with lysin, C - cells in 20mM sodium 
phosphate buffer with lysin, D - cells in PBS  with lysin. Values are the means of results from 
triplicate assays ± standard deviations. 
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Long term Thermostability 
In order to study the effect of storage temperature on lysine stability, LysCD6356 lysin 
was stored for two weeks at room temperature (ranging from 15-20°C) and at 4°C.  
Aliquots were taken at periods of one day, one week and two weeks and were tested for 
structural integrity and biological activity (Figures 4.12 and 4.13). As can be seen from 
figure 4.12, the protein remained largely intact over this time period.     
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Figure 4.11.  Showing the effect of concentration on the lytic activity of the LysCD6356 lysin 
against C. difficile NCTC 11204 , assays were performed at 37°C in pH7 for 1h.  A: PBS, B: 
0.875µg,  C: 1.75 µg , D: 3.5µg ,  E: 7µg. Values are the means of results from triplicate assays ± 
standard deviations. 
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Figure 4.12.  Effect of storage temperature on LysCD6356. Lysin stored at room temperature 
for: (1) one day; (2) one week; and (3) two weeks; lysin stored at 4°C for (4) one day; (5) one 
week; and (6) two weeks (M) Molecular Marker. SDS-PAGE gel of lysin stained with Coomassie 
blue showed that lysin bands were not affected over the time of storage.  
 
Storage of the lysin at room temperature and at 4°C appeared to have little significant 
effect on the activity of lysin (figure 4.13). 
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 Figure 4.13.  Effect of storage temperature on LysCD6356 lysin activity, a7µg of lysin was mixed 
with cells of C. difficile NCTC 11204 in 20mM sodium phosphate, which had been stored under the 
following conditions: (A) 0 time lysin; lysin stored at room temperatures for (1) one day; (2) one week; 
(3) two weeks; lysin  stored at 4°C for (4) one day; (5) one week; (6)two weeks  ,(control): Cells with 
buffer only assays were performed at 37°C, pH7 for 1h. Values are the means of results from triplicate 
assays ± standard deviations. 
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4.3.6   Biological activity 
4.3.6.1   Biological activity of the phage endolysins 
The ability of the endolysins to lyse a dense suspension of a clinical isolate of a 
hypervirulent C. difficile isolate, DS1813, was determined. The results in figure 4.14 
show the relative activity of 7µg of lysin against a mid-log phase cell suspension when 
tested under the same conditions.  The most active lysin was that of LysCD6356 
endolysin, which decreased the optical density of the cell suspension by 66% within 30 
min (p < 0.001). While LysCD6356 endolysin appeared to be the most active lysine, 
LysCD119 was the least active. 
Interestingly, these activity profiles were common for 95% of the C. difficile strains 
tested in our study. We also observed no significant synergistic effects when mixtures of 
lysins were tested against cell suspensions. 
 
Figure 4.14 . Lytic action of all endolysins in a turbidity assay using C. difficile DS1813 cell 
suspensions prepared from mid-log phase growing cultures. Lysis assay performed using 7µg 
at 37°C in pH7 for 1 h. Values are the means of results from duplicate assays ± standard 
deviations. 
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The enzymatic activity of the most active lysin (LysCD6356) against a viable culture of 
C. difficile DS1813 on a CDMN agar was also determined in an agar plate. Following 24 
h incubation, two clear zones of lysis were observed (Figure 4.15).  
 
 
 
 
 
 
 
 
 
 
Figure 4.15.  Spot assay showing the ability of LysCD6356 lysin to lyse on C. difficile 
DS1813 grown on a CDMN plate. A) Control plate, B) Test plate. 
A B 
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4.3.6.2   Biological activity of the endolysin from C. difficile genome 
(LysCD630) 
The study presented here shows the utility of genomic sequencing of C. difficile in the 
identification of candidate lysin. 
The LysCD630 protein expressed and characterised exhibits potent lytic activity in vitro 
against strains of C. difficile. As seen in figure 4.16, LysCD630 demonstrated lytic 
activity that was almost equal to those produced by C. difficile phage endolysin against C. 
difficile 630. Quantitatively speaking, however, the level of activity of these enzymes 
among C. difficile varied somewhat from strain to strain (see figure 4.19). 
 
Figure 4.16.  Lytic action compression between phage endolysins and putative lysin CD630 
in a turbidity assay using  C. difficile 630 cell suspensions prepared from mid-log phase 
growing cultures. Lysis assay was performed using 7µg at 37°C in pH7 for 1h. Values are the 
means of results from duplicate assays ± standard deviations. 
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4.3.6.3   Biological activity of the mutated endolysin (LysCD227) 
Comparison of the lytic activity of the mutated version of the lysin to that of the native 
version  against cells of C. difficile strain NCTC 11204, L. monocytogenes NCTC 5412 
and B. subtilis ATCC 6633, found that the activity of  LysCD227 was significantly 
enhanced compared to that of LysCD27 (Figure 4.17). 
The enhanced activity of LysCD227 for these strains compared to LysCD27 suggests that 
the mutation in the C binding domain had altered the specificity of the lysin. Mayer et al. 
(2011) had previously observed that while L. monocytogenes NCTC 5412 and B. subtilis 
ATCC 6633 were unsusceptible to the full length LysCD27 lysin, the removal of the C 
terminal domain resulted in an enzyme which was able to lyse these bacteria (Figure 
4.17). 
 
Figure 4.17.  Compression of the lytic activities of the LysCD27 and LysCD227 on C. 
difficile strain NCTC 11204, L. monocytogenes NCTC 5412 and B. subtilis ATCC 6633. The 
activity was measured as a percent of OD reduction of bacterial cell suspensions after 30 min of 
incubation using 7µg of endolysin in pH7 at 37°C. Each column represents the mean of results 
from triplicate assays, and error bars indicate the standard deviation 
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Comparison of the lytic activity of LysCD227 and LysCD27 against cells of various 
strains of C. difficile supported the previous result that cell wall binding domain 
modification significantly (Student’s t test; P < 0.05) enhanced the catalytic activity of 
endolysin (Figure 4.18). 
 
 
Figure 4.18.  Lytic activities of LysCD227 and LysCD27 on various ribotypes of C. difficile. 
The activity was measured as percentage OD reduction of bacterial cell suspensions after 30 min 
of incaution using 7µg of endolysin in pH7 at 37°C. Each column represents the mean of results 
from triplicate assays, and error bars indicate the standard deviation 
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4.3.6.4   Spectrum of lytic activity 
 
We determined the ability of all endolysins cloned in this study to target a diverse 
collection of clinical isolates representing the major ribotypes that are prevalent in the 
UK. As can be seen in figure 4.19, LysCD6356 demonstrated the greatest lytic activity 
(one-way ANOVA; P < 0.05) against all strains of C. difficile tested (ribotypes 001, 027, 
106, 014, 002, 005, 078, 020, 010 and 023) with isolates of the 078 ribotype being the 
most susceptible. The second most active endolysin was LysCD38-2, which was the most 
active (one-way ANOVA; P < 0.05) against strains of ribotype 012, 110, 045 and 046, 
based on % of lysis activity after 30 minutes of incubation. Interestingly, both endolysins 
were derived from phages belonging to the Siphoviridae family. 
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Figure 4.19.  Comparison of lytic activities of lysins against a range of ribotypes of C. difficile (n=5 for each ribotype) , lytic activity 
was measured as percent of OD reduction after 30 min of incubation using 7µg of lysin in pH7 at 37°C. These results allowed the direct 
comparison of lysin activities among different ribotypes of C. difficile. Each column represents the mean of results from triplicate assays, 
and error bars indicate the standard deviation. 
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4.3.6.5   Activity of the endolysins against other species of Gram-positive 
bacteria 
The ability of the lysins to target other Gram-positive spore forming bacteria was 
determined using various strains of C.perfringens (Figure 4.20).  
 
Figure 4.20.  Lytic activities of our lysins on various strains of C. perfringens. Graph shows 
percent of reduction in the OD of a bacterial cell suspension after treatment with 7 μg/ml our 
lysin for 30 min. C. difficile DS1813 (ribotype 027), included as a positive sensitive strains. Each 
column represents the mean of results from triplicate assays, and error bars indicate the standard 
deviation. 
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 The lytic activity of our lysins was also evaluated in a few clinical isolates of Gram-
positive bacteria (described in Chapter2, table 2.2) by performing the lysis assay as 
described above. No obvious lytic activity could be determined in any of the clostridium 
isolates, even with the highest protein concentrations used (10 and 15 µg/ml) (Figures 
4.20 and 4.21). However, C. sordellii, which is phylogenetically closely related to C. 
difficile (Collins et al.,1994), seems to be sensitive to some of our lysin; moreover, some 
of our lysins were surprisingly capable of lysing a number of less closely related species, 
such as B. subtilis ATCC 6633, which was significantly sensitive to lysis with 
LysCD227, LysCD630, LysCD119 and LysCD6356. L. monocytogenes NCTC 5412 was 
only significantly sensitive to LysCD227 and LysCD119. 
Interestingly, our lysins were active against species characterised as having 
peptidoglycan type A1γ as described in Mayer et al.( 2011), but not active against strains 
that do not have that type of peptidoglycan, such as Micrococcus luteus (NCTC 2665) 
and Staphylococcus aureus (NCTC 10788) (Schleifer and Kandler, 1972; Mayer et al., 
2011).  
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Figure 4.21.  Lytic activities of our lysins on various strains of Clostridia and other Gram-
positive strains. Graph shows percent of reduction in the OD of a bacterial cell suspension after 
treatment with 7 μg/ml of lysin for 30 min. Each column represents the mean of results from 
triplicate assays, and error bars indicate the standard deviation 
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4.4    Discussion 
4.4.1   Endolysins isolated from C. difficile phages 
All C. difficile specific phages that have been isolated to date and characterised in order 
to develop therapeutic agents have proven to be lysogenic phages, and no lytic phages 
have been isolated (Sell et al.,1983 ; Mahony et al.,1985 ; Dei,  1989; Nagy et al., 1991; 
Goh et al., 2005; Govind et al., 2006; Fortier and Moineau, 2007; Mayer et al., 2008; 
Horgan et al., 2010; Sekulovic, et al., 2011; Meessen-Pinard et al., 2012; Nale et al., 
2012; Shan et al., 2012) and in this study. However, these types of phages are of limited 
value as therapeutic agents (Gill and Hyman, 2010; Meader et al., 2010). 
Although these phages have limited therapeutic potential in their current form, they each 
carry a gene encoding an endolysin which has the ability to degrade the bacterial cell wall 
when applied externally. Thus, these proteins could be developed and used as effective 
therapeutic agents against C. difficile. In theory, endolysins would be well suited as 
treatment of C. difficile, since they target only C. difficile cells without harming the 
normal body microbiota. In this work we have characterised five endolysins from C. 
difficile: φCD27, φC2, φCD119 (Myoviridae family), φCD6356 and φCD38-2 
(Siphoviridae family).  
Bioinformatic analysis of these endolysins revealed that they all contained N-
acetylmuramoyl-L-alanine amidase (amidase3) N-terminal catalytic domains. This class 
of endolysin cut the critical amide bond between N-acetylmuramic acid and L-alanine 
and are predicted to be the most active PG degrading enzymes (Oliveira et al., 2012). 
 Page | 164 
 
This type of endolysin represents one of the most widespread classes of endolysin 
(Fischetti, 2008). In contrast, the C-terminal domains of these endolysins lacked any 
homology, which was somewhat surprising given that these phages are specific for C. 
difficile.   
All endolysin sequences were codon optimised for expression in E. coli, to maximise the 
production of recombinant protein. Comparison of the level of expression of codon 
optimised LysCD27 to that of the non-codon optimised version found a two-fold increase 
in expression  (Mayer et al., 2008). During protein induction at 37°C, the recombinant 
proteins formed insoluble inclusion bodies located in inclusion bodies; these results 
correlate with those generated by a protein solubility prediction program that all of our 
proteins have a high insolubility percent (Table 4.3). However, the culture temperature 
was reduced to 27°C, which is a temperature that has been reported to reduce the 
formation of inclusion bodies (Zimmer et al., 2002; Dhalluin et al., 2005). 
With regards to the level of protein expression of the other endolysins, they were 
expressed at a roughly similar level, ranging from 1-4 mg/100ml.  
Characterisation of the biological activity of the recombinant endolysins across a range of 
pH values was determined. The endolysins maintained their activity over a wide range of 
pHs(4 to 9) including physiological pH, suggesting that they would remain biologically 
active in the gastrointestinal tract (GI) environment. A similar observation was made for 
other previously characterised C.difficile phage endolysin (φCD27 endolysin) (Mayer et 
al., 2008).  The effect of temperature on lytic activity was also determined and was found 
to be stable over a range of temperatures (37-50°C). However, a sharp decrease in  
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activity was seen at temperatures of 60°C and above. With the exception of BHI, the 
buffers tested had no significant effect on the lysins activity. Thus, based on these results, 
we developed a standardised set of assay conditions with which to determine the level of 
activity of each endolysin. 
While the lytic profile of each endolysin for C. difficile PG was similar to that described 
in the literature, this was not the case for LysCD27 (Loeffler et al., 2001; Schuch et al., 
2002; Son et al., 2012). Mayer and colleagues (2008) reported that the lytic activity of 
their version of LysCD27 required a 10 minute incubation step before lytic activity was 
initiated (Mayer et al., 2008). In contrast, our version of LysCD27 was able to lyse the 
PG almost immediately upon addition. Mayer and colleagues (2008)  suggested that this 
delay may have been the result of incorrect folding of the recombinant lysin expressed 
from their E. coli-based system (pET15b, E. coli BL21). Our results suggest that our 
recombinant protein, which is expressed from different host E. coli strains to the Mayer 
and colleagues (2008)  group, is produced in the correct form and hence, is more active. 
Given that one of the differences between the two systems is the codon usage of the gene, 
it is tempting to speculate that this is responsible for the enhanced activity (Zimmer et al., 
2002). 
While the level of activity of individual lysins varied from strain to strain, the 
LysCD6356 endolysin was the most active against all strains of C. difficile tested 
(ribotypes: 001, 027, 106, 014, 002, 005, 078, 020, 010 and 023). The second most active 
endolysin was LysCD38-2, which was the most active against strains of ribotype 012, 
110, 045 and 046, based on % of lysis activity after 30 minute of incubation. 
 
 Page | 166 
 
Interestingly, LysCD6356 shares a high percent amino acid identity (88%) with 
LysCD38-2, and they belong to same phage family and same phage group 
These endolysins also showed activity against other Gram-positive strains, such as C. 
sordellii, which is closely related to C. difficile, and less closely related species B. subtilis 
and L. monocytogenes. However, they were inactive against a number of other Gram-
positive species. 
The host range of each endolysin was significantly broader than that of the phages 
themselves, as previously described for φCD27 (Mayer et al., 2008). Moreover, all C. 
difficile strains tested were at least sensitive to one of our endolysins.  
This phenomenon support the therapeutic potential of endolysins compared to 
bacteriophages. 
 
 
 
4.4.2   Endolysin isolated from the C. difficile genome (LysCD630) 
In this work we have shown the utility of employing a bioinformatics-based approach to 
identify protein sequences with a putative endolysin function. This endolysin is located 
outside of the prophage regions. We selected an endolysin from CD630 for further study 
on the basis that it contained an amidase 3 N-terminal domain, has a 62% amino acid 
identity with known phage endolysin (φCD6356) and the homologues of this gene were 
found to be conserved among all C. difficile strains sequenced to date (Sebaihia et al., 
2006; Stabler et al., 2009; He et al., 2010; Monot et al., 2011). Furthermore, using PCR 
and primers specific to this gene, we were able to detect its presence in all 85 of the 
isolates of C. difficile examined to date (Chapter 5). 
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The apparent universal distribution of the lysin supports the hypothesis that it plays an 
important function in the physiology of C. difficile.  
The fact that the recombinant version of these gene was indeed able to  lyse the C. 
difficile cell wall in a similar manner to phage-derived endolysins, and that it appears to 
be present in all of the isolates of C. difficile we have examined to date, suggests that it 
could be a strong candidate for development as a future therapeutic agent. 
 
 
4.4.3   Mutated endolysin (LysCD227) 
 
Mayer et al. (2010) demonstrated that the isolated enzymatic catalytic domain of the 
endolysin of φCD27 had greater lytic activity against C. difficile than the full length 
endolysin. They also found that it had a wider spectrum of activity when the C terminal 
domain was removed and was able to lyse isolates of L. monocytogenes and L. innocua, 
which were insensitive to the full sequence. A similar pattern of lytic activity has been 
reported for other endolysins where the catalytic domain alone was a more effective for 
cell lysis than the whole endolysin (Loessner et al., 1999; Low et al., 2005; Cheng and 
Fischetti, 2007; Mayer et al., 2010). 
 
However, other scientific research has shown that some phage endolysin activity was 
decreased by removing the CBD; the only explanation for this is that these endolysins 
require the whole endolysin sequence in order to produce lytic activity and the binding 
function is present in an area between ECD and CBD with these phages (Sanz et al., 
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1992; Loessner et al. ,2002; Hermoso et al., 2003; Sass and Bierbaum, 2007; Kikkawa et 
al., 2007; Mayer et al., 2010). 
The results of our study showed that a small modification in the sequence of the CBD 
region of LysCD227 increased the activity of the lysin when compared to LysCD27. This 
suggests that, in C. difficile, the modified CBD was not able to bind the epitope that is 
predominantly found on the C. difficile cell wall and therefore was not able to tether the 
lytic activity of the catalytic domain from targeting other cells. 
It has been proposed that in addition to mediating the specificity of the endolysin, the 
CBD region prevents the lysin from damaging new bacterial hosts by ensuring that the 
enzyme binds irreversibly to specific sites in the cell wall peptidoglycan, which the newly 
released phage may seek to infect (Mayer et al., 2010; Oliveira et al., 2012 ). Thus, there 
is an evolutionary pressure to retain the CBD which is secondary to its enzymatic 
activity. In contrast, the peptidoglycan of Gram-negative bacteria is protected from the 
attention of external endolysins by an outer membrane, which would explain why most 
Gram-negative phage-derived endolysins are described to date lacking a CBD. Also 
interesting was the fact that these modification also extended in the lytic spectrum of 
LysCD227, which was active against other Gram-positive strains, This suggests that the 
LysCD27 CBD may target a bacterial cell wall epitope that is common in some Gram-
positive bacterial species. 
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4.5   Conclusions  
 
The recombinant endolysins examined in this study possessed broad spectrum activity 
against a range of different C. difficile ribotypes with little or no activity against other 
species included in this study, thus highlighting their potential as novel, specific 
microbial agents. Indeed, our characterization of endolysin LysCD27 and its variant, 
LyCD227, provides a starting point from which to investigate the ability of genetic 
engineering to improve the activity of these endolysin. This work demonstrated the utility 
of using C.difficile sequenced genomes as rich pools for the identification of potential 
endolysins 
 
In the context of developing new therapeutics for the treatment of C. difficile, endolysin, 
in contrast to antibiotics, offers a novel approach to the destruction of the specific 
pathogens without damaging the normal microbiota of the GI tract. 
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Chapter Five 
 
 The distribution of endolysins amongst clinical 
isolates of Clostridium difficile 
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5.1   Introduction 
5.1.1   Use of the phage gene as a marker of prophage carriage 
 
As a consequence of the increased interest in bacteriophage research and bacteriophage 
therapy a number of C.difficile-specific temperate bacteriophages have been isolated. Of 
these bacteriophages only seven bacteriophages of C. difficile, namely φCD119, φCD2 
,φCD27 , φMMP03 , φMMP04, φCD6356 and φCD38-2,  have been fully characterized 
at the molecular level (section 1.12).  In addition to these examples,  prophages have also 
been identified in most C.difficile strains sequenced to date (Sebaihia et al., 2006 ; Goh et 
al., 2007; He et al.,2010; Nale et al., 2012 ; Shan et al., 2012).  
 
Prior to the advent of the molecular age bacteriophages were isolated by inducing strains 
chosen at random from clinical or environmental samples with mitogens such as 
mitomycin C.  Although these methods have yielded bacteriophages in the past they are 
extremely time-consuming and dependent on isolating and finding an indicator strain for 
propagation of the initial bacteriophage. Moreover, they cannot predict how novel the 
identified bacteriophage will be relative to previously characterized bacteriophages. 
 
Several bacteriophage genes have been used to study phage diversity, as these genes 
encode for the major capsid protein and portal protein in the myoviruses gp20 and gp23 
respectively (Fuller et al., 1998; Marston and  Sallee, 2003; Short and Suttle, 2005;  Shan 
et al., 2012  ). Phage DNA polymerase and terminase genes have also been used to assess 
phage diversity (Chen and Suttle, 1996; Chen et al., 1996 ; Marston and  Sallee, 2003 
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;Short and Suttle, 2005 ; Shan et al., 2012  ). Furthermore, the holin gene was used to 
study prophage carriage in Streptococcus pneumonia (Romero et al., 2009) and the 
molecular phylogeny of phi29-like phages and their evolutionary relatedness (Pecenkova 
and  Paces, 1999).  
 
In C.difficile studies, only major capsid protein genes and holin genes have been used to 
study prophage diversity (Nale et al., 2012; Shan et al., 2012). None of these genes, 
however, are conserved enough to be targeted in all known C.difficile bacteriophages. 
The endolysin gene may be a suitable bacteriophage gene for studying the genetic 
diversity of C.difficile bacteriophages. The endolysin gene encodes protein that is 
essential for breaking down the cell wall PG bond and releasing the new phage progeny. 
This gene is present in all the seven sequenced C. difficile phages and has been identified 
in all of the C. difficile genomes sequenced to date (Chapter 4) . We selected these 
endolysins as PCR targets due to the fact that they share a high degree of sequence 
homology and belong to a single class of endolysin.  
For this reason we employed a polymerase chain reaction (PCR) based approach to 
determine the distribution of   bacteriophage endolysins across a diverse collection of 
C.difficile clinical isolates.  It was our hypothesis that the presence of an endolysin may 
be indicative of the presence of a bacteriophage.  To do this we designed PCR primers 
which recognized the endolysins present in the C.difficile bacteriophage sequences which 
have been deposited in GeneBank.    
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In addition to searching for known endolysins amongst our collection of strains we also 
sought to identify new endolysins by treating PCR negative isolates with mitomycin C 
and screening for the production of  the bacteriophages,  the premise being that these 
bacteriophages may contain novel endolysins which could be of value as therapeutic 
agents. 
 
 
 
5.1.2   Aim of this study  
The aims of this chapter are: 
 To employ a PCR-based method to screen multiple clinical isolates of C.difficile 
for the presence of homolog to known C.difficile bacteriophage endolysin genes. 
 To characterize the distribution of bacteriophage endolysins. 
 To characterize the distribution of the C.difficile endolysin LysCD630 described 
in Chapter 4. 
 To identify novel bacteriophage endolysins by inducing the expression of 
bacteriophage from  PCR negative C.difficile isolates.  
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5.2   Material and methods 
In this study we examined a much bigger collection of strains than were used in the 
original bacteriophage induction work; strains that were used in this study are described 
in table 2.1 and 2.2. 
 
5.2.1   PCR primer design and synthesis 
The National Center for Biotechnology Information’s (NCBI) nucleotide database  at the 
time of searching contained the complete genome sequences of the following C. difficile 
bacteriophages;  φCD119, φCD27, φC2, φCD6356 and φCD38-2.  The sequences 
encoding the endolysin of each of these bacteriophages were used as templates to design 
specific PCR primers.  
A further putative endolysin gene which was identified by bioinformatics tools in the 
genome of C. difficile 630 Chapter 4 (NC_009089 region: 2201141-2201929) was used 
as template to design PCR primers. 
 PCR primers with specificity for each endolysin were designed with NCBI primer-blast 
(www.ncbi.nlm.nih.gov) and the MWG Operon online PCR primer design tool 
(www.eurofinsdna.com) under the following criteria: (1) primer length was 18–25 bp in 
length, (2) annealing temperature was 55–65°C, (3) guanine-cytosine (GC) content of the 
primer was 40%–60%, and (4) amplicon size 200-700 bp in length (Table 5.1).  
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Endolysin gene Primer sequence (5'->3') Annealing 
temperature, 
0
C 
Product 
size, bp 
LysCD27 F1: TGGAGCATGTACTTCTGCTGATGG 
R1: CGTCTGACCTGGCACGTAATCTTT 
 
F2:TGGAGCATGTACTTCTGCTGAT 
R2:CATGCGCCACCTCCTACAA 
58 
 
 
60 
640 
 
 
672 
LysC2 F1: GCATGCACTTCTGCTGATGGAGTA 
R1: TCCGTCTGACCTGGTACGTAATCT 
 
F2: TGCACTTCTGCTGATGGAGTA 
R2: CCCAACTAAGCACATTCGCA 
56 
 
 
59 
638 
 
 
574 
LysCD119 F1: GCAACACAAGCAAATAGACAAG 
R1: TTCACTGTCCACAAAGCATAC 
 
F2:TGTGGACATACAAAAACAGGAGC 
R2:TCGCATCCTCGTCCTTTTCC 
56 
 
 
56 
246 
 
 
251 
LysCD6356 F1: CGGATGCAAGAGGGCTTTACTGGC 
R1: CGCATGCTCCTCCCCCTACAACA 
 
F2: AGGTTGTACTAACAGCAGGGC 
R2: AAGCCCTCTTGCATCCGATT 
60 
 
 
58 
348 
 
 
374 
LysCD38-2 
 
F1:ACAGCAGGGCATACGCTAACAGG 
R1: TGCGTCCGATTTTGCGCCTCT 
 
F2: TGAGAGTAGCACTAACAGCAG       
R2: CCACCCCCAACAACATAAAG 
59 
 
 
59 
354 
 
 
700 
LysCD630 F1: AGCAGCCACTTTATCAGCATCACCT 
R1: GGAAAAGGTACAGGAGCTGTTGGG 
 
F2: AGCAGCCACTTTATCAGCATCACC 
R2: GGAAAAGGTACAGGAGCTGTTGGGT 
58 
 
 
58 
564 
 
 
564 
 
Table 5.1.  Sequences (listed 5'-3') of primers used for amplification of the C.difficile 
bacteriophages endolysin gene, derived from endolysin genes of φCD27, φC2, φCD119, 
φCD6356, and φCD38-2  and a putative phage endolysin gene within the genome of  C.difficile 
630 (NC_009089 region: 2201141-2201929). 
 
To serve as positive controls previously described primers which target non-repeating 
sequences within the gene of toxin A were employed (Kato et al., 1991). Primers that 
target  the 16S rRNA gene of C.difficile were also employed as  positive control primers 
(Gumerlock et al., 1991). The sequences of these primers are shown in table 5.2. 
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Target Primer sequence (5'->3') Annealing 
temperature, 
0
C 
Product 
size, bp 
Toxin A gene* F1: GGACATGGTAAAGATGAATTC 
R1: CCCAATAGAAGATTCAATATTAAGCTT 
 
F2: GGAAGAAAAGAACTTCTGGCTCACTCAGGT 
R2: CCCAATAGAAGATTCAATATTAAGCTT 
60 
 
 
58 
546 
 
 
252 
16S rRNA gene** F1: CTCTTGAAACTGGGAGACTTGA 
R1: CCGTCAATTCMTTTRAGTTT 
 
55 
 
270 
 
Table 5.2.  Sets of primers were used with PCR reaction as positive control primers: (*) 
primers derived from (Kato et al., 1991) targeting the Toxin A gene of C.difficile ; (**) primers 
derived from (Gumerlock et al., 1991) targeting the 16S rRNA gene of C.difficile. 
 
Primers were synthesized and purified by high-performance liquid chromatography 
(HPLC) supplied by Eurofins MWG Operon (Ebersberg, Germany) and were supplied 
lyophilized, with 100 pmol/µl concentration. Prior to use the primers were resuspended in 
sterile distilled water to the required concentration. 
 
5.2.2   DNA extraction using Chelex 
 
Template DNA was extracted from selected bacterial cultures by the use of a 
commercially available Chelex resin-based DNA extraction kit (InstaGene Matrix; Bio-
Rad).  Colonies from   an overnight culture of  the bacteria on a  blood agar  plate  
incubated at 37
°C in an anaerobic chamber were harvested and resuspended  in 200μl  of 
5% Chelex 100  and  heated  at 56°C in a dry block heater (Techne DB-3D, Bibby 
Scientific Ltd, Staffordshire, UK), for 30 minutes.  The suspension was then vortex 
mixed and then heated again but this time at 100°C for eight minutes.  Bacterial cell 
debris was removed from the suspension by centrifugation at 10,000 g for three minutes 
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at 4
0
C temperature (Eppendorf 5417R centrifuge, fixed angle rotor F45-30-11, UK) and 
the resulting supernatant which contained bacterial DNA was  transferred to new tubes 
and stored at -20
0
C until needed. The extraction method above was adapted from a 
method for purifying C. difficile DNA described by Arroyo et al. (2005). 
 
5.2.3   Spectrophotometric quantification of DNA concentration 
 
The concentration of DNA in a sample  was estimated by measuring the absorbance of  
the solution at 260nm using a cuvette (Cuvette UVette 80 disposable single sealed 
Eppendorf  ,Fisher Scientific, Leicestershire, UK) and an Eppendorf Biophotometer 
(Eppendorf UK Ltd, Cambridge, UK).  An OD260 value of one is equivalent to a DNA 
concentration of 50μg /ml for double-stranded DNA. The purity of the sample was 
assessed by calculating the 260/280 nm absorbance ratio. This approximated to > 1.5 in 
protein-free DNA samples. 
5.2.4   Optimization of the PCR 
Parameters were optimized using known positive strains before we screened our 
collection in order to determine the optimum PCR reaction conditions. These parameters 
included MgCl2 concentration (1.0 to 3.5 mM), primer concentration (0.2 to 2.0 µM) and 
annealing temperature (55 to 66°C). Each component was optimized while others were 
kept constant. Then concurrent optimized parameters were used in subsequent 
experiments; however, other parameters were used according to the manufacturer's 
instructions ( Taq PCR Handbook, 2012; Qiagen, Crawley,UK). 
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5.2.5   PCR reaction conditions  
PCR amplifications were undertaken using a standard PCR reaction mix, the composition 
of which is shown in table 5.3. The following components, CoralLoad PCR Buffer dNTP 
mix (10 mM each), Q-Solution, 5X Taq DNA Polymerase, and optimized MgCl2 (25 
mM), were obtained from the Taq PCR Core Kit (Qiagen, Crawley, UK). To confirm the 
success of the PCR reaction, positive control primers which recognized a conserved 
target present in C.difficile 630 were included in each PCR amplification run (Table 5.2.). 
DNA extracted from C.sordellii, a strain not known to contain any of the target 
endolysins, was included as a negative control. 
 
Components Volume for 1 reaction (µl) Final concentration 
CoralLoad PCR Buffer 3.75 µL 1x 
dNTP mix (10 mM each) 0.6 µL 200 μM of each dNTP 
Q-Solution 6 µL 1x 
Taq DNA Polymerase 0.15 µL 2.5 units/reaction 
MgCl2  (25 mM) 2.4µL 2.0 mM 
Distilled water 14.1 µL  
Primer mix (F&R) 1.5 µL 0.5μM each 
Template DNA  1.5 µL  
Total volume 30 µL  
       
       Table 5.3.  PCR reaction composition 
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PCR amplifications were carried out in a Touchgene Gradient Thermal Cycler (Techne 
(Cambridge) Ltd, UK). The following programme was used;  one cycle of 3 minute at     
94 °C for initial denaturation followed by 35 cycles (45 second at 94 °C, 45 second              
at 55-63 °C and 1 minute at 72 °C) and a final extension of 10 minute at 72 °C.  
PCR products were subsequently analysed by agarose gel electrophoresis. 
5.2.6   DNA gel electrophoresis 
Agarose gels were prepared by melting 1% (w/v) agarose (Sigma-Aldrich, Gillingham, 
UK) in 100ml of 1x Tris-borate EDTA (TBE)  (1xTBE: 89mM Tris base; 89 mM boric 
acid; 2 mM EDTA; pH 8.0)( Fisher Scientific, UK), in a 100ml glass Duran bottle using  
a microwave oven .  
Following heating the agarose was cooled to 45°C  and 2.5μl of Safe View dye (NBS 
Biologicals)  was added  after which  the  agarose  was poured into a gel cast mould 
(10x15 cm) (Bio-Rad Laboratories, UK). Following cooling the gel was placed in a tank 
(Bio-Rad Laboratories, UK) and overlaid with 800ml of 1% TBE buffer supplemented 
with 30 ul of Safe View dye. The gel was then loaded with 10 ul volume of amplified 
PCR product in loading buffer. 
Gels were subjected to electrophoresis for 45 minutes at 100 V (constant). The size of the 
PCR products was determined by comparison with a  GelPilot 1 kb Plus Ladder (100-
10,000bp) (Qiagen, Crawley, UK).     
Gel images were acquired by a CCD camera with Bio-Rad Image Lab™ software version 
3.0.  Each PCR assay was repeated three times for each DNA sample template. 
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5.2.7   Induction of bacteriophage expression from PCR negative strains of 
C.difficile 
In an attempt to isolate bacteriophages which had not been previously described we 
employed the mitomycin C induction method described in Chapter 3 section (3.2.4) on 
strains which were PCR negative for bacteriophage endolysin. C.difficile strains from a 
previous study were used as a positive control strain ( NCTC12727, inducible strain) and 
negative control strain (DS1813, non-inducible stain) . Following mitomycin C treatment 
the cultures were screened for the presence of bacteriophages by electron microscopy as 
described in Chapter 3 section (3.2.7).  
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5.3   Results 
 
5.3.1   Bioinformatics analysis  
C.difficile bacteriophages which have been isolated and sequenced to date have been 
shown to share sequence homology of at least 59%, despite the fact that they belong to 
different morphological families. 
Genomic details for each bacteriophage are shown in table 5.4 . Table 5.5 shows the 
percentage of homology between these bacteriophages across the entire genome. 
Bacteriophage Accession 
number 
Genome 
length (bp) 
GC content 
(%) 
Bacteriophage 
family 
φCD119 AY 855346 53325  28.7 dsDNA, Myoviridae 
φC2 NC 009231 56538 28.72 dsDNA, Myoviridae 
φCD27 EU 719189 50930  29.4 dsDNA, Myoviridae 
φCD6356 GU 94955 37664  28.4 dsDNA, Siphoviridae 
φCD38-2 NC 015568 41090 30.83 dsDNA, Siphoviridae 
       Table 5.4.  C.difficile bacteriophages: genomic details. 
Bacteriophage Bacteriophage % of homology 
 
φC2 φCD27 69.0 
φC2 φCD6356 66.0 
φC2 φCD119 64.0 
φC2 φCD38-2 63.0 
φCD27 φCD6356 64.0 
φCD27 φCD119 59.0 
φCD27 φCD38-2 60.0 
φCD6356 φCD119 64.0 
φCD6356 φCD38-2 59.0 
φCD119 φCD38-2 61.0 
Table 5.5.  shows the percentage of homology between the C.difficile bacteriophages used in 
this study. 
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The gene sequences of the five endolysins were compared using the Multiple Sequence 
Alignment (MSA) program ClustalW2 (European Bioinformatics Institute) to determine 
the degree of similarity between the endolysins.    As can be seen from figure 5.1.  the 
endolysins cluster in three distinct groups, LysCD27 and LysC2, LysCD6356 and Lys 
CD38-2  and finally Lys CD119. 
 
 
 
 
 
Figure 5.1.  Neighbor-joining phylogenetic tree showing the relationship between the 
endolysins of the following C.difficile bacteriophages φCD119, φCD27, φC2, 
φCD6356 and  φCD38-2. The phylogenetic tree was constructed based on multiple 
alignments using the DNA sequences generated from Clustalw2.  
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Within each group the homology of the individual lysins was determined. In the case of 
LysCD6356 and LysCD38-2   they shared only 89% similarity. In contrast LysCD27 and  
LysC2  showed the greatest similarity at  96%, suggesting that they may have evolved 
from a common ancestor. This high level of homology could also be a result of gene 
transfer between the bacteriophages and their hosts and gene transfer among the 
bacteriophages (Meessen-Pinard et al., 2012). 
Comparison of the nucleotide sequences  revealed that the endolysin genes were  more 
closely related than the  holin genes which have previously been used as phage genetic 
markers for studying the prophage diversity within C.difficile isolates (Shan et al., 2012)   
(Table 5.6). 
 Indeed the endolysin sequences were more conserved than the capsid genes which have 
also been used to study phylogenetic relationships between bacteriophage bacterial 
species (Nale et al., 2012). 
 
Bacteriophage Bacteriophage  Endolysin gene homology 
(%) 
 
Holin gene homology 
(%) 
φCD27 φC2 96.0 87.0 
φCD27 φCD119 63.0 87.0 
φCD27 φCD6356 69.0 53.0 
φCD27 φCD38-2 70.0 49.0 
 
Table 5.6.  Multiple sequence alignment showing percent identity between bacteriophage 
endolysin and holin genes of φCD27 and other   C.difficile bacteriophages using ClustalW2. 
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According to Oakley et al. (2011) the endolysin genes of four closely related 
C.perfringens bacteriophages were the most variable (ranging from 69 to 100% 
similarity) of the bacteriophage genes, possibly due to the fact they were under different 
selective pressures than the rest of the genome.  In contrast, the holin genes were the most 
conserved genes (ranging from 97 to 100% similarity) among these bacteriophages 
(Oakley et al., 2011).  This does not appear to be the case for the C.difficile 
bacteriophages examined in this study. 
A major aim of this study was to determine how widely each endolysin was distributed 
across our study population of clinical isolates  of C.difficile, and for this reason two sets 
of primers were designed for each endolysin gene. 
The endolysin genes from previously sequenced bacteriophages of C.difficile (Table 5.4) 
were used to design the primers employed in this study. They represented all of the 
C.difficile bacteriophage sequences deposited in GeneBank until 2012  but did not 
include the sequences of φMMP03 and φMMP04  which were published in 2012 
(Meessen-Pinard et al., 2012).  The specificity of individual primer sequences was 
confirmed by running nucleotide blast searches (NCBI). 
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5.3.2   PCR results  
The MgCl2 concentration, annealing temperature and primer pair concentration for each 
endolysin were individually optimized as described below.   The Mg
2+
 concentration is a 
crucial parameter that can affect the performance of Taq DNA polymerase.  High levels 
of Mg
2+
 may lead to false negative reaction whereas low levels may cause failure of the 
PCR reaction (Innis and Gelfand, 1990). The effect of altering the Mg
2+
 concentration on 
the PCR reaction using primers for  the LysC2 gene  is shown in figure  5.2. 
 
Figure 5.2. Optimization of  MgCl2 concentration for the detection of endolysin using LysC2 
primer-1 and genomic DNA  from  C.difficile DS1813 (ribotype 027) as the template. The 
expected product size is 638 bp.   Lane M shows a   GelPilot 1 kb Plus Ladder (100-10,000bp). 
Lanes 1 to 6 show the PCR products obtained using (0.5, 1.0 ,1.5 ,2.0 ,2.5  and 3.0 mM) MgCl2 . 
 
 
From this result we concluded that the optimum MgCl2 concentration was between 1.5 
and 3.0 mM. A similar optimization was performed for all of the primer pairs.  
The annealing temperature of each primer depends on the length and composition of the 
primer which may be above or below the estimated Tm (Taq PCR Handbook, 2012). 
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 This is usually adjusted to improve the specificity and yield of PCR reaction (Wu et al., 
1991).  We determined the annealing temperature for each primer pair which gave the 
highest amount of specific product with the least amount of non-specific PCR product. 
As can be seen in figure 5.3 the annealing temperatures that yielded the greatest amount 
of amplicon using primer-2 for LysCD27  were between  57°C and 58°C.  
 
Figure 5.3.  Optimization of annealing temperatures for the detection of endolysin  using 
LysCD27 primer-2 and genomic DNA from C.difficile  DS1759 (ribotype 001). The expected 
PCR product size is 672bp.   Lane M: GelPilot 1 kb Plus Ladder (100-10,000bp). Lanes 1 to 12 
show the PCR products obtained using (55 to 66 
0
C) annealing temperature need more detail.  
 
The optimum annealing temperature for each primer was determined individually, but all 
primers seem to produce the best annealing result between 55 and 60
0
C (Table 5.1). 
Finally we determined the effect of altering the primer concentration on the quality of the 
PCR product.  As can be seen in the example shown in figure 5.4 the optimum endolysin 
primer pair concentrations were 1.0 and  0.5 µM.  
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Figure 5.4 Optimization of primer concentration for the detection of endolysin using 
LysCD38-2  primer-2 with  genomic DNA from C.difficile DS20291 (ribotype 027). The 
expected  product size was  700bp.   Lane M: GelPilot 1 kb Plus Ladder (100-10,000bp). Lanes 1 
to 7 show the PCR products obtained using (1.0,0.5 ,0.4 ,0.3 ,0.2 ,0.1 ,0.05 and 0.025 µM) of 
primer .  
 
The optimized PCR reaction conditions for all primer pairs are those described in table 
5.3  and they were employed throughout  the remainder of the study.  
Following  PCR optimization specific oligonucleotide primers for each   endolysin gene  
were  run against genomic DNA from 85 isolates of C.difficile, 12 isolates of  
C.perfringens and individual isolates of  C. sordellii R20453,   C. septicum R22030  and  
C.novyi R14479. 
The PCR products obtained following amplification using primers specific to  LysCD27   
are shown in figures  5.5 and 5.6. The expected size of the amplicon is 672 nucleotides. 
The samples were run on two separate gel due to the number of samples involved. 
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Figure 5.5.  The results obtained from screening genomic DNA from isolates of C.difficile 
representing a range of ribotypes with PCR primers 2 specific to  LysCD27. The expected 
size of the amplicon is  672 bp and PCR products were  separated  by  electrophoresis on a 1% 
gel.  Lane M: GelPilot 1 kb Plus Ladder (100-10,000bp).Lanes 2-6: 001 ribotype.; Lanes 7-11: 
027 ribotype. Lanes12-17:106 ribotype. Lanes 18-22:  014 ribotype. Lanes 23-27: 002 ribotype. 
Lanes 28-30: 005 ribotype. 
 
 
 
Figure 5.6. The results obtained from screening genomic DNA from isolates of C.difficile 
representing a range of ribotypes with PCR primers 2 specific to  LysCD27. The expected 
size of the amplicon is  672bp and PCR products were  separated  by  electrophoresis on a 1% 
gel. Lane M: GelPilot 1 kb Plus Ladder (100-10,000bp). Lanes 1-6: 012 ribotype. Lane 7: 
positive control primer-1 (toxin A gene) with C.difficile 630 ( product size : 546 bp). Lane 8: 
negative control (no DNA). 
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Figure 5.7 summarizes the results obtained using primers which recognised the 
endolysins of the following members of the Myoviridae family:  φC2, φCD27 and 
φCD119.  
 
 
 
Figure 5.7.  The percentage of C.difficile isolates  of each ribotype  (n=5)  which produced 
an amplicon  of the correct size  suggesting the presence of a homolog to an endolysin  of the 
Myoviridae bacteriophages φCD27, φC2 and φCD119. 
 
 
The two bacteriophage endolysins with the greatest homology, φC2 and φCD27, 
occurred at an identical frequency in all of the strains tested. In contrast, φCD119 
appeared less frequently and was absent from strains of the following ribotypes: 002, 
056, 046 and 045. 
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Figure 5.8 shows the results obtained using primers which recognised the endolysins of 
members of the Siphoviridae family, φCD6356 and φCD38-2. Each lysin had the same  
percentage distribution for ribotypes  001, 027, 106, 002, 010, 017 and 046.  The 
distribution across the other ribotypes was much more varied. 
 
 
 
 
 
 
Figure 5.8.  The percentage of C.difficile isolates  of each ribotype  (n=5)  which produced 
an amplicon  of the correct size  suggesting the presence of a homolog to an endolysin  of the  
Siphoviridae bacteriophages φ CD6356 and φCD38-2. 
  
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
001 027 106 014 002 005 012 078 020 010 023 017 047 056 110 046 045
%
 
C.difficile ribotype 
φCD6356 φCD38-2 
 Page | 191 
 
The frequency of endolysin detection for all of the bacteriophage derived targets across  
all of the C.difficile isolates tested in this study is summarized in figure 5.9. The most 
common hits were the endolysins of  φCD27 and φC2  while the least commonly seen 
endolysin was that of  φCD119.  
 
 
 
Figure 5.9.  The percentage distribution of PCR hits for  C.difficile bacteriophage endolysin 
genes  from 85 isolates of C.difficile. 
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5.3.3   Induction of bacteriophage expression from PCR negative strains of 
C.difficile 
Interestingly, we observed six isolates which failed to yield any product when probed 
with these  primers. These strains were  DS1787, R28614 (ribotype 106),  R31710, 
R31708 (ribotype  078), R30967 (ribotype 110), and  R30072 (ribotype 045) .  This 
failure to amplify on repeated occasions  (six separate reactions and on each occasion the 
positive controls  produced the expected amplicons)   suggested that either the isolates 
lack the endolysin gene and by extension the whole bacteriophage or that the DNA 
sequence recognized by the primers had altered in some  manner. 
To determine if these PCR negative isolates contained inducible bacteriophages we 
employed the mitomycin C induction method described in Chapter 3 (3.2.4).  Two of the 
isolates, R30967 (ribotype 110) and R30072 (ribotype 045) yielded detectable 
bacteriophage like particles when examined by electron microscopy. 
The two bacteriophages had an isometric capsid with a diameter of 97-52 nm connected 
to a contractile tail 180-150 nm in length and approximately 18-13 nm in width (Table 
5.7). They were structurally similar to previously described C. difficile bacteriophages 
and can be classified as members of the Myoviridae family of the order Caudovirales. 
We have made several attempts to identify a susceptible indicator strain that supports 
virulent phage production of these two phages through plaque assays methods described 
earlier in Chapter 3. Unfortunately, no sensitive strain was found despite testing them on 
85 different C. difficile strains 
Induction of other negative strains failed to identify any new phage particles under the 
induction conditions described in Chapter 3, section (3.2.4). 
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Ribotype Strain Bacteriophage Morphology Tail Capsid 
 
 
 
 
110 
 
 
 
R30967 
 
 
 
 
Myoviridae 
 
 
 
(180±0.5)x(18.4±0.6) 
 
 
 
97.2±0.5 
 
 
 
045 
 
 
 
R30072  
 
 
 
 
Myoviridae 
 
 
 
(150±0.4)x(13.3±0.3) 
 
 
 
52.7±0.6 
 
Table 5.5.  Electron microscopy images of temperate bacteriophages isolated from  PCR 
negative  isolates of C.difficile,  R30967 and R30072. Bacteriophages were induced with 
3ug/ml mitomycin C. 
 
 
 
5.3.4   Putative bacteriophage endolysin from C.difficile 630 (LysCD630) 
A gene (NC_009089 region: 2201141-2201929) of  719 bp  which encodes a putative 
phage endolysin (Sebaihia et al., 2006; Monot et al., 2010) was identified in the C. 
difficile 630 genome sequence through sequence similarity analysis using blast search 
(BLASTn ) with C.difficile bacteriophage endolysins. This gene is located outside 
prophage regions that were identified in C.difficile 630 (prophage 1 and 2) (Sebaihia et 
al., 2006; Monot et al., 2010). Furthermore, BLASTn search revealed that a homolog  
(96% homology or higher)  of this gene  has been found in all nine strains of  C.difficile  
 Page | 194 
 
sequenced  to date (Sebaihia et al., 2006; Stabler et al., 2009; He et al., 2010), suggesting 
that it has an essential function. 
The endolysin protein has a structural organization similar to those seen in C.difficile 
bacteriophage endolysins with an N-terminal domain comprising an  amidase 3 class 
enzyme and a putative C-terminal domain. 
Using PCR primers designed as part of this study we found that an amplicon of the 
correct size (564 bp) was produced by all of  the  C. difficile isolates analysed  (n=85) in 
the study. As can be seen in figures 5.10 and 5.11  PCR reactions using primers  
LysCD630-1 against genomic DNA  isolated from strains of C.difficile representing 
different ribotypes  yielded a product of the expected size. Testing of the remaining 
isolates yielded identical results.  
 
Figure 5.10.  The results obtained from screening genomic DNA from isolates of C.difficile 
representing a range of ribotypes with PCR primers 1 specific to  LysCD630. The expected 
size of the amplicon is  564 bp and PCR products were  separated  by  electrophoresis on a 1% 
gel.  Lane M: GelPilot 1 kb Plus Ladder (100-10,000bp). Lanes 2-6: 001 ribotype. Lanes 7-11: 
027 ribotype. Lanes 12-17:106 ribotype. Lanes 18-22:  014 ribotype. Lanes 23-27: 002 ribotype. 
Lanes 28-30: 005 ribotype. 
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Figure 5.11.  The results obtained from screening genomic DNA from isolates of C.difficile 
representing a range of ribotypes with PCR primers 1 specific to  LysCD630. The expected 
size of the amplicon is  564 bp and PCR products were  separated  by  electrophoresis on a 1% 
gel. Lane M: GelPilot 1 kb Plus Ladder (100-10,000bp). Lanes 2-3: 005 ribotype. Lanes 4-8: 012 
ribotype. Lanes 9-15: 078 ribotype. Lane 12: negative control, Lanes 16-20: 020 ribotype. Lanes 
21-25: 010 ribotype. Lanes 26-30: 023 ribotype. 
 
As expected, all of the other clostridia strains failed to generate PCR products with any of 
the endolysin specific primers. 
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5.4   Discussion  
5.4.1   Use of the phage endolysin gene as a marker of prophage carriage 
Bacteriophages are known to have a major influence on the activity, structure, biological 
diversity and evolution of a microbial community (Letarov and Kulikov, 2009).   
Therefore by studying bacteriophages diversity across  multiple C.difficile isolates we 
hope to be able to gain a better understanding of the role  of these mobile genetic 
elements in shaping the biology of their host genome.  
For example, it has been reported that some lysogenic phages are able to increase the 
production of toxin B in toxigenic strains of C.difficile while having no effect on  toxin A  
production (Goh et al., 2005b). Interestingly, a homolog of  one of the  genes thought to 
be involved in the regulation of toxin expression, tcdE,  has been  detected in the 
genomes of three phages belonging to the Myoviridae family, φC2, φC6 and φC8, 
suggesting that this gene could be a remnant of an ancient prophage (Goh et al., 2005a). 
Further evidence that phages  could play a role in the regulation of host gene expression 
was  provided by Govind  and colleagues  who observed  a decrease in the level of  
expression of  the genes in the pathogenicity locus (PaLoc) in strains which had been  
lysogenized by φCD119 (Govind et al., 2009).   This effect was attributed to the presence 
of DNA homology between repR, a putative repressor gene of φCD119, and DNA 
sequences upstream of tcdR, which causes the down regulation of tcdA and tcdb 
promoters (Govind et al., 2009). Furthermore, a recent study suggests that lysogenization 
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of a NAP1/027 isolate with φCD38-2 led to increased production of both toxin A and B 
toxin (Sekulovic et al., 2011).  
In addition  to influencing the expression of host genes bacteriophages   are also capable 
of conferring resistance to infection by related lysogenic phages (or superinfection 
immunity), which may explain the narrow host range for C. difficile phages (Mayer et al., 
2008; Fortier and Moineau, 2007; Horgan et al., 2010;Nale et al., 2012).That said it is not 
uncommon for a bacterial host such as C.difficile 630 to harbor more than one unrelated 
prophage in its genome  (Sebaihia et al., 2006; Monot et al., 2010), suggesting isolates of 
C.difficile are repeatedly under attack by bacteriophages.  
So far, only seven bacteriophages, namely φCD119, φCD2, φCD27, φMMP03, 
φMMP04, φCD6356 and φCD38-2, have been isolated from C.difficile and studied at the 
molecular level.  The genetic diversity of these bacteriophages and their possible role in 
the biology of C. difficile  has yet to be  fully determined.  The studies which have been 
undertaken have focused on comparing the similarity of two genes which encode the 
major capsid protein and the holin (Nale et al., 2012 : Shan et al., 2012). Unfortunately 
homologs of these genes  have not been found in all of the C.difficile specific phages 
sequenced to date.  For example,  the genome of  φCD27 (Mayer et al., 2008)  has no 
recognizable major capsid gene( Nale et al., 2012). In a recent paper Shan and colleagues 
(2012) isolated phages from isolates of C.difficile belonging to ribotypes 078 and 220 
which also lacked a recognizable major capsid gene (Nale et al., 2012; Shan et al., 2012). 
Indeed the data suggest that this gene target is  only conserved among bacteriophages 
belonging to the Myoviridae family (Nale et al., 2012). 
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The holin gene is also subject to considerable diversity: for example, the holin gene of the 
newly sequenced C.difficile bacteriophage φMMP04  (Meessen-Pinard et al., 2012) had 
little similarity  (41 to 50%) to previously  identified holin genes (Shan et al., 2012). 
For this reason we hypothesized that bacteriophage endolysins could serve as a more 
effective marker of current or past phage infection. Indeed bioinformatics analysis of all 
of the C. difficile bacteriophages sequenced to date have revealed the presence of a 
recognizable  endolysin gene . 
To determine if homologs to these genes were present in other clinical isolates of 
C.difficile we designed gene specific PCR primers and used them to screen our collection 
of isolates.     
 A homolog of at least one of the bacteriophage endolysins was found  in 79 of the 85 
isolates,  suggesting that  the majority of  our study population may had been infected by 
a  bacteriophage.  The primers which gave the greatest number of positive hits (77% 
each) were  those which recognised the endolysins  present in  φCD27 and φC2, two 
closely related bacteriophages of the  Myoviridae family.   In contrast, the endolysin of 
φCD119 was only detected  in 28% of the isolates.  Thus, despite the fact that these 
bacteriophages are members of the same family they differ markedly in their ability to 
infect the same  C.difficile  isolates. 
There are at least three possible explanations as to why this occurs;  the phages  bind to 
different bacterial receptors or differ in their ability  to recognize the same receptor; the 
host strains are  currently  infected with a lysogenic phage of the same family; and finally 
infection with a related phage in the past  has generated immunity  which is mediated by 
the CRISPR system. 
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As previously described (Chapter 1) the role of the CRISPR system is thought to be to 
prevent superinfection by other bacteriophages  (Sebaihia et al., 2006; Sorek et al., 2008; 
Karginov and Hannon, 2010).  Thus it is tempting to speculate , based on our results that 
repeated infection with different bacteriophages has resulted in a bacterial population 
which is inherently resistant to infection with temperate phages.  
 
In contrast, the primers with specificity to endolysins of members of the Siphoviridae 
bacteriophage family φCD6356 and φCD38-2   gave positive results with 48% and 59% 
of  the isolates respectively. The limited results of this study suggest that infection with 
members of the Siphoviridae family is less common than that seen with bacteriophages of 
the Myoviridae family.  This observation is supported by previous results which showed 
that of all of the C.difficile phages isolated to date  28 belong to the  Myoviridae family 
while only 11 belong to the Siphoviridae (Chapter 1, table 1.2). 
 
In addition to observing differences in the degree to which  individual endolysins were 
detected across  the entire collection of clinical isolates  we also observed differences in 
the responses of individual  ribotypes. All strains belonging to ribotype 017 appear to  
have been infected by all of the phages examined in this study. In contrast,  strains 
belonging to certain ribotypes appeared to have been infected by only one phage family. 
For example, isolates DS1759 and 1747 (ribotype 001) gave hits with primers specific to 
endolysins belonging to members of the  Myoviridae family while all of the ribotype 023 
isolates  (n=4) were only infected by Siphoviridae family phages. Therefore, it can be 
concluded from these results that there is no correlation between phage infection and 
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C.difficile ribotype. Owing, however, to the low number of samples used per ribotype, 
further work would be required to improve the result. 
 
In addition to generating information concerning the distribution of bacteriophage 
endolysins across our collection of clinical isolates we also sought to identify new 
bacteriophages.  Our hypothesis was that clinical isolates which gave no hits when 
probed with our PCR primers may carry previously unseen bacteriophages. To determine 
if this was the case we treated PCR negative isolates of C. difficile  with mitomycin C and 
screened for the release  of bacteriophages.  Two of the six PCR negative isolates yielded 
low levels of bacteriophages  upon induction.  Examination by electron microscopy 
showed a clear resemblance to other C. difficile bacteriophages  and their morphology 
indicated that each phage belonged  to the Myoviridae family.    Unfortunately the yield 
of each bacteriophage was such that we were unable to isolate sufficient bacteriophages 
to perform sequencing studies and also we failed to identify an indicator strains that 
supports these phage propagation. Consequently we were unable to characterize the 
endolysin associated with these bacteriophages. 
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5.4.2   Putative bacteriophage endolysin from C.difficile 630 (LysCD630) 
 
This endolysin was identified owing to its  sequence homology with  endolysins  of  
known C.difficile phages.     Moreover the nucleotide sequence of this gene was found to 
be highly conserved (at least 96%)  amongst all C.difficile  isolates sequenced to date.   
As one would expect given the sequence homology,  the protein sequence of this gene 
has a structural organization similar to those seen in C.difficile bacteriophage endolysin 
with an N-terminal domain comprising an N-acetylmuramoyl-L-Ala amidase  class 
enzyme and a putative C-terminal domain. We sub-cloned and expressed the 
corresponding protein in E.coli (M15) and have confirmed its lytic activity against the 
vegetative form of a number of different strains of C.difficile  (Chapter 4). 
 
The presence of a homolog to this endolysin in all of the C.difficile isolates tested in our 
study suggests that this gene could represent an evolutionary relic of past phage infection 
of an early ancestor of C.difficile.   Further characterization of the expression  and 
function of this gene is required to determine what role, if any, it plays in the biology of 
this strain. 
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5.5   Conclusions  
 
 The results of this study suggest that prophage carriage is a common event for 
clinical isolates of C.difficile.  
 
 This approach was able to identify what appear to be novel bacteriophages. 
 
 Propagation of these novel phages and characterisation of their endolysins could 
reveal new classes of endolysin with therapeutic potential. 
 
 PCR negative strains could also be used as an indicator strain for the previously 
isolated phages, because such strains are assumed to be sensitive.  
 
 We identified an endolysin from the genome of CD630 which was present in 
every clinical isolate of C.difficile examined during our study.  This gene might 
have potential as a diagnostic marker. Owing to its universal and conserved  
nature further studies are warranted to determine its role in the physiology of the 
host bacteria. 
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Chapter Six 
 
Germination-specific cortex-lytic enzymes of 
Clostridium difficile 
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6.1    Introduction 
Dormant Spores of Bacillus and Clostridium species are extremely resistant and can 
survive for years; these features are largely attributed to their unique structures (Popham 
et al., 1995). These endospores are generally formed under conditions of environmental 
stress such as a reduction in the availability of nutrients (Popham et al., 1995).  In the 
case of C.difficile this ability to form spores allows the organism to survive on 
contaminated surfaces for extended periods of time and increases its resistance to 
chemical and physical agents (Setlow, 2007). It is this feature that makes C. difficile an 
enormous challenge for infection control systems in hospitals and health care facilities; 
therefore, there is a need for new strategies to reduce the burden of C. difficile spores in 
contaminated environments (Nerandzic and Donskey, 2010). 
The mechanisms by which this pathogen forms spores and then subsequently germinates 
are poorly understood, due, until recently, to a lack of appropriate genetic tools with 
which to study these processes (Burns et al., 2010). Access to the bacterial genome 
sequencing projects has enabled researchers to search for homologs to genes known to be 
involves in the germination of other spore-forming bacteria (Burns et al., 2010) 
 
 
 
6.1.1   Structure of the C.difficile spore 
Spores of Bacillus and Clostridium are normally surrounded by several envelope layers, 
as described in the introduction,  and their role is to protect the organism  and interact 
with the environment (Russell, 1990).   
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Structurally, the bacterial spore comprises a core containing nucleic acid and enzymes, 
which is surrounded by the spore’s inner membrane. Next comes the cortex region, which 
comprises a major part of the spore and consists of a layer of spore peptidoglycan.  This 
cortex is surrounded by an inner spore coat, while the outer surface of the spore coat is 
surrounded in some species by a closely fitting structure known as the exosporium 
(Gerhardt and Ribi, 1964; Russell, 1990; Lawley et al., 2009). 
 
 
 
6.1.2   Structure of the cortex peptidoglycan  
 
Following the triggering of germination, spore lytic enzymes are activated, which break 
down the structure of the peptidoglycan within the spore cortex (Moir, 2006).  While 
little is known about the composition of the peptidoglycan of the cortex of C.difficile 
spores, it has been reported that the peptidoglycan of the spore and vegetative forms of B. 
subtilis differ markedly (Atrih and Foster, 1999). In the case of B.subtilis spore 
peptidoglycan, only 3% of N-acetylmuramic acid (NAM) residues carry peptide chains 
which are cross-linked via tetrapeptide side chains (Figure 6.1).  A further 26% of NAM 
residues have tetrapeptide side chains,  20% have L-alanine side chains, while  a small 
percentage carry tripeptides (Leighton and Doi, 1971; Popham et al., 1996; Atrih and 
Foster, 1999).  In addition, Muramic acid -lactam, which has no side chains, accounts 
for almost half of the muramic acid residues in spore peptidoglycan (PG), and as a 
consequence, spore PG has considerably less structural integrity than vegetative cell PG 
(Warth and Strominger, 1969; Warth and Strominger, 1972; Smith, Blackman and Foster, 
2000; Meador-Parton and Popham, 2000; Dowd, et al., 2008).  
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A similar peptidoglycan structure is also found in the spore cortex of B. cereus, B. 
megaterium and C. botulinum spores (Popham et al., 1996; Atrih and Foster, 2001). In 
C.perfringens spore coat PG, no NAM residues have single alanine side chains and some 
NAM are connected with dipeptide terminating in D-glutamate and with tripeptide 
terminating in diaminopimelic. Like B. subtilis s, only 3% of NAM residues are cross 
linked (Marquis and Bender, 1990; Makino and Moriyama, 2002).  
 
 Figure 6.1. Simplified schematic structure of the  peptidoglycan  composition of  the 
vegetative cell wall and spore cortex of B.subtilis , showing  the representative action of 
germination-specific cortex-lytic enzymes (GSLEs) (glucosaminidase and lytic transglycosylase) 
involved in cortex lysis during germination. GlcNAc, N-acetylglucosamine; MurNac, N-
acetylmuramic acid; L-Ala, L-alanine; D-Glu, D-glutamic acid; meso-A2pm, meso 
diaminopimelic acid; D-ala, D-alanine; δ, δ-lactam. Modified from Smith, et al, (2000) ,Atrih and 
Foster (2002) and Kumazawa et al., (2007). 
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6.1.3   Germination-specific cortex lytic enzymes 
During germination, hydrolysis of the cortex is essential to allow the production of new 
vegetative cells and to initiate outgrowth (Paredes-Sabja et al., 2009a). Hydrolysis is 
believed to be mediated by a group of recently identified enzymes called germination-
specific cortex-lytic enzymes (GSLEs) (Makino and Moriyama, 2002; Okamura et al., 
2000; Urakami et al., 1999).  According to Makino and Moriyama (2002), these enzymes 
can be classified into two types based on their activity: spore cortex-lytic enzymes 
(SCLEs) and cortical fragment-lytic enzymes (CFLEs).  Both SCLEs and CFLEs 
recognise the muramic-δ-lactam of spore peptidoglycan as a substrate but have no 
activity against vegetative cell peptidoglycans (Makino and Moriyama, 2002) and they 
are believed to be located  in inner spore coat (Bagyan and Setlow, 2002). 
In the case of B. subtilis, two SCLEs capable of degrading spore peptidoglycan muramic-
δ-lactam have been identified (Popham et al., 1996).  The first is called SleB and is 
located in the inner and outer layers of the spore. It possesses lytic transglycosylase 
Muramidase activity and requires a second enzyme called YpeB for its activation (Boland 
et al., 2000; Masayama et al., 2006).   
The other SCLE is called CwlJ and is found in the spore coat in association with GerQ 
during sporulation; it requires CaDPA for activation and is essential for CaDPA-mediated 
germination (Paidhungat et al., 2001; Bagyan and Setlow, 2002). Inactivation of both 
cwlJ and sleB results in a spore that is unable to complete cortex hydrolysis during 
nutrient germination (Ishikawa et al., 1998). 
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Unlike the SCLEs of Bacillus, Clostridium SCLEs are less well-defined. In the case of 
C.perfringens, SleC (Miyata et al., 1995) and SleM (Chen et al., 1997) have been 
identified in all strains of the organism that have been sequenced to date and have been 
shown to possess the ability to degrade cortex peptidoglycan (PG) in vitro  (Shimizu et 
al., 2002; Myers et al., 2006).  
A recent study has demonstrated that only SleC is essential for cortex hydrolysis and 
viability of C.perfringens spores, whereas SleM is not essential (Kumazawa et al., 2007; 
Paredes-Sabja et al., 2009a).   Of considerable interest, in the context of this study, is the 
fact that the SleC of  C.perfringens retains its lytic activity following extraction from the 
spore coat (Gould and Hitchins, 1963; Gombas and Labbe, 1981; Makino and Moriyama, 
2002).  
6.1.4   Characterisation of SleC of  C. perfringens 
During the process of C.perfringens spore development, SleC is produced at stages II to 
III of forespore formation (Masayama et al., 2006). It is thought to be synthesized as a 50 
kDa precursor of 438 amino acids comprising four domains (Figure 6.2). These are an N-
terminal presequence (113 amino acid residues); an N-terminal prosequence (35 amino 
acid residues); a mature enzyme with amidase activity (264 amino acid residues); and a 
C-terminal prosequence of 25 residues (Miyata et al., 1995; Urakami et al., 1999; 
Makino and Moriyama, 2002).  
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During sporulation (stages IV to VI) the N-terminal presequence and the C-terminal 
prosequence are cleaved to generate an inactive proenzyme with a mass of 35 kDa , 
which is localized outside the cortex layer (Miyata et al., 1995; Urakami et al., 1999).  
During the germination, The active form of this enzyme is a 31 kDa fragment (C31), 
which is achieved by the  proteolytic cleavage of an N-terminal prosequence from the 35 
kDa fragment by a germination specific protease (GSP)  (Urakami et al., 1999). This 
enzyme is a cysteine-dependent serine protease, which cleaves C35 at Val-149 and Val-
150 to generate the mature form of the enzyme (Figure 6.2). GSP is thought to be located 
close to the spore cortex in proximity to the major cortex-lytic enzymes (Shimamoto et 
al., 2001). The production of this protease is encoded by three genes, cspA, cspB and 
cspC, which are located upstream of the sleC gene (Shimamoto et al., 2001; Xiao et al., 
2011). In addition, it has recently been shown that the germination-specific serine 
protease CspB is essential for converting inactive pro-SleC to an active enzyme (Paredes-
Sabja, et al., 2009). However, the mechanism of regulation of these genes is currently 
unclear (Paredes-Sabja et al., 2009; Paredes-Sabja et al., 2011). 
  
6.1.5   Spore cortex-lytic enzymes of C.difficile 
In the last decade, the genome sequences of a number of C. difficile strains have been 
completed, enabling researchers to search for homologs to genes known to be involved in 
Bacillus and Clostridium spore germination 
A study undertaken by David et al. (2009) found that C. difficile 630 contained a gene 
(CD3563) with homology to the cwlJ and sleB genes of B. subtilis in that it shared 30% 
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and 45% amino acid identity respectively. A second C.difficile gene, CD0552, of 238 
residue proteins has also been annotated as sleB but shares no similarity with any known 
SCLE (Sebaihia et al., 2006; Monot et al., 2011). A third C.difficile gene, CD0551, 
shares 53% amino acid identity with the SleC gene of C. perfringens (David et al., 2009). 
Furthermore, equivalent homologs of these genes are also present in other C.difficile 
strains, such as the BI/NAP1/027 strain, R20291 (David et al., 2009). Interestingly 
C.difficile contains no gene with homology to C. perfringens SleM. 
The essential role of SleC in the germination of C.difficile spores was recently confirmed 
by David and colleagues, who found that while the inactivation of CD3563 (cwlJ/sleB- 
homolog) and CD0552 (sleB homolog) had no effect on the germination of both 
C.difficile 630 and R20291, the inactivation of CD0551 (sleC homolog) resulted in a 
mutant that was unable to form colonies following the induction of germination (David et 
al., 2009).     
 
Furthermore, genome analysis has revealed the presence of homologues of the Csp 
proteases of C.perfringens in the genome sequence of several C. difficile strains, such as 
630 and R20291  (David et al., 2009).  For example, the genome of C. difficile 630 
strains contains CD2246 (annotated as cspC ) that has 32% amino acid identity to both 
CspA and CspC of C. perfringens and CD2247 (annotated as cspBA) that  shows 36% 
and 35% identity to C. perfringens CspA and CspB, respectively (David et al., 2009).   
Thus it would appear, on the basis of gene homology, that C.perfringens and C.difficile 
share a common means of SleC activation and spore lysis.  
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Figure 6.2. Schematic representation of a possible mechanism of cortex hydrolysis during 
germination of C. perfringens spores. Four domains in the diagram of pro SleC (C50) represent the N-
terminal presequence (115 aa), the N-terminal prosequence (35aa), the mature region (264aa) and the C-
terminal prosequence (25aa) respectively. For full spore germination, lysis of Cortex PG is required, which 
is mediated by Spore Cortex-Lytic Enzymes (SCLE) and Cortex Fragment-Lytic Enzymes (CFLE). In the 
spore cortex, a pro SleC enzyme is activated by germination-specific proteases (GSP) by cutting its pro-
site, causing partial hydrolysis of spore cortex, then (CFLE ) SleM can function.   Modified from Okamura 
et al. (2000), Makino and Moriyama (2002) and Xiao et al. (2011).  
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6.1.6   Aim of this study 
The aims of this chapter are: 
 To employ the SleC lysin of C. perfringens as a model to identify, clone and 
characterise the SleC of C.difficile 
 To determine the ability of recombinant C.difficile SleC to lyse spore 
peptidoglycan 
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6.2. Materials and methods  
This cloning project was approved by Cardiff University’s Genetic Modification Safety 
Committee (GMSC) and the Health and Safety Executive (HSE) as a containment level 1 
procedure. 
6.2.1   Microbiological materials and methods 
6.2.1.1  Bacterial strain, growth conditions and media  
The C. difficile strains employed in this study were DS1813, CD630 and R20291. These 
strains were grown on CDMN agar, BHI agar and in BHI broth under anaerobic 
conditions at 37
0
C as described in Chapter 2 (section 2.1.3).   
C. perfringens strains R31973, R31782 and R31742 were cultivated in blood agar, BHI 
agar and BHI broth under an anaerobic environment at 37
0
C as described in Chapter 2 
(section 2.1.3).  All strains were kindly donated by the Anaerobe Reference Laboratory, 
Cardiff. 
E. coli M15 and SG3009 were used throughout as a cloning host, and were supplied as 
part of the QIA express System (Qiagen Ltd, Crawley, UK). All E. coli strains were 
cultured using Luria-Bertani (LB) broth or agar, as appropriate, at 37 °C, with 300 rpm 
shaking for liquid cultures. Media was supplemented as appropriate with kanamycin (25 
μg/ml) and ampicillin (100 μg/ml).   
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6.2.1.2   Spore preparation 
Spores of C. difficile strains were prepared as described previously in Chapter 2 section 
2.1.6.  C. perfringens spores were prepared by growth for 48 h on a BHI agar plate 
(supplemented with 5% w/v defibrinated horse blood; Oxoid, Basingstoke, UK). Plates 
were incubated anaerobically at 37
0
C, after which two to three colonies were subcultured 
into sterile BHI broth (45ml) for five days. After incubation, cultures were repeatedly 
washed with ice-cold distilled H2O (dH2O) until no cell debris or vegetative cells could 
be observed following spore and Gram staining. The spores were resuspended in distilled 
water to a final optical density of 600 nm (OD600) of 0.8 –1.0 and stored at -20°C. 
 
6.2.1.3    Preparation of decoated spores 
Spore produced as previously described were decoated chemically by agents which 
rupture disulfide bonds in the spore’s coat (Gould and Hitchins, 1963) using the method 
described elsewhere (Popham et al. 1995 ; Paredes-Sabja et al., 2009a ; David et 
al.,2009).Briefly, spores were suspended in 1 ml of 50 mM Tris-HCl (pH 8.0), 8 M urea 
1% (wt/vol), Sodium dodecyl-sulfate and 50 mM dithiothreitol to an OD600 of 20  and 
incubated at 37°C for 90 min. Following this incubation, decoated spores were washed 
three times in PBS (Popham et al., 1995). To confirm that the decoating process had no 
effect on spore viability, treated and untreated spores were serially diluted and plated 
onto BHI agar plates supplemented with lysozyme (1 µg/ml)  and incubated overnight at 
37 °C under anaerobic conditions. 
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6.2.1.4   Preparation of exosporium deficient C.difficile spores 
C. difficile spores were sonicated in order to remove the exosporium using the method 
described by Redmond et al., (2004), with some modifications. Briefly, prior to 
sonication, the spores were re-suspended to an optical density at 600 nm (OD600) of 1 in 
1 ml of 50 mM Tris-HCl (Fisher Scientific, Leicestershire, UK) and 0.5 mM EDTA 
buffer (Acros Organics, Geel, Belgium) adjusted to pH 7.5. 
To determine the optimal condition, the spores were sonicated using a Sanyo Soniprep 
150 ultrasonic disintegrator (Sanyo Gallenkamp, Uxbridge, UK). During sonication, the 
tip of the probe was kept just below the surface of the samples, which were kept on ice at 
all times. The settings for the sonicator were as follows:  
Amplitude (microns): 12 and 15 
Number of bursts : 4, 7, 9 and 16 
Length of bursts: 50 seconds and 1 minute 
The samples were allowed to cool for 98 seconds in ice between each pulse.  
Sonicated spores were then centrifuged at 9,000xg for 5 minutes. On completion, the 
spore pellets were washed once in 50 mM Tris-HCl, 0.5 mM EDTA (pH 7.5) and stored 
at 4
0
C for further analysis. 
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6.2.1.5   Transmission Electron Microscopy (TEM) 
In order to check the efficacy of the decoating and exosporium removal procedures, 
normal and treated spores were subject to TEM analysis. 
The samples were diluted in sterile distilled water, placed on Formvar-coated grids and 
examined after negative staining in 2% methylamine tungstate. After 15-30 seconds the 
excess stain was removed using filter paper. The grids were then washed twice with 
water and dried by filter paper.  Samples were examined immediately using a Phillips 
EM 208 transmission electron microscope with an accelerating voltage of 80 kilovolts 
(kV), and magnifications between 20,000x and 55,000x were used. 
All TEM materials and chemicals were supplied by Agar Scientific (Essex, UK). 
 
6.2.2   Bioinformatics analysis of spore cortex-lytic enzyme sequences 
Using previously published data on the structure and function of the SleC of 
C.perfringens S40 as a starting point, we identified homologous regions with the amino 
acid sequence of  CD0551(annotated as sleC), a gene within the nucleotide sequence  of 
C.difficile 630 which shares 53% amino acid identity (David et al., 2009).  The 
nucleotide sequences of the bases encoding the amino acid regions corresponding to the 
full-length (C50) and catalytic domains (C31) of C.perfringens and C.difficile were  
downloaded from the National Center for Biotechnology Information (NCBI)  database 
and subjected to bioinformatics analysis.  Table 6.1 shows the details of these fragments. 
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 Fragment NA sequence 
Region 
Gene 
length 
(bp) 
Reference 
C. perfringens S40 SleC 
(# D45024) 
C50 852-2168 1317 (Miyata et al., 1995) 
C31 1297-2091 795 (Okamura et al. ,2000). 
C.difficile 630 SleC 
(#AM180355 ) 
C50 656969-658240  1272 (Sebaihia et al., 2006) 
C31 656969-657778 810 This study 
 
Table 6.1.  C. perfringens S40 and C.difficile 630 C50 and C31 nucleotide sequences 
details used in this study (C50 = the whole sequence of SleC). 
 
 
 
 
6.2.3   Molecular biological materials and methods  
6.2.3.1   Optimisation of recombinant protein expression, analysis and 
purification  
  
Specific SleC sequences designed during this project were codon optimized to enhance 
expression from E.coli  using a  commercial  algorithm (Genscript Inc). Sequences were 
then chemically synthesized and cloned into pUC57 by Genscript, after which they were 
sub-cloned into pQE30 (QIAgen Inc.) to generate N-terminal histidine tagged fusion 
proteins. 
The constructed plasmids were subsequently transformed into chemically competent E. 
coli M15 [pREP4] and SG13009 [pREP4] as described in Chapter 2 (2.2.4).  
Recombinant proteins were expressed, analyzed, and purified under native conditions, as 
described in Chapter 2 (2.2.5 and 2.2.6) 
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6.2.3.2  Germination-specific protease (GSP) extraction and recombinant 
SleC protein digestion 
Germination-specific protease (GSP) was extracted from spores of the following strains: 
C. difficile CD630, R20291, DS1813  and C. perfringens  R31973, R31782, R31742 
using the method  described by Urakami et al., 1999 and Okamura et al. (2000).  A spore 
packed weight of 100-400 mg was  resuspended in  4 ml of 0.25 M KCl/50 mM 
Potassium phosphate pH 7.0 (SIGMA, UK) containing 0.2% CHAPS  3-((3-
cholamidopropyl) dimethylammonio)-1-propanesulfonate (Thermo, UK) at 30°C for 2 h 
(Urakami et al., 1999).  The cell debris was then removed by centrifugation (14,000 g for 
10 minutes at 4°C, Beckman Coulter Optima L-100K centrifuge, rotor 14) and the 
supernatant was heated at 52°C in a water bath (Fisher Scientific, Leicestershire, UK) for 
20 minutes to inactivate any SCLE that might be present.  Following heating, GSP was 
recovered from the supernatant by centrifugation (14,000 g for 10 min at 4°C). The 
extract was used as GSP solution without further purification. 
To digest the  full length lysin (C50), 50 µg/ml of recombinant protein was mixed with 
30µl of GSP extract in a 1.5ml microcentrifuge tube and incubated at 32°C for 1 h.  To 
determine whether the  recombinant protein had been cleaved, 40 ul of digested protein 
was mixed with 40 ul  of 2% SDS-PAGE sample buffer and denatured  using a heating 
block at 95
°
C for 5 minutes, after which 10 ul volumes were loaded onto pre-cast gels of 
4–20% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad). Gels were then subjected to 
electrophoresis for 45 minutes at 150 V (400 mA), as described in Chapter 2 (section 
2.2.8). 
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 Following separation, gels were washed twice with SDS and strained with Coomassie 
stain for 24 h at room temperature followed by de-staining with 25% methanol until all 
background stain had been removed as described in Chapter 2 (section 2.2.8). 
 
6.2.3.3   Proteins identified by MALDI TOF/TOF mass spectrometry 
In order to determine the identity of the protein fragments generated following exposure 
to GSP, individual bands were extracted from  4–20% Mini-PROTEAN® TGX™  SDS-
PAGE gels and subjected to trypsin digestion and matrix-assisted laser desorption-
ionization–time-of-flight (MALDI–TOF) mass spectrometry (MS) by the CBS 
Proteomics Facility, Cardiff University. 
Sample preparation  
Individual bands were manually excised from the SDS-PAGE gels and the resulting 1.5 
mm gel plugs were placed in a 96-well plate prior to trypsin digestion.  Sequencing grade 
modified trypsin (Promega UK Ltd) at a concentration of 6.25 ng/ul in 25mM 
(NH4HCO3) was added and the samples were incubated for 3 h at 37ºC. The resulting 
dried peptides were resuspended in 50% (v/v) acetonitrile in 5ul 0.1% (v/v) 
trifluoroacetic acid (TFA) for analysis using MS.  A 0.5ul aliquot corresponding to 10% 
of the material was spotted onto a 384-well MS plate, allowed to dry and then overlaid 
with ά-cyano-4-hydroxycinnamic acid (CHCA, Sigma, UK; 0.5 ul prepared by mixing a 
5 mg matrix with 1 ml of 50% (v/v) acetonitrile in 0.1% (v/v). 
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MALDI TOF/TOF mass spectrometer analysis 
Mass spectrometry was performed using a MALDI TOF/TOF mass spectrometer 
(Applied Biosystems 4800 MALDI TOF/TOF Analyzer; Foster City, CA, USA) with a 
200 Hz solid state laser operating at a wavelength of 355nm (Medzihradszky et al., 2000; 
Bienvenut et al., 2002; Glückmann et al., 2007; Brennan et al., 2009). MALDI mass 
spectra and subsequent MS/MS spectra of the eight most abundant MALDI peaks were 
obtained following routine calibration. Common trypsin autolysis peaks and matrix ion 
signals and precursors within 300 resolution of each other were excluded from the 
selection, and the peaks were analysed starting with the strongest peak. A total of 800 
laser shots were averaged (mass range 700–4000 Da; focus mass 2000) to produce 
positive-ion reflector mode spectra. In MS/MS positive ion mode, 4000 spectra were 
averaged based on a 1 kV collision energy (collision gas was air at a pressure of 1.6 x 10
-
6
 Torr) and default calibration.  
Combined PMF and MS/MS queries were performed using the MASCOT Database 
search engine v2.1 (Matrix Science Ltd, London, UK) (Perkins et al., 1999), embedded 
into Global Proteome Server (GPS) Explorer software v3.6 (Applied Biosystems) on the 
Swiss-Prot database (download date 13/07/2012), and TrEMBL (download date 
22/07/2011). Searches were restricted to bacteria domain taxonomy with trypsin 
specificity (one missed cleavage allowed); the tolerances for peptide identification 
searches were set at 50 ppm for MS and 0.3 Da for MS/MS. Modification of cysteine by 
iodoacetamide was employed as a fixed modification, with methionine oxidation as a 
variable modification. Search results were evaluated by manual inspection and conclusive 
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identification confirmed whether high quality tandem MS (good y-ion) data had been 
produced for ≥2 peptides (E value p < 0.05 for each peptide; overall p < 0.0025) or one 
peptide (only if E value was p < 0.0001). 
 
6.2.4   Assay of SCLE activity 
The lytic activity of recombinant cortex-lytic enzyme fragments was determined by 
measuring the decrease in optical density of coated and decoated spore suspensions 
following the addition of lysin using the methods described by Miyata et al. (1995a) and 
Okamura et al. (2000). with the following  modification : spores, resuspended in 200ul of  
40 mM potassium phosphate (pH 7) to an OD600 nm  of  0.8–1.5, were mixed with 100 
µg/ml of recombinant protein in the wells of a Bioscreen C System multiwall plate, and 
were incubated at  32°C  with shaking (every 2 min).  Changes in optical density (OD600) 
were measured every 2 min over a 3 h period.  Chicken egg white lysozyme (SIGMA, 
UK)  at 100µg/ml was used as a positive control and spores with no enzyme were used as 
a negative control. Lytic assays were repeated three times, every time a new spore 
preparation and recombinant protein extraction was used 
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6.3   Results 
6.3.1   Bioinformatics results 
 
A gene (1272 bp) encoding a Spore cortex-lytic enzyme pre-pro-form was identified in 
the C. difficile 630 genome sequence through sequence similarity analysis with C. 
perfringens S40.  The protein sequence of this gene (#CAJ67384)  was found to share 
53% amino acid identity with the SleC gene (#BAA08081) of C.perfringens S40 (David 
et al., 2009). Multiple sequence alignment of these sequences using the ClustalW2  
analysis programme revealed the presence of  amino acids that were  highly conserved, 
particularly in the region that encoded the enzymic center (mature region), as can be seen 
in figure 6.3.  
Interestingly, our BLASTn searches revealed that the nucleotide sequence of this gene 
appears to be highly conserved in that a  homology (98% homology or higher)  has been 
found in all nine strains of  C.difficile  sequenced  to date (Sebaihia et al., 2006; Stabler et 
al., 2009; He et al., 2010). 
 Fragment Gene 
length (bp) 
Protein 
length 
(aa) 
MW(kDa) Protein Solubility 
prediction 
C. perfringens 
S40 SleC 
 
C50 1317 438           49.65 77.6% 
C31 795 265 30.34 87.3% 
C.difficile 630 
SleC 
C50 1272 423 47.34 74% 
C31 810 270 30.45 66.9% 
 
Table 6.2.  Showing the details of spore cortex-lytic enzyme sequences used in this study,  
and the predicted MW, which was generated using ExPASy tools 
(http://web.expasy.org/compute_pi/)   and protein solubility, estimated according to Wilkinson-
Harrison (Wilkinson and Harrison, 1991; Davis et al., 1999; Harrison, 2000) using their web-
server (http://www.biotech.ou.edu/). 
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The structural similarity of the SleC produced by C.perfringens and C.difficile strain 630 
suggests that the SleC produced by C.difficile may also function as a spore cortex-lytic 
enzyme. 
 
 
C.perfringens (SleC)      MAVGGLKVQCFSEQRRYIPIDKCKVKITPTGEDGVAVGDTIE-LYTDDTGSTDTIELDAP 59 
C.difficile (SleC)        MQDGFLTVSIIDATN-NRPIQNAVVNIYSMSNGSQSSSTLYQNLRSNESGQVTGLVLPAP 59 
                          *  * *.*. :.  .   **::. *:* . .:.. : .   : * ::::*..  : * ** 
 
C.perfringens (SleC)      PIENSNQPG-TIPYSFAEVIVEREGFLPVAVNGVQIYPSRIALQNVNLP----ETRGYYR 114 
C.difficile (SleC)        DVDYSLQPSDVRPYSQYIVEAIADGYETVVIEGTQLLATIEARQGVPMSPRTRSKRSFSR 119 
                           :: * **. . ***   * .  :*: .*.::*.*: .:  * *.* :.    ..*.: * 
 
C.perfringens (SleC)      Q-EEVIDIQPNRLVGNFPPKIPEAEEKELPPPKGTVVLPEPVVPEYIVVHNGRPNDNSVA 173 
C.difficile (SleC)        QSELIFDIGEHTLYGTYPPKIPESNLKPLPPPTGFVVLDNPVVPEFIVVHDGLPEDSSAP 179 
                          * * ::**  : * *.:******:: * ****.* *** :*****:****:* *:*.*.. 
 
C.perfringens (SleC)      NYKVNYKDYIKNVACCEIFSTWSENTIRANVYAIISFTLNRIYTEWYRGKGKNFDITNST 233 
C.difficile (SleC)        NYWIPFKEYIKNIASSEIYSTWPEQTIYANVIAIISFTLNRVFTEWYRNKGYNFTITSTT 239 
                          ** : :*:****:*..**:***.*:** *** *********::*****.** ** **.:* 
 
C.perfringens (SleC)      AFDHAFSYGRNFYDNISRIVDEIFSTYMKR-FNSKQPLLAQYCDGINVQCPGWMTQWGSK 292 
C.difficile (SleC)        AYDHKFINNRNLFEPINVVVDAIFNTFIKRPPTSRQPLLAQYCDGQKSQCPDQMTQWGSK 299 
                          *:** *  .**::: *. :** **.*::**  .*:********** : ***. ******* 
 
C.perfringens (SleC)      YLGDEGKVPYDILTSFYGDDLELKSAKKVKGSPRSYPGYTLKTGYSGEPVRVIQEQLNAI 352 
C.difficile (SleC)        DLGDQGYDYESILRYFYGDEIVFERAPIVSGVPVSFPGTTLQVGSSGQYVRTIQNQLNAI 359 
                           ***:*    .**  ****:: :: *  *.* * *:** **:.* **: **.**:***** 
 
C.perfringens (SleC)      SRAYPLIPKIAVDGKYGPKTREAVKTFQKIFNLPQTGEVDYATWYKISDVYVAVTKIAEL 412 
C.difficile (SleC)        SNSYPAVPKVIEDGIYGTDTENAVKIFQGIFGLPQSGVVDFKTWYEISRVYVATTRIASL 419 
                          *.:** :**:  ** **..*.:*** ** **.***:* **: ***:** ****.*:**.* 
 
C.perfringens (SleC)      RSSVEKKIFYPPTIMDRRENVPKIIY 438 
C.difficile (SleC)        N----------PLI------------ 423 
                          .          * * 
Figure 6.3.  A) Schematic representation of the different regions of SleC in the C.difficile 630 
gene homolog using the SleC of C.perfringens S40 as a guide (Okamura et al., (2000). Homologous 
regions are highlighted by different colors are shown with number of identical amino acid. Overall, 
the amino acid sequences of C.perfringens SleC and C.difficile SleC are 53 % identical.  B) 
Alignment of the amino acid sequence of C. perfringens SleC aligned C.difficile SleC identified by 
BLAST analysis. Alignment was produced with ClustalW2; identical amino acids are marked with a 
star. Positions of the GPS cleavage sites are indicated by arrows. 
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6.3.2   Cloning and expression of spore cortex-lytic enzymes  
6.3.2.1   DNA Manipulation 
Individual protein sequences were codon optimized, synthesized and cloned into pUC57 
and then sub-cloned into the QIAgen expression vector pQE30. Plasmid was transformed 
into competent cells of  E.coli M15[pREP4] and SG13009[pREP4] for the protein 
expression.  Positive transformants were identified by culture on LB agar plates 
containing ampicillin (100 μg/ml) and kanamycin (25 μg/ml). 
The transformation efficiency of pQE30 plasmid containing the cortex-lytic enzyme gene 
sequences (C.perfringens C50 ,C31 and C.difficile C50, C31)  for  competent cells of  E. coli 
M15 and  SG13009  were determined and were found to be lower than that seen for the 
positive control (pQE-40). M15 seems to provide a statistically significantly better 
transformation ratio than SG13009; therefore, E. coli M15 was select for further work. 
 
Construct 
 
Transformants /µg of plasmid DNA 
M15 SG13009 
C. perfringens C50 152.7 ± 33X10
3
 180 ± 10.2X10
3
 
C. perfringens C31 202 ± 2.6X10
3
 143.2 ± 1.7X10
3
 
C. difficile C50 355.5 ± 7.2X10
3
 353.8 ±6.2X10
3
 
C. difficile C31 264.5 ± 5X10
3
 146.4 ±4X10
3
 
pQE40 435.8 ± 440X10
3
 
 
294.6±400X10
3
 
 
Table 6.3. Transformation efficacy in E. coli M15 and SG13009 , using 100 μl of the 
overnight culture plated out on LB-agar plates for 24h (readings represent the mean of three 
results± sd). pQE-40 control plasmid which expresses 6xHis-tagged DHFR is optimized for high-
level transformation  into these E.coli strains. 
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6.3.2.2   Optimization of recombinant protein expression, analysis and 
purification 
Fragments from C. difficile (C50 and C31) and C. perfringens (C50 and C31) were subcloned 
into the BamHI and Sall restriction sites of the expression vector pQE-30 in E. coli M15 
(pREP4). The expression of individual histidine tagged recombinant proteins was 
induced when the culture reached an OD600 0.6 by the addition of 1mM IPTG as 
described in Chapter 2 (section 2.2.5). The induced culture was incubated for a further 4 
h at 27
0
C, which represents the optimum induction conditions for each recombinant 
protein as determined by experimentation (Figures 6.4, 6.5, 6.6 and 6.7).  
Recombinant proteins were purified using affinity chromatography under native 
conditions.  Protein bands were analyzed by SDS-PAGE using pre-cast gels 4–20% Mini-
PROTEAN® TGX™ Precast Gel (Bio-Rad).  Bands with molecular weights of 
approximately 47 and 30 kDa (the predicted sizes of C.difficile C50 and C31) and 49 and 
30 kDa (the predicted sizes of C.perfringens C50 and C31)  were visualized in SDS-PAGE  
gel stained with Coomassie stain following IPTG  induction (Figures 6.4, 6.5, 6.6 and 
6.7).  The expression and purification of each recombinant protein fragment is 
summarized in the following series of SDS-PAGE  Coomassie stained gels (Figures 6.4, 
6.5, 6.6 and 6.7). 
Figure 6.4 showed the expression and purification of the C.difficile C50 recombinant 
protein. Time-course analysis of protein expression revealed that prior to, and 1 h post, 
IPTG induction there was no obvious expression of C50. In contrast, 4 h post induction, a 
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thick band of approximately 47 kDa in size can be observed, indicating that C50 protein 
was successfully expressed.  
Three rounds of protein binding and elution were sufficient to recover ~ 1-2mg of 
recombinant protein from 100 ml of starting culture, as determined using the BCA 
protein assay (section 2.2.7).  It was noted that the recombinant proteins precipitated in 
the recommended elution buffer and therefore the purified His-tagged protein were 
dialyzed against 20 mM sodium phosphate buffer (NaPhos) (pH6) and stored at 40C 
before further use. 
 
Figure 6.4.  Expression and purification  of C.difficile  C50 protein (expected size 47.34 kDa): 
Lanes: 1, Molecular marker ; 2, non-induced culture ; 3, 1h induced culture; 4, total protein 
extracts after 4 h of induction with IPTG; 5, column flowthrough; 6, primary wash effluent; 7, 
secondary wash effluent; 8, 1
st
 eluate (E1); and 9, 2
nd
 eluate (E2); 10, 3
rd 
eluate (E3) ;11 , buffer 
exchange 20mM NaPhos pH 6; 12, Molecular marker 
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In figure 6.5, the expression and purification of the C.difficile C31 recombinant protein is 
summerised.   The culture and induction conditions were identical to those used to 
express C50. 
After 4 h, a thick band of approximately 30 kDa was observed (lane 4), suggesting that 
C31 protein was successfully expressed.   Three rounds of protein binding and elution 
were sufficient to recover ~ 0.8-1.5mg (BCA assay) of recombinant protein from 100ml 
of starting culture.  The purified protein was finally resuspended in 20mM sodium 
phosphate buffer pH 6 with minimal loss of protein concentration. 
 
Figure 6.5.  Expression and purification of C.difficile  C31(expected size 30.45 kDa), Lanes: 1, 
marker; 2, non-induced culture; 3, 1h induced culture; 4, total protein extracts after 4 h of 
induction with IPTG; 5, column flowthrough; 6, primary wash effluent; 7, secondary wash 
effluent; 8, 1
st
 eluate (E1); and 9, 2
nd
 eluate (E2), 10, 3
rd 
eluate (E3) , 11 , buffer exchange 20mM 
NaPhos pH 6; 12, marker 
 
 Page | 228 
 
Figures 6.6 and 6.7 show the expression and purification of  recombinant C.perfringens 
C50 and C31.   The optimal induction and expression conditions were the same as those for 
the C.difficile proteins, with maximal expression occurring after 4 h of induction, at 
which time thick bands of approximately 49 and 30 kDa in size were observed, 
suggesting that both proteins were successfully expressed.  
Three rounds of protein binding and elution were sufficient to recover ~ 0.5 -1mg of C50, 
and 0.5–1mg of C31  from 100 ml of culture ( BCA assay, section 2.2.7) .  As was the 
case with the other proteins, C.perfringens C50 and C31 precipitated in the elution buffer 
and therefore the purified His-tagged protein were dialyzed against 20 mM Sodium 
phosphate buffer (pH6) and stored at 4
0
C  before further use. 
 
Figure 6.6  Expression and purification  of C.perfringens C50 (expected size 49.65 kDa) : 
Lanes: 1, marker; 2, non-induced culture; 3, 1h  induced culture; 4, total protein extracts after 4 h 
of induction with IPTG; 5, column flowthrough; 6, primary wash effluent; 7, secondary wash 
effluent; 8, 1
st
 eluate (E1);  9, 2
nd
 eluate (E2); 10, 3
rd 
eluate (E3); 11, buffer exchange 20mM 
NaPhos pH 6; 12, marker 
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Figure 6.7.  Expression and purification  of C.perfringens C31 (expected size 30.34 kDa): 
Lanes: 1, marker; 2, non-induced culture; 3, 1h  induced culture; 4, total protein extracts after 4 h 
of induction with IPTG; 5, column flowthrough; 6, primary wash effluent; 7, secondary wash 
effluent; 8, 1
st
 eluate (E1); 9, 2
nd
 eluate (E2); 10, 3
rd 
eluate (E3); 11 , buffer exchange 20mM 
NaPhos pH 6; 12, marker 
 
 
 
6.3.2.3   Protein detection: Western blot 
The identity of the recombinant spore lytic proteins were confirmed by probing  western 
blots with an antibody, Penta-His, which recognized the N terminal histidine tag (as 
described in Chapter 2 section 2.2.9). As can be seen in figure 6.8, signals were observed 
which corresponded in size to the expected molecular weights of  47, 30, 49 and 30 kDa.   
A protein marker (6x His-protein ladder) confirmed the size of the signals. 
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Figure 6.8.  Western blot analysis of purified spore cortex-lytic enzymes, (1) C.difficile C31 
(30 kDa)  (2) C.perfringens C31 (30 kDa)    (3) C.difficile C50 (47 kDa) and (4) C.perfringens C50 
(49 kDa), Western blot technique. M: protein marker (6x His-protein ladder 100-15 kDa); C: 
negative control (buffer only). 
 
 
 
 
6.3.4   GSP  activation of  recombinant lysin proteins 
The GSP extracted from C.perfringens S40 spores cleaves full-length SleC (C50) to 
generate a protein band 34kDa (Okamura et al. 2000), which was determined to have a 
lytic activity.  We determined whether GSPs isolated from spores of a range of 
C.perfringens (R31973, R31782, R31742) and C.difficile (CD630, R20291, DS1813) 
isolates behaved in a similar manner and were able to cleave the recombinant C50 protein 
derived from C. perfringens and C. difficile.    
As can be seen from the results presented in figure 6.9, only one extract obtained from 
spores produced by C.difficile DS1813 was able to digest the C50 of  C. perfringens  to 
M 
 Page | 231 
 
produce bands  of ~ 34 kDa and ~ 16 kDa.  The failure of the other spore extracts to 
cleave the recombinant protein is intriguing, although it could reflect problems with the  
spore extraction method.  
 
Figure 6.9.  Treatment of recombinant full length SleC (C50) from C.perfringens with 
Germination specific proteases (GSP) isolated from C.perfringens and C.difficile spores.     
1: Molecular weight marker, 2: Nondigested protein, 3: protein with buffer; 4: protein with GSP 
from DS1813; 5: protein with GSP from 630, 6: protein with GSP from DS20291;  7:  protein 
with GSP from R31742; 8: protein with GSP from R31972;  9:  protein with GSP from 
R3174510: Molecular weight marker; 11: protein with GSP from DS20291; 11: protein with GSP 
from 630; 12: protein with GSP from R31782; 13: protein with GSP from R31742; 14: protein 
with GSP from R31972; 15: Molecular weight marker.  
 
Interestingly, we saw a similar pattern of activity when the various spore extracts were 
mixed with the C.difficile recombinant C50 in that only the extract from C.difficile 
DS1813 appeared to cleave the recombinant protein (Figure 6.10). 
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Figure 6.10. Treatment of recombinant full length SleC (C50) from C.difficile with 
Germination specific proteases (GSP) isolated from C.perfringens and C.difficile spores.  1:  
Molecular weight marker;  2: Nondigested protein;  3: protein with buffer;, 4: protein with GSP 
from DS1813;, 5: protein with GSP from 630;  6: protein with GSP from DS20291;  7:  protein 
with GSP from R31742; 8: protein with GSP from R31972;  9: protein with GSP from R31745; 
10: Molecular weight marker;  11: protein with GSP from DS20291;, 11: protein with GSP from 
630;  12: protein with GSP from R31782; 13: protein with GSP from R31742; 14: protein with 
GSP from R31972; 15: Molecular weight marker (250-10 kDa)  
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6.3.5  Identification of SleC digestion products using MALDI TOF/TOF mass 
spectrometry 
Individual SleC digestion products resolved on SDS-PAGE gels (Figures 6.11 A and B) 
were excised, trypsin-digested and analyzed by MALDI TOF/TOF MS, with the resulting 
MS data being queried using Mascot.  The sequences and expected values (Exp) for each 
peptide are displayed in table 6.4 and appendix 3. 
 
Figure 6.11.  Showing the site of samples generated from treatment of recombinant full 
length SleC (C50) from C.difficile (A) and C.perfringens (B) with GPS isolated from C. 
difficile and C.perfringens strains, as described above in figures 6.9 and 6.10. 
 
 
 
 
 
A                                                                                    B 
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e value Peptide sequences Total 
number of 
peptides 
with MS/MS 
data 
Total number of 
peptides (MS 
and MS/MS) 
Sequence 
coverage 
(%) 
Mascot 
score 
Name and 
Accession 
Number 
ID category Sample 
5.50E-07 YFYGDEIVFER 3 9 28 291 A 1 1 
1.70E-05 APIVSGVPVSFPGTTLQVGS
SGQYVR 
0.079 VFTEWYR 
5.60E-09 DLGDQGYDYESILR 3 10 31 471 A 1 2 
8.60E-07 YFYGDEIVFER 
1.70E-06 APIVSGVPVSFPGTTLQVGS
SGQYVR 
0.0012 VIQEQLNAISR 2 17 31 322 B 1 3 
0.0051 IALQNVNLPETR 
1.10E-05 VIQEQLNAISR 2 6 25 194 B 2 4 
0.0053 IYTEWYR 
1.20E-05 IALQNVNLPETR 2 12 23 256 B 1 5 
0.00083 EGFLPVAVNGVQIYPSR 
0.078 VQCFSEQR 
  
Table 6.4.  MALDI-TOF/TOF  mass spectrum of an in-gel tryptic digest of the spore cortex-lytic enzyme band cut from the 1-D 
SDS–PAGE gel in Figure 6. 11  
Spore cortex-lytic enzyme pre-pro-form OS=Clostridium difficile (strain 630), accession No  ACQ188Z5_CLOD6  
Spore cortex-lytic enzyme SleC OS=Clostridium perfringens CPE str, Accession No B1RFT4_CLOPE  
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Mass spectrophotometer analysis of recombinant protein digestion fragment bands 
revealed the presence of amino acid sequences  which corresponded to the published 
amino acid sequences of the SleC of  C.difficile and C.perfringens (Table 6.4 and 
appendix 3). 
 
6.3.6   Production of exosporium deficient and decoated spores 
To determine the activity of recombinant lytic enzymes against spore peptidoglycan, we 
removed the outer layers of the spore to enhance the ability of the lysins to access the 
cortex. To achieve this aim, C.perfringens spores were decoated while C.difficile spores 
were subjected to decoating and sonication.  The efficiency of each process was  
determined using  TEM. Electron microscopy of negatively stained C.difficile DS1813 
spores revealed the presence of a core, cortex, coat and exosporium (Figure 6.12).  
To determine whether the recombinant lysins were able to lyse spores lacking the 
exosporium, spores of C.difficile DS1813 were subjected to sonication.  As can be seen 
from the images of negatively stained spores presented in figure 6.13 (A and B), a 
sonication  regimen of  50 seconds bursts over 16 cycles (amplitude15 μm) with each 
burst separated by 98 seconds of cooling on ice successfully remove the exosporium 
without visually damaging the underlying spore structure. In contrast, images of decoated 
spores of C. difficile DS1813 confirmed the absence of the coat and exosporium (Figure 
6.13 C and D).    
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Coated and decoated spores of C. perfringens R31782 were also negatively stained and 
examined using TEM.  As can be seen from figure 6.14,  untreated spores appeared as 
expected with a core, cortex and coat.  In contrast, the decoated spores lacked the coat. 
 
 
Figure 6.12.  TEM of untreated C. difficile DS1813, stained negatively with 2% methylamine 
tungstate. ( Scale bar:  100nm ), Representation from 20 field of view 
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Figure 6.13.   A , B )TEM  of sonicated C.difficile  DS1813  spores , stained negatively with 
2% methylamine tungstate 
 C, D )TEM  of decoated C. difficile DS1813 spore, stained negatively with 2% methylamine 
tungstate ( Scale bar :300nm ) ; Representation from 20 field of view 
 
B 
 
Exosporium 
A B B 
C D 
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Figure 6.14.  TEM of a normal coated (A) and decoated  (B) C. perfringens R31782 spore, 
stained negatively with 2% methylamine tungstate 
(bar :1µm ) * Representation from 20 field of view. 
 
 
 
 
 
 
 
 
 
 
 
A             B 
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6.3.7   Lytic activity of spore cortex-lytic enzymes 
In this assay, coated and decoated spores of C.perfringens R31782, and for C. difficile, 
DS1813, coated, decoated and sonicated spores were used.  Samples were subjected to 
digestion by the following lysins: full length SleC (C50),  the active section of the enzyme 
(C31) and the product of the C50 digested by GPS with 34 kDa, which will be referred to 
as (C34). 
Lysozyme at 100µg/ml was employed as a positive control. Untreated coated and 
decoated spores of the corresponding strain were employed as negative controls.   
Decoated spores of C.perfringens were considerably more sensitive to lysozyme and C31 
than were their  intact counterparts, suggesting that the outer layers of the spore act as a 
permeability barrier (Figures 6.15 and 6.16). 
The full length recombinant C.perfringens SleC (C50) showed no lytic activity against 
decoated spores of C.perfringens, whereas C31 and C34 produced significant lytic activity 
(P < 0.05 for both) after 3 h of incubation, the recombinant C31 being the most active 
(Figure 6.16).  
It is important to mention that we looked at the activity of C.difficile DS1813 spore 
extract containing GPS alone against coated and decoated spores of C.perfringens and 
observed no evidence of lysis in this assay.  
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Figure 6.15.  Lytic activity of the C50,C34,C31 of  C.perfringens proteins and lysozyme against 
normal coated spores of C.perfingens R31782. Values are the means of results from triplicate 
assays ± standard deviations. 
 
 
 
 
 
Figure 6.16 Lytic activity of the C50,C34,C31 of  C.perfringens proteins and lysozyme against 
decoated spores of C.perfingens R31782 . Values are the means of results from triplicate assays ± 
standard deviations. 
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We  subsequently  determined the activity of  C50,C34 and C31 from C.perfringens against  
C.difficile spores (coated, decoated and exosporium deficient ) and observed no evidence 
of lysis. This result is important, as it suggests that while the SleC of C.perfringens and 
C.difficile are similar, either they may have different spore peptidoglycans or the two 
lysins may recognise different sites. This was also the case for the C.difficile lysins 
against C.perfringens spores (coated and decoated). 
We next determined the ability of full length C.difficile  SleC (C50),  its GPS  generated 
digestion product, C34 and recombinantly expressed C31 to lyse intact spores of C.difficile 
(Figure 6.17).  As can be seen, little activity was detected, suggesting that as was the case 
for C.perfringens, the spore coat of C.dfficile acts as a permeability barrier. 
 
 
 
 
 
Figure 6.17 . Lytic activity of the C50,C34,C31 of  C.difficile proteins and lysozyme against 
normal coated spores of C.difficile DS1813 . Values are the means of results from triplicate 
assays ± standard deviations 
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A similar lack of activity was observed for spores  of C.difficile in which the exosporium 
had been removed, suggesting that the outer layer of the spore does not represent a 
significant permeability barrier for spore lysins (Figure 6.18).  
 
 
 
 
Figure 6.18. Lytic activity of the C50,C34,C31 of  C.difficile proteins and lysozyme against 
exosporium deficient spores of C.difficile DS1813. Values are the means of results from 
triplicate assays ± standard deviations 
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As was the case for C.perfringens spores, it required the removal of the spore coat to 
achieve lysine-mediated spore degradation. As can be seen from figure 6.19, in C.difficile  
C31 was  considerably more active than C50 and C34.  
 
Despite the fact that C.difficile C31 was  inactive against coated spores, with decoated 
spores it showed significant activity  (P < 0.05) in comparison to pro form C50 
 
 
 
Figure 6.19 . Lytic activity of the C50,C34,C31 of  C.difficile proteins and lysozyme against 
decoated spores of C.difficile DS1813. Values are the means of results from triplicate assays ± 
standard deviations 
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6.4   Discussion 
Little is known about the process that triggers C.difficile spore germination and the 
subsequent lysis of the spore cortex. While a bioinformatic comparison between the 
genome sequence of C.difficile and other Gram positive spore formers has found no 
homology to known germination receptors, it has revealed homology to spore 
peptidoglycan lytic enzymes such as SleC (David et al., 2009; Ramirez et al., 2010).   
Indeed, a recent study showed that the inactivation of the gene in C.difficile prevented 
germination (David et al., 2009).   
 
In this study, we identified and characterized a putative spore cortex lytic enzyme 
encoded by the SleC gene of C.difficile 630 with homology to the SleC gene of C. 
perfringens.  This was achieved by codon optimizing the gene sequences of each gene for 
expression in E.coli and subsequently expressing the full-length (C50) and catalytic 
domain (C31) of each gene. The lytic activity of each recombinant protein against coated 
and decoated spores of C.perfringens and against coated, decoated and exosporium 
deficient (sonicated) spores of C.difficile was determined. 
 
To be biologically active, the full length  SleC fragment (C50) is cleaved during 
sporulation to generate the inactive proenzyme (C35), which is then proteolytically 
cleaved by a spore associated protease  (GSP) to generate the active form C31 (Urakami et 
al., 1999).  
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Miyata and colleagues were able to isolate the SleC in an active from (C31) from 
germinated spores, which showed lytic activity against coatless spores (Miyata et al., 
1995a). 
Furthermore, a study by Urakami and colleagues reported that the inactive form of SleC 
(C35), which was isolated from dormant spores, exhibited lytic activity against coatless 
spores only after treatment with a GSP (Urakami et al., 1999). 
However, the previous study reported that the full length SleC sequence (C50) 
C.perfringens (as a recombinant protein) produced only one fragment with ~ 34 kDa after 
treatment with GSP: this fragment also showed lytic activity against decoated spores 
(Okamura et al., 2000).  
 
Our results revealed that the full length recombinant SleC (C50) derived from 
C.perfringens and C.difficile were digested by GSP but only by the spore extract obtained 
from C.difficile DS1813.   The failure of spore extracts from other strains  examined in 
this study to lyse SleC could be due to the inefficiency of the GSP extraction method.  
That the spore extract of C.difficile DS1813 produced similarly sized digestion products 
supports the hypothesis that the SleC homolog in C.difficile plays a similar role to that of 
SleC in the germination of C.perfringens. Indeed, these data support the idea that  
C.difficile and C.perfringens may share a common ancestor.  
 
In our study, spores were decoated chemically by agents that rupture disulfide bonds in 
the spore coat, such as urea and DTT (Gould and Hitchins, 1963). The TEM results 
showed that this method was able to remove the spore coat and no broken spores were 
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found. With exosporium deficient C.difficile spores, spores were sonicated at 15 μm, in 
50 seconds bursts over 16 cycles. We also demonstrated by TEM results that this method 
successfully removed spore exosporium  without damaging the spore coat, maintaining 
the spore ultrastructure: this result is supported by previous results seen by Escobar-
Cortés et al. (2013). 
 
Lysozyme was used in this study to gauge the lytic activity of our spore lysin enzymes, 
since it is well known as a PG hydrolase and is widely used (Heffron et al., 2011). Under 
our reaction conditions, lysozyme exhibited a high level of activity compared to those 
seen by the spore lysin enzymes and was only active against decoated spores of 
C.difficile (Escobar-Cortés et al., 2013) and C.perfringens (Ando, 1979) 
The biological activity of our  recombinant proteins was determined against coated and 
decoated spores of C.perfringens spores and against coated, decoated and exosporium 
deficient spores  of  C.difficile. We found that only the C31 form of both lysins was able 
to break down spore peptidoglycan, but to do so required the removal of the exosporium 
and spore coat.  As with other studies, our work confirmed that the spore coat was the 
major barrier to access of externally applied lysins (Escobar-Cortés et al., 2013). 
Further biochemical characterisation of these enzymes would be required in order to 
achieve the full lytic activity. 
We also found that the activated products of SleC failed to lyse the peptidoglycan of 
vegetative bacteria, while phage derived endolysins also lacked activity against decoated 
spores of C.difficile.  This finding confirms that fundamental differences exist in the 
structure of vegetative and spore derived peptidoglycan.  
 Page | 247 
 
6.5   Conclusions 
 
 The SleC of C.difficile is similar to that of C.perfringens and plays a key role in 
mediating germination. 
 The spore coat acts a permeability barrier to externally applied SleC, which could 
hinder its future development as a therapeutic agent. 
 The peptidoglycans of the vegetative and spore form of C.difficile differ in 
structure. 
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Chapter Seven 
 
General discussion 
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7.1   Introduction 
Clostridium difficile produces large oval sub-terminal spores which facilitate 
environmental survival due to their resistance to heat, drying, and exposure to commonly 
used disinfectants. Healthy adults are protected from C.difficile colonization and disease 
by normal human colonic microbiota; however, disruption of this protective community 
by broad spectrum antibiotics allows spores, acquired via the faecal-oral route, to 
colonize and germinate in the small bowel upon exposure to bile acid, and thereafter to 
produce vegetative cells which proliferate in the colon, where they bring about the 
pathological effects of the disease.
 
 
While the current treatments of choice, metronidazole and vancomycin, are generally 
effective in promoting recovery, the increased incidence of CDI and treatment failure 
associated with antibiotic resistance combined with the emergence of hypervirulent 
strains highlights the need to develop approaches which specifically target the pathogen 
without causing collateral damage to the protective microbiota. Several non-antibiotic 
approaches have been investigated, such as toxin-binding resins, probiotics, 
immunotherapy and faecal bacteriotherapy. While promising, these approaches have yet 
to demonstrate their efficacy in large-scale controlled studies.  
In this study, we attempted to isolate lytic bacteriophages capable of specifically 
targeting C.difficile in a manner that enables the re-establishment of a protective bacterial 
ecosystem. 
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We also investigated the potential of employing recombinant bacteriophage derived 
endolysins as therapeutics capable of targeting vegetative C.difficile. To complement this 
effort, we investigated the feasibility of using a spore cortex lytic enzyme (SleC) as a 
means of directly targeting the spore form of the bacterial cell. 
 
7.2   Bacteriophages and their products as potential therapeutics 
Our attempts to isolate a virulent, lytic bacteriophage specific for C.difficile that could 
form the basis of a future therapeutic were not successful. This result was consistent with 
earlier attempts, which also failed to isolate such a phage (Goh et al., 2005b; Horgan et 
al., 2010). Failure to isolate such a phage could in part be due to the fact that the host cell 
spends much of its time as a spore and as such lacks the receptors that enable phages to 
initiate an infection (Goh et al., 2005b). It is also believed that there is a selective 
pressure for C.difficile-specific bacteriophages to be lysogenic: the spore provides 
protection for the bacteriophage against harsh environmental conditions while the 
bacteriophage carries genes with functions that can be adapted and used by the host 
(Stewart and Levin, 1984; Letarov and Kulikov, 2009; Horgan et al., 2010). Based on our 
results, when attempting to recover C.difficile-specific bacteriophages from the 
environment, it may make more sense to first isolate the bacteria and then attempt to 
recover any bacteriophages that they may contain. Such an approach would differ 
markedly from approaches previously reported in the literature. 
  
 Page | 251 
 
While we failed to isolate lytic phages, we were able to induce the expression of 
temperate phages, with twelve Myoviridae family phages being recovered from twenty-
three clinical isolates following treatment of mid-log phase cultures of C.difficile with 
mitomycin C . This mitogen was found to be more efficient than norfloxacin, possibly 
due to its different mechanism of action (Ingrey et al., 2003; Shan et al., 2012; Meessen-
Pinard et al., 2012).  
 
The expression of temperate phages of C.difficile has been shown to occur at every stage 
of cell growth, with phages being recovered during the early (Fortier and Moineau, 
2007), mid-log (Shan et al., 2012) and stationary phases (Sell et al., 1983; Goh et al., 
2005; Mayer et al., 2008; Horgan et al., 2010). Some strains of C.difficile have even been 
reported to release phages following sporulation (Nale et al., 2012). In common with 
these studies, we found that induction during mid-log phase growth yielded the greatest 
phage recovery, for reasons that have yet to be determined.  
 
Our ability to recover phages from the clinical isolates examined in this study was greatly 
hindered by our inability to identify a susceptible indicator strain which could be used to 
propagate newly induced prophages. Other researchers have reported a similar problem 
(Fortier and Moineau, 2007; Nale et al., 2012). One possible explanation is that 
C.difficile has developed immunity to phage infection through the use of mechanisms 
such as the CRISPR system, where the bacterial cell retains a small region of DNA from 
the infecting phage, which it uses to inhibit subsequent infection with related phages 
(Barrangou et al., 2007; Deveau et al., 2008; Sebaihia et al., 2006).  
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Evidence to support the hypothesis that C.difficile isolates have been exposed to constant 
rounds of bacteriophage infection is provided in Chapter 5. Our results suggest that 
bacteriophage infection is a common event amongst clinical isolates of C.difficile, an 
observation supported by the fact that all strains of C.difficile sequenced to date were 
found to harbour at least one phage at their genome (Sebaihia et al., 2006 Goh et al., 
2007, He et al., 2010; Nale et al., 2012; Shan et al., 2012 ). 
In this study, we found that seventy-nine of the eighty-five clinical C. difficile isolates 
examined by PCR gave at least one positive hit, with some isolates responding to all five 
primer pairs, suggesting a history of multiple infections. Interestingly we found no 
correlation between phage infection and C.difficile ribotype. 
 
Thus it is tempting to speculate, based on our results, that repeated infection with 
different bacteriophages has resulted in a bacterial population that is inherently resistant 
to infection with temperate phages, which may explain the difficulty we have faced in 
finding an isolate of C.difficile that supports virulent phage production (Goh et al., 
2005b; Fortier and Moineau, 2007; Mayer et al., 2008; Horgan et al., 2010; Nale et al., 
2012; Shan et al., 2012).  
 
The fact that we were able to recover temperate phages from clinical isolates that were 
PCR negative suggest that new bacteriophages await discovery and that the burden of 
past phage infection is likely to extend beyond the phages that have been identified to 
date. In addition, these new phages, once characterised, could represent a new source of 
endolysins. 
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The possibility of employing temperate phages to treat C.difficile infection has been 
described in the literature. Ramesh and colleagues reported that C.difficile-specific phage 
140 was able to prevent C.difficile-induced ileocecitis in hamsters (Ramesh et al.,1999), 
while φCD27 has been successfully shown to target C.difficile and inhibit toxin 
production in a laboratory model of a human colon system (Meader et al., 2010 ). While 
these results are promising, there are many problems associated with the use of this type 
of phage as a therapeutic agent. They include: 
 The phages have a narrow host range.  
 They are susceptible to gastric acidity. 
 Phage treatment can increase the sporulation rate in C.difficile, which may 
increase the risk of transmission and relapse infection. 
 Treatment with these phages could result in their integration into the genome, 
which could render the bacteria resistant to further infection with related phages 
and could increase the risk of gene transfer. 
 These phages are not stable (Clokie et al., 2011) 
For these reasons, alternative approaches are currently being investigated, such as 
exploiting the potential of genomics. Access to an increasing number of C.difficile-
specific temperate phage genomes has enabled researchers to identify genes that play a 
key role in the biology of the virus. Indeed, an alternative approach to employing the 
entire phage is to investigate the therapeutic potential of individual phage proteins such 
as the endolysins. These enzymes are responsible for lysing the vegetative cell wall of the 
bacterial cells and allowing it to escape from its prey to infect other neighbouring 
bacteria.  
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Endolysin genes have been cloned and expressed as recombinant proteins and have been 
shown to lyse the target bacterial cells when applied externally (Fischetti, 2005; Loessner 
et al., 1998, Meyer et al., 2008). One advantage of employing endolysins over the whole 
phage is the fact that treatment with endolysins is unlikely to lead to the development of 
resistance even following repeated exposure (Borysowski et al., 2006; Loeffler et al., 
2001; Schuch et al., 2002). This is thought to be due to the fact that the endolysins targets 
molecules in the cell wall that are important in bacterial viability (Borysowski et al., 
2006).  
As part of this study, we identify and expressed as recombinant proteins five C.difficile 
phage encoded endolysins from φCD119, φCD2 ,φCD27 φCD6356 and φCD38-2. They 
all shared the same modular structure, comprising a single N-terminal and C-terminal 
domain, and were all class 3 amidase endolysins. However, despite the fact that they 
shared a high percentage of amino acid identity, they differed in their lytic activity, 
possibly due to differences in the binding affinity of their C terminal domains (CBD). 
Interestingly, the lytic activity of the endolysins derived from Siphoviridae phages 
(φCD6356 and φCD38-2) differed markedly from that seen using endolysins derived 
from Myoviridae family phages (φCD27, φC2, and φCD119). In addition, the failure to 
observe synergistic activity between combinations of these endolysins supports the 
hypothesis that they act against the same target, as one might expect, given that they are 
all class 3 amidases (Proença et al., 2012). 
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The recombinant endolysins produced in this study were found to be biologically active 
against a wide range of C.difficile isolates representing a diversity of ribotypes. They 
were also found to be specific for C.difficile in that they showed little or no activity 
against the other bacterial species included in this study, thus highlighting their potential 
as novel, specific microbial agents. Indeed, our characterization of endolysin LysCD27 
and its variant, LyCD227, provides a starting point from which to investigate the ability 
of genetic engineering to improve the activity of these endolysins. As we demonstrated in 
Chapter 4, subtle change in endolysin sequences seems to have a major impact on the 
endolysin activity. 
 
While these endolysins showed impressive activity under in vitro conditions, further 
studies need to be undertaken under in vivo conditions to assess their efficacy in the 
complex biological environment that is the gut. Moreover, studies need to be undertaken 
to determine the most efficient method of formulating and delivering endolysins to their 
target bacteria in the gut. A number of approaches could be employed to achieve this aim, 
such as encapsulation (Zhong and Jin, 2009; Liu et al., 2010) or the expression of a 
C.difficile-specific phage lysin from a strain capable of colonizing the gut, such as 
Lactococcus Lactis (Mayer et al., 2008) . 
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7.3    C. difficile genome-encoded lysins as potential therapeutics 
In addition to examining the potential of bacteriophage-derived endolysins, we also 
demonstrated the feasibility of employing a bioinformatics-based approach to identify 
potential endolysins located in the genome of C.difficile. Among the sequences identified 
within the genome of C.difficile 630 was a putative endolysin gene (CD630, 
YP_001088405). A copy of this gene, as determined by PCR, was detected in all of the 
C.difficile isolates examined in this study, suggesting that this gene could represent an 
evolutionary relic of past phage infection of an early ancestor of C.difficile. Furthermore, 
a recombinant version of this gene was indeed able to lyse the C.difficile cell wall in a 
manner similar to that of the phage-derived endolysins, suggesting that it could be a 
strong candidate for development as a future therapeutic agent. Furthermore, its universal 
and conserved nature suggests that it may have potential as a diagnostic marker. 
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7.4    Germination-specific cortex-lytic enzymes of C. difficile as potential 
therapeutics 
 
The mechanism of spore germination in C.difficile is unclear; however, it has been shown 
that bile salts play an important role in mediating germination (Wilson, et al., 1982; 
Wilson, 1983; Sorg and Sonenshein, 2008; Giel, et al., 2010).  
While it has been proposed that C.difficile spores have a germination receptor which 
responds to taurocholate and glycine, to date, no homologs to known germination 
receptors have been identified in the C.difficile genome (Ramirez, et al., 2010). While 
studies have failed to identify germination receptors, they have revealed the presence of 
genes with homology to previously described spore cortex lysins, which in the case of 
C.difficile CD630 comprise four genes, CD0551 (sleC), CD0552 (sleB), CD0106 (cwID) 
and CD3563, which is thought to encode a putative cortex lytic enzyme (Sebaihia et al., 
2006; David et al., 2009). 
 
Our bioinformatics analysis of these genes revealed that CD0551, which encodes for a 
homolog of sleC, was highly conserved (98% homology or higher) in the nine C.difficile 
strains sequenced to date and shared 53% amino acid identity with the SleC gene of C. 
perfringens (David et al., 2009). In this strain, SleC plays an essential role in 
germination, as it lyses the peptidoglycan in the spore cortex (Paredes-Sabja, et al., 
2009a). Subsequent gene knock-out studies by David and colleagues confirmed that the 
SleC of C.difficile plays a similar role in the germination of C.difficile (David et al., 
2009).  
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Further confirmation of the similarity of the SleC of the two bacteria was provided by the 
observation that full length recombinant SleC (C50) derived from C.perfringens and 
C.difficile when digested by GSP isolated from spores of C.difficile DS1813 generated 
identical sized fragments of approximately 34 kDa and 16 kDa. The ability of the GSP 
from C.difficile to process the SleC of C.perfringens lends support to the idea that the two 
bacteria employ the same process. However, our results showed that even though these 
enzymes play the same role, they only have lytic activity against their own bacteria. 
Another similarity was also seen when the lytic activity of these enzymes was tested 
against coated and decoated spores. These enzymes were shown to be active against 
coatless spores only, showing that spore coat is a major barrier in both strains and these 
enzymes are not permeable. Furthermore, due to this property, it would be expected that 
the enzyme is located in the spore coat, as in the case of C.perfringens SleC.  
 
This study confirmed that there are fundamental differences in the structure of vegetative 
and spore derived peptidoglycan. We found that the recombinant SleC of C.difficile failed 
to lyse peptidoglycan extracted from vegetative bacteria, while phage derived endolysins 
had no activity against decoated spores of C.difficile. We also found that lysozyme failed 
to lyse the PG of vegetative cells but was active against decoated spores. This finding is 
in agreement with the previous studies by Peltier and colleagues, who linked lysosome 
resistance to the presence of a high proportion of non-acetylated amino sugars in the 
peptidoglycan of vegetative cells (Peltier et al., 2011), and another study by Escobar-
Cortés and colleagues, who showed that lysozyme was active against coatless spores of 
C.difficile (Escobar-Cortés et al., 2013). 
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As far as we are aware, this is the first report of such differences in C.difficile, although 
other bacteria such as B.subtilis (Atrih and Foster, 1999) and C.perfringens (Marquis and 
Bender, 1990; Makino and Moriyama, 2002) are known to differ in a similar manner. 
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7.5   Suggestions for future studies  
 
 Investigate the potential of the gene encoding the CD630 lysin as a diagnostic 
marker of C.difficile. 
 Isolate further bacterial lysins and determine their ability to target vegetative 
C.difficile - seek to identify a lysin with glucosaminidase activity which could be 
used in combination with the lysins with class 3 amidase activity that we have 
already isolated. 
 Determine the activity of each endolysin in combination with antibiotics with a 
view to identifying synergistic formulations such as the endolysin (Cpl-1) and 
penicillin, which has been shown to have synergistic activity against a penicillin-
resistant strain of S. pneumoniae (Djurkovic et al.,2005) .  
 Studies should be undertaken to examine the administration of the endolysin in 
combination with therapies that neutralise the activity of the toxins, such as 
antibodies and tolevamer (Babcock et al., 2006; Barker et al., 2006). 
 Investigate the feasibility of employing molecular biology to enhance the activity 
of recombinant lysins by modifying lysin structure, as has been demonstrated by 
Meyer et al. (2010). 
 Examine means of delivering the lysins to the gut. Approaches that could be 
employed include the use of genetically-modified lactic acid strain such as 
Lactococcus Lactis, in order to overcome the challenge of delivering a 
bacteriophage endolysin to the GI tract. 
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 The failure of SleC to lyse the cortex of whole spores when applied externally 
represents an obstacle to its use as a therapeutic agent. Studies are required to 
identify spore permabilising agents that could be used to enable SleC to access its 
target site. 
 Further studies should be undertaken to characterise the processing of SleC in 
C.difficile spores following the induction of germination.  
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7.6   Conclusions 
Our attempts to isolate lytic bacteriophages which could form the basis of a treatment for 
C.difficile were unsuccessful. This failure may in part be due to repeated episodes of 
phage infection over time which have resulted in the emergence of “phage resistant” 
species mediated by systems such as CRISPR. For this reason, we investigated the 
antibacterial potential of phage-encoded lytic enzymes and were able to demonstrate their 
activity against multiple clinical isolates of the vegetative form of the pathogen.  
 
We also found that a genome associated lysin (CD630, YP_001088405) was able to lyse 
vegetative C.difficile and that this gene was present in all of the clinical isolates of 
C.difficile examined in this study. Given its apparent universal nature, this gene has the 
potential to be developed as a diagnostic marker for this pathogen. 
 
In addition to examining bacteriophage-associated endolysins, we cloned and expressed a 
C.difficile spore cortex enzyme (SleC), which was able to lyse the peptidoglycan of the 
spore when applied externally, but only once the outer layers of the spore had been 
removed, suggesting that they acted as a permeability barrier. The sequence similarity 
between the SleC genes of C.perfringens and C.difficile and the fact that their expressed 
proteins are processed in a similar manner suggest that these bacteria share similar 
germination pathways. 
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The finding that phage lysins were unable to lyse spore peptidoglycan and that SleC was 
equally ineffective against vegetative peptidoglycan supports the supposition that the 
peptidoglycan compositions of these two structures differ markedly. Thus, any lysin-
based therapeutic agent which seeks to target all phases of the pathogen’s life cycle 
should include phage and spore derived lysins. 
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Appendix 1:  The C. difficile isolates used in this study 
Ribotype Strain Patient 
Sex 
Patient 
Age 
Origin Year 
referred 
001 DS1759 M 87 Maidstone * 
DS1747 F 82 St James Leeds * 
R8652 * * NCTC 11209 * 
DS1750 F 88 St James Leeds * 
R9399 * * * 1996 
R12824 * * * 1999 
R17752 * * * 2002 
027 DS1813 M 80 Hinchingbrooke * 
DS1801 F 64 Leicester * 
R20291   Stoke Mandeville * 
DS1807 F 31 Salford * 
R24626 * * Bath 2007 
R26390 * * Stevenage 2008 
106 R10459 * * Dudley * 
DS1798 M 94 Poole * 
DS1787 M 83 Leicester * 
DS1771 M 88 Bristol Southmead * 
R28614 * * Newport 2009 
014 DS1742 M 27 Bristol Frenchay  
R30061 * * Stock on Trent 2010 
R22537 * * Surry 2006 
R31755 * * Waterford 2011 
R31757 * * Waterford 2001 
002 DS1748 F 83 Leeds * 
R25577 * * Oldham 2008 
R27039 * * Wakefiled 2008 
R31760 * * Waterford 2011 
R31763 * * Waterford 2001 
005 DS1721 M 66 Leicester * 
R27038 * * Margate 2008 
R25028 * * * 2007 
R31762 * * Waterford 2011 
R31778 * * Swansea 2011 
012 DS1752 F 81 Bradford * 
R31771 * * Swansea 2011 
R31080 * * London 2011 
R30904 * * London 2011 
R30851 * * London 2011 
078 
 
DS1723 M 71 Leicester * 
R19058 * * * 2003 
R31710 * * Durham 2011 
R31708 * * Cardiff 2011 
R31777 * * Swansea 2011 
020 DS1724 M 83 Leicester * 
R31774 * * Swansea 2011 
R31550 * * London 2011 
R31464 * * London 2011 
R31502 * * Naas Ireland 2011 
 
 Page | 296 
 
Appendix 1(continued):  The C. difficile isolates used in this study 
Ribotype Strain Patient 
Sex 
Patient 
Age 
Origin Year 
referred 
010 DS1684 F 92 Brighton * 
R31750 * * Waterford 2011 
R31722 * * London 2011 
R30762 * * Sligo Ireland 2010 
R30327 * * London 2010 
023 DS1665 * * * * 
R15552 * * * * 
R31377 * * Wales study 2011 
R31148 * * Wales study 2011 
R31314 * * Wales study 2011 
017 R9557 * * * 1996 
R13695 * * * 2000 
R18091 * * * 2003 
R2139 * * * 1985 
R19222 * * * 2004 
R22660 * * * * 
047 R10542 * * * 1997 
R18045 * * * 2003 
R25961 * * * * 
R17732 * * Leeds 2008 
R10543 * * * * 
056 R24498 * * * 2007 
DS2008 * * * 2008 
R26796 * * Wales study 2008 
R31312 * * Wales study 2011 
R31229 * * Wales study 2011 
110 R7771 * * * 1994 
R17978 * * * 2003 
R30967 * * * * 
R18040 * * Birmingham 2011 
R17985 * * * * 
046 R19168 * * * 2004 
R31583 * * London 2011 
R31263 * * London 2011 
R30869 * * London 2011 
R30870 * * London 2011 
045 R20408 * * * 2004 
R30776 * * London 2010 
R28450 * * Leeds 2009 
R30072 * * Exeter 2010 
R27086 * * * * 
*Information not available 
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Appendix 2: Evolutionary relationship of lysin sequences encoded peptidoglycan hydrolase, 
N-acetylmuramoyl-L-alanine amidase from C.difficile genomes and phages. The evolutionary 
history was inferred by using the Maximum Likelihood method based on the JTT matrix-based 
model. The bootstrap consensus tree inferred from 1000 replicates is taken to represent the 
evolutionary history of the taxa analyzed. Branches corresponding to partitions reproduced in less 
than 50% bootstrap replicates are collapsed. The percentage of replicate trees in which the 
associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the 
branches. Initial tree(s) for the heuristic search were obtained automatically by applying 
Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a JTT 
model, and then selecting the topology with superior log likelihood value. The analysis involved 
65 amino acid sequences including C. difficile phage endolysins (φCD119, φCD2, φCD27, 
φMMP03, φMMP04, φCD6356 and φCD38-2), C. perfringens phage endolysin (φ39-O, 
φCP13O, φCP26F, φCP34O, φCP9O) and C. sporogenes phage (φ8074-B1). All positions 
containing gaps and missing data were eliminated. There were a total of 180 positions in the final 
dataset. Evolutionary analyses were conducted in MEGA5  
 
 
 
Siphoviridae 
 
C. sporogenes 
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C. perfringens 
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Myoviridae 
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Appendix 3: The Peptide sequences identified in C.difficile C50 digestion gel (Figure 6.11 
and table 6.4 ) match with spore cortex-lytic enzyme pre-pro-form OS=Clostridium difficile 
(strain 630) , GenBank : CAJ67384.1 
 
 
Matched peptides 
 
Sample 
    
     1 MQDGFLTVSI IDATNNRPIQ NAVVNIYSMS NGSQSSSTLY QNLRSNESGQ  
    51 VTGLVLPAPD VDYSLQPSDV RPYSQYIVEA IADGYETVVI EGTQLLATIE  
   101 ARQGVPMSPR TRSKRSFSRQ SELIFDIGEH TLYGTYPPKI PESNLKPLPP  
   151 PTGFVVLDNP VVPEFIVVHD GLPEDSSAPN YWIPFKEYIK NIASSEIYST  
   201 WPEQTIYANV IAIISFTLNR VFTEWYRNKG YNFTITSTTA YDHKFINNRN  
   251 LFEPINVVVD AIFNTFIKRP PTSRQPLLAQ YCDGQKSQCP DQMTQWGSKD  
   301 LGDQGYDYES ILRYFYGDEI VFERAPIVSG VPVSFPGTTL QVGSSGQYVR  
   351 TIQNQLNAIS NSYPAVPKVI EDGIYGTDTE NAVKIFQGIF GLPQSGVVDF  
   401 KTWYEISRVY VATTRIASLN PLI 
 
1 
     
     1 MQDGFLTVSI IDATNNRPIQ NAVVNIYSMS NGSQSSSTLY QNLRSNESGQ  
    51 VTGLVLPAPD VDYSLQPSDV RPYSQYIVEA IADGYETVVI EGTQLLATIE  
   101 ARQGVPMSPR TRSKRSFSRQ SELIFDIGEH TLYGTYPPKI PESNLKPLPP  
   151 PTGFVVLDNP VVPEFIVVHD GLPEDSSAPN YWIPFKEYIK NIASSEIYST  
   201 WPEQTIYANV IAIISFTLNR VFTEWYRNKG YNFTITSTTA YDHKFINNRN  
   251 LFEPINVVVD AIFNTFIKRP PTSRQPLLAQ YCDGQKSQCP DQMTQWGSKD  
   301 LGDQGYDYES ILRYFYGDEI VFERAPIVSG VPVSFPGTTL QVGSSGQYVR  
   351 TIQNQLNAIS NSYPAVPKVI EDGIYGTDTE NAVKIFQGIF GLPQSGVVDF  
   401 KTWYEISRVY VATTRIASLN PLI 
 
2 
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Appendix 4: The Peptide sequences identified in C.perfringens C50 digestion gel (Figure 
6.11 and table 6.4 ) match with spore cortex-lytic enzyme SleC OS=C.perfringens CPE str , 
GenBank: BAA08081.1 
 
Matched peptides 
 
Sample 
    
     1 MAVGGLKVQC FSEQRRYIPI DKCKVKITPT GEDGVAVGDT IELYTDDTGS  
    51 TDTIELDAPP IENSNQPGTI PYSFAEVIVE REGFLPVAVN GVQIYPSRIA  
   101 LQNVNLPETR GYYRQEEVID IQPNRLVGNF PPKIPEAEEK ELPPPKGTVV  
   151 LPEPVVPEYI VVHNGRPNDN SVANYKVNYK DYIKNVACCE IFSTWSENTI  
   201 RANVYAIISF TLNRIYTEWY RGKGKNFDIT NSTAFDHAFS YGRNFYDNIS  
   251 RIVDEIFSTY MKRFNSKQPL LAQYCDGINV QCPGWMTQWG SKYLGDEGKV  
   301 PYDILTSFYG DDLELKSAKK VKGSPRSYPG YTLKTGYSGE PVRVIQEQLN  
   351 AISRAYPLIP KIAVDGKYGP KTREAVKTFQ KIFNLPQTGE VDYATWYKIS  
   401 DVYVAVTKIA ELRSSVEKKI FYPPTIMDRR ENVPKIIY 
 
3 
     
     1 MAVGGLKVQC FSEQRRYIPI DKCKVKITPT GEDGVAVGDT IELYTDDTGS  
    51 TDTIELDAPP IENSNQPGTI PYSFAEVIVE REGFLPVAVN GVQIYPSRIA  
   101 LQNVNLPETR GYYRQEEVID IQPNRLVGNF PPKIPEAEEK ELPPPKGTVV  
   151 LPEPVVPEYI VVHNGRPNDN SVANYKVNYK DYIKNVACCE IFSTWSENTI  
   201 RANVYAIISF TLNRIYTEWY RGKGKNFDIT NSTAFDHAFS YGRNFYDNIS  
   251 RIVDEIFSTY MKRFNSKQPL LAQYCDGINV QCPGWMTQWG SKYLGDEGKV  
   301 PYDILTSFYG DDLELKSAKK VKGSPRSYPG YTLKTGYSGE PVRVIQEQLN  
   351 AISRAYPLIP KIAVDGKYGP KTREAVKTFQ KIFNLPQTGE VDYATWYKIS  
   401 DVYVAVTKIA ELRSSVEKKI FYPPTIMDRR ENVPKII 
 
4 
 
     
     1 MAVGGLKVQC FSEQRRYIPI DKCKVKITPT GEDGVAVGDT IELYTDDTGS  
    51 TDTIELDAPP IENSNQPGTI PYSFAEVIVE REGFLPVAVN GVQIYPSRIA  
   101 LQNVNLPETR GYYRQEEVID IQPNRLVGNF PPKIPEAEEK ELPPPKGTVV  
   151 LPEPVVPEYI VVHNGRPNDN SVANYKVNYK DYIKNVACCE IFSTWSENTI  
   201 RANVYAIISF TLNRIYTEWY RGKGKNFDIT NSTAFDHAFS YGRNFYDNIS  
   251 RIVDEIFSTY MKRFNSKQPL LAQYCDGINV QCPGWMTQWG SKYLGDEGKV  
   301 PYDILTSFYG DDLELKSAKK VKGSPRSYPG YTLKTGYSGE PVRVIQEQLN  
   351 AISRAYPLIP KIAVDGKYGP KTREAVKTFQ KIFNLPQTGE VDYATWYKIS  
   401 DVYVAVTKIA ELRSSVEKKI FYPPTIMDRR ENVPKIIY 
 
5 
 
 
 
 
 
 
 
 
 
